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Abstract 
 
A series of 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide 
esters and  N-{para-(ferrocenyl)  ethynyl benzoyl}, N-{6-(ferrocenyl) ethynyl-2-
naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} amino acid and dipeptide esters 
were prepared. The novel ferrocenyl based bioconjugates were prepared by coupling 1-
alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoic acid and N-{para-
(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-
(ferrocenyl) ethynyl-2-furanoyl} benzoic acid to α-amino acid ethyl esters and 
dipeptide ethyl esters using the conventional N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimidehydrochloride (EDC), 1-hydroxybenzotriazole (HOBt) protocol. The 
new classes of compounds were characterized by a combination of 
1
H NMR, 
13
C NMR, 
DEPT-135 and 
1
H-
13
C COSY (HMQC) spectroscopy, electrospray ionization mass 
spectrometry (ESI-MS). Biological evaluation of the 1-alkyl-1’-N-para, N-meta and N-
ortho-(ferrocenyl) benzoyl dipeptide esters were carried out in the H1299 non-small 
cell lung cancer (NSCLC) cells. 
The most active derivatives of the 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters are the 1-methyl-1’-N-{para-(ferrocenyl) benzoyl} glycine 
glycine ethyl ester  with an IC50 value of 2.8 ± 1.23 µM, the 1-ethyl-1’–N-{para-
(ferrocenyl) benzoyl} glycine glycine ethyl  ester with an IC50 value of 3.5 ± 0.82 µM 
and the 1-methyl-1’-N-{meta-(ferrocenyl) benzoyl} glycine glycine ethyl ester with an 
IC50 of 2.6 ± 0.62 µM and these derivatives are more cytotoxic in vitro than the 
clinically employed anti-cancer drug carboplatin. In addition, these compounds display 
improved bioactivity in comparison to the corresponding most active benzoyl 
analogues which were the N-{meta-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester 
and N-{para-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester which displayed IC50 
values of 4.0 µM and 6.6 µM respectively 
The biological evaluation of N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) 
ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} amino acid and 
dipeptide esters were also carried out in the H1299 non-small cell lung cancer 
(NSCLC) cells. The most active derivatives of the N-{para-(ferrocenyl) ethynyl 
benzoyl}, N-{6-(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-
 V 
furanoyl} amino acid and dipeptide esters are the N-{para-(ferrocenyl) ethynyl 
benzoyl} glycine L-alanine ethyl ester with an IC50 value of 3.8 ± 1.92 M and the N-
{6-(ferrocenyl) ethynyl-2-naphthoyl} sarcosine L-alanine ethyl ester with an IC50 value 
of 3.2 ± 2.64 M. These compounds are more active than carboplatin with an IC50 
value of 10 ± 1.60 M but are less effective than cisplatin with an IC50 value of 1.5 ± 
0.10 M which are clinically employed anti-cancer drugs. However, the presence of the 
ethynyl moiety had a negative effect of anti-proliferative effect compared to analogous 
compounds prepared previously lacking the ethynyl group.  For example for N-{6-
(ferrocenyl) ethynyl-2-naphthoyl} γ-aminobutyric acid ethyl ester the IC50 value is 7.2 
± 1.51 M whereas for N-(6-ferrocenyl-2-naphthoyl) γ-aminobutyric acid ethyl ester 
the IC50 value was 0.62 ± 0.03 M 
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 1 
Chapter 1 
 
1.1 Cancer 
 
Cancer is a set of diseases in which the affected cells display the following 
abnormalities: (i) uncontrolled growth and division beyond what is normal, (ii) invasion 
and destruction of neighbouring cells and (iii) metastasis may occur, that is the 
spreading of the disease to other locations.
[1] 
The biochemistry of cancer is enormously 
complex, but one cause that has been generally accepted is that reactive oxygen species, 
(ROS) play many important roles, in carcinogenesis and the progression of tumour. 
Examples of these reactive oxygen species produced in cells of living organisms 
include: (i) superoxide anion radical (O2
−
), (ii) hydrogen peroxide (H2O2) and (iii) 
hydroxyl radical (·OH).
[2]
 Typically these ROS are generated during continuous 
exposure to irradiation by X-ray or gamma rays, are present as pollutants in the 
atmosphere or are by-products of mitochondria-catalyzed electron transport reactions.
[2]
  
In biological systems, these reactive oxygen species are well known to play a dual role, 
they can either be harmful or beneficial to living systems.
[2]
 The beneficial effects of 
ROS involve physiological roles in the cellular response to noxia, as for example in 
defence against infectious agents and in the function of a number of cellular signalling 
systems.  In living organisms, normally the harmful effects of the ROS are regulated by 
the detoxifying action of a variety of cell protective enzymes such as superoxide 
dismutase, catalase and heme oxidase. However, high accumulation of ROS can be 
catastrophic to cells because they trigger chemical chain reactions such as lipid 
peroxidation, or they can cause the oxidation of DNA which causes DNA mutations 
which may result in the development of cancer. In many cancer cells it has been 
observed that there is an elevated concentration of ROS and a strongly reduced activity 
of the ROS regulating enzymes compared to normal cells.
[2]
 
The most frequent types of cancer which cause the most deaths include lung, stomach, 
liver, colon and breast cancer. According to reports from the World Health 
Organization (WHO), cancer accounts for 7.9 million deaths and around 13 % for all 
deaths in 2007.
[3] 
Lung cancer is the most common cancer in the world and 
approximately 1.35 million new cases of lung cancer occur worldwide every year.
[3] 
 2 
Lung cancer is divided into two major types based on histological appearance: small 
cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Approximately 20% 
of all lung cancers are SCLC, which is a very aggressive form of cancer due to early 
metastasis.
[4]
 Chemotherapy is the most common treatment for SCLC because of early 
metastatic spread. However, even with treatment, long-term survival remains poor. The 
remaining 80% of all lung cancers are NSCLC, which comprise of adenocarcinomas, 
squamous cell and large cell carcinomas.
[4] 
Surgery is generally regarded as the best 
treatment option for NSCLC. However, 75% of NSCLC tumours are inoperable at the 
time of diagnosis.
[5]
 A further 20% of patients with locally advanced disease receive 
radiotherapy. In these cases, chemotherapy following standard treatment has been 
shown to help patients live longer.
[6]
 
Consequently, the research within this project is focussed on the synthesis 1-alkyl-1’-N-
para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters and N-{para-
(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-
(ferrocenyl) ethynyl-2-furanoyl} amino acid and dipeptide esters and their biological 
evaluation as potential chemotherapeutic agents for the treatment of non-small cell lung 
cancer (NSCLC). 
 
1.1.2 Cancer treatment  
 
Cancer can be treated by surgery, immuno therapy, radiation therapy and chemotherapy 
or a combination of them depending on the location and stage of the disease.
[7] 
Chemotherapy is the treatment of cancer using drugs. Traditionally, the drugs that have 
been used in cancer chemotherapy have been predominantly organic compounds which 
have been synthesized or have been isolated from natural sources. These conventional 
chemotherapeutic drugs elicit cancer cell death by interfering with the cell replication 
process. This can be accomplished by disrupting the function of DNA, either by acting 
directly on DNA (alkylating agents) or by inhibiting the enzymes involved in DNA 
synthesis using antimetabolites.
[8]
 Alternatively, chemotherapeutic may act by 
interfering with the mechanics of cell division for example, by binding to  
microtubules.
[8]
  
 3 
Dacarbazine 1 (figure 1.1) is an alkylating agent prodrug, currently used in the 
treatment of metastatic melanoma cancer.
[8]
 Dacarbazine undergoes activation via 
cytochrome P450 in the liver to form a reactive compound, methyltriazenoimidazole 
carboxamide (MTIC) 2 (figure 1.1).
[9]
 This reactive compound spontaneously degrades 
to form diazomethane, a potent alkylating agent. Alkylating agents in cancer treatment 
are highly electrophilic compounds that attach alkyl groups to DNA by reacting at the 
nucleophilic sites present in the DNA bases.
[10] 
The main nucleophilic sites are the N-1 
and N-3 of adenine, N-3 of cytosine and in particular, the N-7 of guanine. Thus, 
alkylation prevents DNA replication and RNA transcription which results in cell death 
of affected cells. 
 
                             1                                                                       2 
Figure 1.1:  Structure of dacarbazine (1) and its active form MTIC (2). 
 
Antimetabolite drugs were among the first effective chemotherapeutic agents 
discovered and are currently still being used in cancer treatment.
[11] 
Generally, 
antimetabolites induce cell death during the S phase of cell growth when incorporated 
into RNA and DNA. Gemcitabine 3 (figure 1.2) is a pyrimidine antimetabolite which 
has shown good clinical activity in pancreatic, breast, ovarian, non small cell lung, and 
bladder cancer.
[12]
 Gemcitabine, is a fluorinated analogue of the naturally occurring 
DNA building block 2-deoxycytidine 4 (figure 1.2).  The mode of action of 
gemcitabine occurs as a result of intracellular conversion of the prodrug into two active 
metabolites, gemcitabine diphosphate and gemcitabine triphosphate.
[13] 
Gemcitabine 
diphosphate inhibits the enzyme responsible for catalyzing the synthesis of 
deoxynucleoside triphosphates required for DNA synthesis, and gemcitabine 
 4 
triphosphate competes with endogenous deoxynucleoside triphosphates required in the 
synthesis of DNA.
[13] 
Thus, the gemcitabine diphosphate induced reduction of the 
intracellular concentrations of deoxynucleoside triphosphates results in increased 
incorporation of gemcitabine triphosphate into DNA and, consequently, resulting in 
inhibition of DNA synthesis. 
 
3     4  
Figure 1.2: Structure of gemcitabine 3 and 2-deoxycytidine 4.  
 
Etopside 5 (figure 1.3) is a semi-synthetic derivative of the naturally occurring 
podophyllotoxin, and exerts its anticancer activity by inhibiting the DNA-
topoisomerase II enzyme.
[8]
 The DNA topoisomerase II enzyme is essential for the 
separation of entangled daughter strands during replication.
[14]
 Failure to separate these 
strands as a result of inhibition of the enzyme leads to cell death 
                                  
5 
Figure 1.3: Structure of etopside 5. 
 5 
Antimicrotubule agents prevent cell mitosis by interfering with the formation of the 
mitotic spindle required for cell division.
[10] 
The main cellular target of these 
compounds is the structural protein tubulin. During mitosis, tubulin undergoes 
polymerisation to form the mitotic spindle. The vinca alkaloids (figure 1.4), vinblastine 
(6) and vincristine (7) bind to tubulin and prevent polymerisation from occurring thus 
resulting in cell death. These compounds are frequently used in combination therapies 
for the treatment of lung cancer and melanoma.
[10]
 
 
6, R= CH3; 7, R = CHO 
 
Figure 1.4: Structures of vinblastine (6) and vincristine (7). 
 
The selectivity of these drugs are based primarily on the fact that cancer cells divide 
more rapidly than normal cells.
[10]
 Unfortunately, there are also cells in the bone 
marrow, digestive tract and hair follicles that divide rapidly under normal 
circumstances. Most cytotoxic agents also act on these cells and for this reason 
myelosuppression (decreased production of blood cells), mucositis (inflammation of 
lining of the digestive tract) and hair loss are all common side effects.  
The appearance of cancer cells resistant is also a serious problem in cancer 
chemotherapy. There are two main types of cancer resistance.
[15]
 Intrinsic drug 
resistance is present at the time of diagnosis in tumours that fail to respond to first-line 
chemotherapy. In contrast, acquired drug resistance occurs in tumours that can often be 
highly responsive to initial treatment, but display strong resistance to the original 
 6 
treatment upon tumour reocurrence.
[15] 
In such cases, the tumour becomes resistant to 
previously used drugs. A large number of metal containing compounds with antitumour 
properties have been reported in the literature, some of which are in clinical use and 
others still being evaluated as potential anticancer agents.
[18]
 
1.1.3 Bioorganometallic chemistry 
 
The discovery of cisplatin a coordination metal complex by Rosenberg in 1965 marked 
the genesis of bioorganometallic chemistry due to the success of cisplatin against 
various types of cancer.
[16]
 Despite the success of cisplatin as a clinical anticancer drug 
over the past decades, side effects accompany its use in the treatment of cancer, for 
instance it causes the formation of lung adenomas, also repeating cancer cell lines 
develop resistance during long term therapy. As a result of the drawbacks associated 
with the administration of cisplatin, this has prompted the search for alternative 
anticancer drugs which are non toxic whilst retaining therapeutic efficacy. To date, 
bioorganometallic chemistry is a rapidly growing area of science that is being 
conducted at the interface between organometallic chemistry and biology and it has 
provided significant structural and molecular recognition advancement in the 
exploration of new innovative solutions to the emerging existing problems encountered 
in biomedical applications. Metallocenes in the recent years has come to play a pre-
eminent part in research in a wide range of biological application.
[17]
 Amongst the 
numerous examples, ferrocene has in recent years gained increasing interest as the 
building block in the development of a number of promising ferrocene based 
biomedical therapeutic agents. The biomedical application of ferrocene based prodrugs 
is currently an active field of research with many reports showing its activity in vivo 
and in vitro as a potential therapeutic in cancer, malaria and fungal infection  
treatments.
[18]
 Taking this into consideration the stability of ferrocenyl groups in 
aerobic media and its vast potential for derivatization and its favourable 
electrochemical properties have made it an excellent candidate in the synthesis of 
anticancer therapeutics the ultimate goal of this research.
[19]
  
 
 
 7 
1.2 Examples of biomedical application of organometallic compounds   
1.2.1 Anticancer therapeutics 
 
1.2.1.1 Platinum complexes as anticancer agents 
 
Cisplatin 8 (figure 1.5) was the first potent and effective metal-based complex used in 
cancer treatment.
[16]
 It was discovered serendipitously by Rosenberg et al. in 1965 and 
it was later approved for clinical use in 1978. By 1983 cisplatin was the US’s biggest 
selling antitumor drug 
 
8 
Figure 1.5: Structure of cisplatin 8. 
 
Its importance as a chemotherapeutic agent is largely derived from its ability to confer 
complete remission in patients with advance testicular cancer and it also is effective 
against ovarian, bladder and neck cancers. 
Despite its success, the clinical use of cisplatin coincides with marked toxic effects due 
to its lack of selectivity to tumour tissues and as a result, this has lead to severe side 
effects such as neurotoxicity, nephrotoxicity and in addition there is a propensity for 
tumours to develop resistance during long term therapy.
[20]
 As a result the toxic effects 
of cisplatin limit the dose and frequency with which the drug can be administered to 
patients.
[20]
 However, the effectiveness of cisplatin against a wide range of human 
tumours has spawned the preparation and evaluation of new organometallic complexes 
as potential anticancer therapeutics. Three other metal-based complexes of platinum are 
now used in cancer treatment namely carboplatin 9, oxaliplatin 10 and nedaplatin 11 
(figure 1.6) and they all appear to have similar modes of action.
[21]
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9                                       10                                     11 
Figure 1.6: Structures of carboplatin 9, oxaliplatin 10 and nedaplatin 11. 
 
Carboplatin was the first second generation analogue of cisplatin to be synthesized, 
which showed less toxic side effects associated with its administration compared to 
cisplatin and also it was effective against a wide range of tumours, whilst oxaliplatin is 
the only platinum based complex that displays activity against colorectal cancer.
[21]
 
The in vivo anticancer activity of cisplatin and its analogues is due to the replacement 
of the chloride ligands by neutral water ligands to give reactive positively charged 
species (scheme 1.1).
[10]
 This process is facilitated within the cell by the relatively low 
cellular concentration of chloride ions.
[10]
 The platinum atom of these positively 
charged species binds strongly to DNA, forming covalent bonds with the N-7 positions  
of guanine bases in DNA of infected cancer cells thus, preventing replication and/or 
transcription, thereby halting cancer cell proliferation (scheme 1.1).
[22] 
 
Scheme 1.1: Mode of action of cisplatin. 
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Despite the success of cisplatin and its analogues as clinical antitumor drugs marked 
side effects still accompany its administration, to circumvent the side effects novel 
thioplatin 12 
 
and picoplatin 13 (figure 1.7), third generation platinum compounds  have 
been developed and growing interest in other metal complexes are being  
investigated.
[23-24]
 
                                              
12 13 
 
Figure 1.7: Structures of thioplatin 12 and picoplatin 13. 
 
The picoplatin analogue is under clinical trials, because it exhibits reduced reactivity 
towards biomolecules and a lower susceptibility to become activated allows oral 
administration of this drug which is effective against non small cell lung cancer. 
Clinically the platinum agents are widely used as a first line treatment for SCLC, either 
as a single agent or in combination with etopside 5, whilst for NSCLC, the platinum 
agent are used in combination with a second agent, usually gemcitabine 3.
[4]
 
 
1.2.1.2 Titanium derivatives as anticancer agents 
 
Since the mode of action of platinum complexes involved a cis coordination to DNA, 
initial research has focused on a variety of transition metals complexes bearing cis 
ligands. Amongst the metals studied, two families of titanium complexes, the 
titanocene dichloride and derivatives, and budotitane and analogues showed interesting 
activity towards a number of tumour cells, including those resistant to cisplatin and 
furthermore they showed reduced toxicity compared to cisplatin. Keppler et al. 
succeeded in synthesizing the first non platinum metal based complex to undergo phase 
1 clinical trials.
[25]
 Budotitane 14 (figure 1.8), which consisted of a titanium (IV) metal 
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centre surrounded by two β-diketone ligands and two good leaving ligands either 
halides or alkoxide was shown to be effective against Ehrlich ascites tumour cells and it 
was observed that its asymmetry was considered essential for antitumor activity.
[25]
 
Other metal complexes with β-diketone ligands complex structures as in budotitane 
were studied with metals such as hafnium and zirconium, but their anticancer activities 
were not as active as the titanium (IV) metal complex. 
 
14 
Figure 1.8: Structure of budotitane 14. 
 
However, due to poor water solubility and rapid hydrolysis of first the OR ligands, 
followed by the more inert ones the two β-diketone, resulted in budotitane being 
removed from clinical trials due to the drawbacks associated with its use. Another 
reason that held back any further promising development of budotitane and its 
analogues as a potential anticancer drug was the discovery of titanocene dichloride. 
Whilst Kopf-Maier et al. were screening the metallocene dichlorides of vanadium, 
niobium, molybdenium and titanium for anticancer activity in 1979; they discovered 
that titanocene dichloride 15 (figure 1.9), exhibited the most promising 
chemotherapeutic activity.
[26] 
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Figure 1.9: Structure of titanocene dichloride 15. 
 
Kopf-Maier et al. showed that titanocene dichloride was effective against a wide 
range of cancer tumors which included B16 melanoma, Ehrlich ascites tumors, 
colon B adenocarcinoma and sarcoma 189. In phase I clinical trials, titanocene 
dichloride showed no toxic effects on the kidney as opposed to cisplatin, however, 
clinical trials for this compound were stopped in phase II.
[26]
 It was shown that upon 
dissolution in water, the chloride ligands of titanocene dichloride rapidly 
hydrolyzed which lead to the formation of an insoluble titanium complex which 
was biologically inactive and showed no antitumor activity. To circumvent this 
problem of lack of hydrolytic stability, modification of the ligand or encapsulation 
is an active area of research.
[27]
 
 
1.2.1.3 Ruthenium derivatives as anticancer drugs 
 
Apart from cisplatin derivatives and titanium complexes that have been widely studied, 
the antineoplastic potential of ruthenium has been well known for more than 2 decades. 
Despite exhibiting lower cytotoxic activity than cisplatin they are better tolerated in 
vivo and ruthenium complexes also offer a number of advantageous characteristics for 
their use as potential anticancer agents such as (i) ruthenium complexes have the ability 
to mimic iron in binding to biomolecules such as transferrin and human serum which 
makes them remarkably less toxic than the clinically used cisplatin and its analogues, 
(ii) ruthenium
III 
complexes maintain their metal oxidation state until they reach the 
cancer tumor where the low oxygen  levels in the cancer turmors permits their 
reduction to their active state ruthenium
II
;
 
(iii) their greatest interest is their 
characteristic inhibition of angiogenesis and matrix metalloproteinases and, hence, 
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metastasis in vivo.
[28]
 The most interesting ruthenium-based drug candidates that have 
entered clinical trials include the following (figure 1.10) KP1019, indazolium [trans-
tetrachlorobis(1H-indazole) ruthenate (III)] 16 and (ii) NAMI-A, imidazole [trans-
tetrachloro(dimethylsulfoxide) imidazoleruthenate (III)] 17 NAMI-A was the first 
ruthenium agent to enter clinical trials and was developed by Alessio  et al.
[29]
 whilst 
KP1019 was developed by Keppler et al.
[30]
 
  
 
16                                                17 
Figure 1.10: Structures of KP1019; indazolium [trans-tetrachlorobis( 1H-indazole) 
ruthenate (III)] 16 and NAMI-A; imidazole [trans-tetrachloro(dimethylsulfoxide)- 
imidazoleruthenate (III)] 17. 
 
In vitro tests of KP1019 have shown inhibition effects on cultured cancer cells in 
contrast to NAMI-A which was shown to have a marginally cytotoxic effect; however, 
in vivo, NAMI-A lowered the growth of lung metastasis in mice bearing mammary 
carcinoma.
[31]
 Despite NAMI-A not being cyotoxic to primary tumors, it is potentially 
useful because although great progress has been made in treating primary cancers 
secondary metastases represents a major clinical challenge and the incorporation of 
NAMI-A may enhance cancer treatment using the available cancer treatments.
[31]
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Although the mode of action of NAMI-A is not fully understood, it has been reported 
that NAMI-A seems to act as an anti-angiogenic, has the ability to scavenge NO 
produced by epithelial cells in tumour cells and also it acts as an anti-invasive agent 
which results in its interaction with extracellular or external cell membrane receptor 
proteins which may result in its antimetastastic properties.
[31]
  Whilst KP1019 is a 
cytotoxin, which is active against primary tumors, it is thought to cause cancer cell 
apoptosis via the mitochondrial pathway however the mode of action is not fully 
understood.
[32]
 With the success of these two ruthenium complexes that have entered 
clinical trials, more recently, two new classes of ruthenium compounds have been 
developed. 
 
 
                                           18                                                       19  
 
Figure 1.11: Structures of water-soluble ruthenium complex 18 and ruthenium arene 1, 
3, 5-triaza-7-phosphaadamantane (RAPTA) 19. 
 
Sadler et al. have reported the synthesis of a new stable water-soluble ruthenium 
complex 18 (figure 1.11), which was shown to be as potent as cisplatin and its 
analogues in some primary cell lines and, moreover, they exhibit a wide spectrum 
of activity and are also active against some tumors which have become resistant to 
cisplatin.
[33] 
The mode of action is thought to be similar to that of cisplatin, and it 
may involve coordination to the N-7 of guanine bases in DNA resulting in cell 
death.
[33] 
The second class of the new ruthenium complexes was developed by 
Dyson et al. the ruthenium arene 1, 3, 5-triaza-7-phosphaadamantane (RAPTA) 19 
(figure 1.11). Like NAMI-A, RAPTA was found to be inactive against primary 
tumors but was found in vivo to have activity against metastases.
[34]
 Although less 
potent than NAMI-A, RAPTA is less toxic and thus can be administered in higher 
doses. As a result of these promising results there is ongoing research in the use of 
ruthenium complexes as potential anticancer agents.
[34]
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1.2.1.4 Iron derivatives as anticancer drugs 
 
In the last two decades, a range of both charged and neutral ferrocene derivatives have 
been shown to exhibit antitumour activity. The first iron complexes to exhibit 
antitumour activity were reported by Kopf-Maier et al. in 1984 and these include the 
salts of ferricenium picrate 20 and ferricenium trichloroacetate 21 (figure 1.12).
[35]
 
The ferricenium salts reported by Kopf-Maier et al. showed inhibition in the growth of 
Ehlrich ascites tumours, B16 melanoma, colon 38 carcinoma and furthermore the cure 
rate of 100% was obtained in mice bearing Ehlrich ascites tumours.
[35]
 
 
 
20                                           21  
Figure 1.12: Structures of ferricenium picrate 20 and ferricenium trichloroacetate 21. 
 
These observation of antitumour activity of ferricenium salts prompted further 
investigation on the use of these salts as potential anticancer agents. Osella et al. 
reported the synthesis of decamethylferriceniumtetrafluoroborate 22 (figure 1.13) 
another example of a ferricenium salt that showed anticancer activity against MCF-7 
breast cancer cells with an IC50 value of 35 µM.
[36]
 
 
                                    22                                                           23 
Figure 1.13: Structures of Decamethylferriceniumtetrafluoroborate 22 and 
 ferriceniumtetrachloroferrate 23. 
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Osella et al proposed that the antitumour activity of ferricenium salts was due to the 
generation of 
.
OH radicals under physiological conditions which resulted in oxidative 
DNA damage to cancer cells. The use of ferricenium salts has been a growing area of 
research. Houlton et al. have also reported the synthesis of ferriceniumtetrachloroferrate 
23 (figure 1.13), which showed anticancer activity against CH 1 human ovarian 
carcinoma cells with an IC50 value of 10 µM.
[37]
  Despite the enormous research in the 
use of ferricenium salts in cancer chemotherapy, it has emerged that neutral ferrocene 
derivatives also exhibit antitumour activity. It has been known that ferrocene on its own 
exhibites no antitumour activity; however, neutral ferrocene derivatives have been 
reported to show anticancer activity or enhance anticancer activity when incorporated 
into existing therapeutics.
[37]
 The mechanism of action of these ferrocene derivatives in 
the treatment of cancer has been studied by several groups and they have reported that 
the ferrocene moiety undergoes metabolism in cancer cells resulting in the formation of 
ferricenium ions which induces oxidative cleavage.
[38]
    
 Romao et al. have reported the synthesis of 1,2-disubstituted ferrocene derivatives that 
have shown antitumour activity in vitro against Ehrlich ascites tumor cells whilst 
neither ferrocene nor N,N-dimethylaminomethylferrocene showed any anticancer 
activity. With the 1, 2-disubstituted ferrocene derivatives IC50 values ranging from 71.2 
µM for 2-(N,N-dimethylaminomethyl)ferrocene 24 (figure 1.14) to 376.6 µM for 1,2- 
diformylferrocene 25 (figure 1.14) where observed.
[39]
  
   
 
                                 24                                                 25  
Figure 1.14: Structures of 2-(N,N-dimethylaminomethyl)ferrocene 24 and  
1, 2- diformylferrocene 25. 
 
Ling Ming Gao et al have reported the preparation of a series of ferrocenyl ester 
derivatives and the cytotoxicities of the derivatives were tested against colon cancer 
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cells HT-29 and breast cancer MCF-7 cells and the ferrocenyl ester derivative 
Fe(C5H4CO2CH2CH=CH2)2 26 (figure 1.15), showed the highest anticancer activity 
with an IC50 value of 180 µM  for HT-29 and 190 µM  for MCF-7 cell lines.
[40]
 
 
                                                             26 
Figure 1.15: Structure of Fe(C5H4CO2CH2CH=CH2)2 26. 
 
The incorporation of a C-F bond is a recognized strategy often employed in the 
development of pharmaceuticals and this is evident by the success of a large number of 
fluorinated drugs approved by the FDA which are being used as anticancer, antiviral 
and antidepressant agents. Kenny et al. have reported the preparation of a series of N-
(ferrocenylmethyl) fluorobenzene carboxamide derivatives which combine the 
ferrocene moiety with a substituent containing one or more C-F bonds and the 
cytotoxicities of these derivatives were screened in vitro against MDA-MB-435-S-F 
breast cancer cell lines. The most active derivative found was N-(ferrocenylmethyl) 4 
fluorobenzene-carboxamide 27 (figure 1.16) with an IC50 value in the range of 11-14 
µM.
[41] 
 
 
27 
Figure 1.16: Structure of N-(ferrocenylmethyl) 4-fluorobenzene carboxamide 27. 
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Kenny et al. have also reported the synthesis of ferrocene derivatives in which various 
amino acid and dipeptides have been coupled to the ferrocene moiety via a benzoyl 
spacer moiety. In particular, N-para, N-meta and N-ortho-(ferrocenyl) benzoyl 
dipeptide esters have been found to possess good anticancer activity against carboplatin 
resistant variant H1299 lung cancer cells and the most active derivative was N-{meta-
(ferrocenyl) benzoyl} glycine L-alanine ethyl ester 28 (figure 1.17) with an IC50 value 
of 4.0 ± 0.71 µM.
[42 - 45]  
 
 
 
28 
Figure 1.17: Structure of N-{meta-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester 
28.   
 
The N-(ferrocenyl) benzoyl dipeptide esters consist of three key components: (i) the 
electroactive core, the ferrocene moiety; (ii) a conjugated linker that lowers the 
oxidation potential and (iii) a peptide derivative that can interact with other 
biomolecules via secondary interactions, such as hydrogen bonding. Kenny et al. have 
reported that the possible mode of action for the anticancer activity of the N-
(ferrocenyl) benzoyl dipeptide esters is possibly due to their low redox potentials and 
their ability to form reactive oxygenated species (ROS) under physiological 
conditions.
 [42 - 45]  
 It is envisaged that the peptide chain of these derivatives may have a 
secondary mode of action. The role of the dipeptide is not clear, however, it is plausible 
that the lipophilic ferrocenyl benzoyl moiety anchors to the cell membrane of the 
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cancer cell and the peptide chain blocks the opening of the channels in the cell 
membrane, leading to cell death.
[42]
 
In order to improve the cytotoxicity of the N-(ferrocenyl) benzoyl dipeptide esters, 
Kenny et al. have reported the synthesis of N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl tri- and tetrapeptide esters. They showed that extending the peptide chain had a 
negative effect on cytotoxicity as the tri- and tetrapeptide derivatives had IC50 values 
 >50 µM for instance N-{ortho-(ferrocenyl) benzoyl} glycyl glycyl glycine ethyl ester 
an IC50 value of 63 ± 1.11µM.
[45]
  
Kenny et al. have shown that the cytotoxicity of the N-(ferrocenyl) benzoyl dipeptide 
esters can be enhanced when the benzoyl conjugate is replaced by a polyaromatic 
conjugate and they have reported a series of N-(ferrocenyl) naphthoyl dipeptide ethyl 
esters with IC50 values against H1299 lung cancer cells ranging from 1.2 – 8.0 µM.
[46]
 
The N-(6-ferrocenyl-2-naphthoyl) glycine L-alanine ethyl ester 29 (figure 1.18) was 
found to be the most active derivative of the naphthoyl series to date, displaying an IC50 
value of 1.3 ± 0.13 µM and this value is slightly lower than that found for the clinically 
used cisplatin which has an IC50 value of 1.5 ± 0.11 µM against the H1299 lung cancer 
cell line. 
 
 
29 
Figure 1.18: Structure of N-(6-ferrocenyl-2-naphthoyl) glycine L-alanine ethyl ester 
29. 
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To date, the biological evaluation of N-(ferrocenyl) benzoyl and N-(ferrocenyl) 
naphthoyl derivatives has focussed on determining their anti-proliferative effect in the   
non small cell lung cancer (NSCLC) cell line, H1299. This is due to the fact that lung 
cancer is the leading cause of cancer mortality worldwide with approximately 75–85% 
of all lung cancer cases being NSCLC.
[47]
 European national cancer registries have 
shown a rising incidence of melanoma during the past two decades.
[48]
 Most localised 
melanoma can be effectively treated early by wide localised excision; however, patients 
with advanced stage of the disease have a poor prognosis, with a 1 year survival rate of 
less than 5%. The poor prognosis is due to the resistant of metastatic melanoma to 
cytotoxic chemotherapy.
[49]
 More efficacious novel chemotherapeutic drugs are 
urgently required to improve the prognosis for malignant melanoma patients. Thus, 
Kenny et al. have reported the synthesis, characterisation and biological evaluation of a 
series of N-(ferrocenyl) naphthoyl amino acid esters, which have been screened in vitro 
for anti-proliferative effect against NSCLC cell line, H1299 and Sk-Mel-28 malignant 
melanoma cell line.
[50]
  The N-(6-ferrocenyl-2-naphthoyl) γ -aminobutyric acid ethyl 
ester 30 (figure 1.19)  was found to be the most active derivative of the naphthoyl 
amino acid series displaying a high activity in both the H1299 cell line with an IC50 
value of  0.62 ± 0.06 µM and in the Sk-Mel-28 cell line an IC50 1.41 ± 0.04 µM .  
 
30 
Figure 1.19: Structure of N-(6-ferrocenyl-2-naphthoyl) γ-aminobutyric acid ethyl ester 
30. 
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From futher SAR studies of the N-(6-ferrocenyl-2-naphthoyl) derivatives, by replacing 
the alanine amino ethyl ester of compound 30 (figure 1.19) with glycine, Kenny et al. 
have recently reported a three fold improvement in antiproliferative effect in the non 
small cell lung cancer (NSCLC) cell line, H1299 with the N-{6-(ferrocenyl)-2-
napthoyl} glycine glycine ethyl ester 31 (figure 1.20) showing an IC50 value of 
 0.13 ± 0.01 µM.
[51]
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Figure 1.20: Structure of N-{6-(ferrocenyl)-2-napthoyl} glycine glycine ethyl ester 31. 
 
Kondopi et al. have reported the preparation of several ferrocene derivatives and found 
out that thiomorpholideamidemethylferrocene 32 (figure 1.21) showed the highest 
antiproliferative activity against colo 205 colon adenocarcinoma compared to the other 
derivatives prepared with IC50 an value of 50 µM.
[52]
 
 
32 
Figure 1.21: Structure of thiomorpholideamidemethylferrocene 32. 
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Kondopi et al. also suggested that the mode of action was as a result of a competitive 
binding between ATP to the catalytic enzyme topoisomerase II which resulted in its 
inhibition. Topoisomerase II is an enzyme responsible for maintaining the topology of 
DNA and it is well known that, in cancer cells, there is an increased topoisomerase II 
activity, hence, the inhibition of topoisomerase II results in antiproliferative  
activity.
[53]  
In addition to the reported ferrocene derivatives that have shown anticancer 
activity, the incorporation of ferrocene into large bioactive molecules have been 
explored as promising strategy against cancer activity. The incorporation of a 
metallocene into compounds with medicinal applications was rare prior to the 1980s. 
To date there has been several reported successes of increased efficacy of ferrocenyl 
analogues of known drugs. Jaouen et al. reported that the incorporation of a ferrocene 
moiety in tamoxifen showed antitumour activity in both hormone-dependent and 
hormone-independent breast cancer.
[54]
 Breast cancer is the most common cancer in 
women and it affects one in every eight women in the world. It is classified into two 
types, which are distinguished by the presence or absence of estrogen receptors (ER); 
ER(+) is used to distinguish breast cancer that is dependent on the presence of the 
estrogen receptor, which account for two-thirds of breast cancer, whilst ER(-) is used to 
distinguish breast cancer which is independent of the estrogen receptor. Tamoxifen 33 
(figure 1.22) is widely prescribed to patients diagnosed with ER(+) breast cancer. The 
antiproliferative effect arises from the competitive binding of hydroxytamoxifen 34 (the 
active form of tamoxifen) to the estrogen receptor instead of estradiol 35 (figure 1.22) 
which results in the repression of the estradiol-mediated DNA transcription.
[55] 
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                 33: R=H; 34: R=OH                                                                 35 
 
Figure 1.22: Tamoxifen 33 and hydroxytamoxifen 34 and estradiol 35. 
 
Although the administration of tamoxifen is well tolerated, unfortunately some 
drawbacks are associated with its use, for instance long term use of tamoxifen increases 
the risk of uterine cancer and blood clotting in the lungs. Overtime, some cancer cells 
develop resistance to tamoxifen administration and, furthermore, tamoxifen is not 
effective against the ER(-) breast cancer form. In trying to find better alternatives to 
tamoxifen, Jaouen et al. investigated ferrocifen 36 (figure 1.23), a tamoxifen analogs 
that contained an organometallic moiety. Whilst they were studying the effects of 
hydroxyferrocifen (active form of ferrocifen) on the proliferation of the ER(+) and  
ER(-) breast cancer cell lines they observed the following. In ER(+) MCF-7 cells, 
hydroxyferrocifen showed an antiestrogenic effect similar in ER(-) MDA-MB-231 cell 
lines, the hydroxyferrocifen showed antiproliferative activity with an IC50 value in the 
order of 0.5 µM, whereas, there was no anticancer activity observed when  
hydroxytamoxifen 34 (figure 1.22) was used. The hydroxyferrocifen 37 (figure 1.23), 
which is the ferrocenyl analogue of hydroxytamoxifen synthesized by Jaouen et al. was 
the first molecule that have been shown to be to be active in both hormone-dependent 
and hormone-independent breast cancer tumours and furthermore showed a wide 
therapeutic window against kidney cancer, ovarian and prostate cancer. 
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                                                   36: R=H; 37: R=OH 
 
Figure 1.23: Structure of ferrocifen 36 and hydroxyferrocifen 37. 
 
Jaouen et al have also reported the incorporation of ferrocene to a polyphenolic system 
yielding compound 38 (figure 1.24) which also showed antiproliferation effects in both 
hormone-dependent and hormone-independent tumours in ER(+) MCF-7 cells and in 
ER(-) MDA-MB-231 cell lines. The antiproliferative effect observed was stronger than 
that observed for hydroxytamoxifen. This high effect may lead to the generation of a 
potent cytotoxic compound.
[56]
 
 
 
38 
 
Figure 1.24: Structure of ferrocenyl polyphenolic 38. 
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1.2.2 Antimalarial organometallic therapeutics 
 
For many years, malaria has continued to be a major cause of death in many developing 
countries. According to reports from the World Health Organization (WHO), 
approximately 40 % of the world’s population is at risk of malaria infection.[57] 
To date, chloroquine 39, and quinine 40 and mefloquine 41 (figure 1.25) have been the 
most effective antimalarial agents used against the four known malaria parasites namely  
Plasmodium falciparum, P. vixax, P. ovale and P. malariae, of which P. falciparum is 
the most dangerous and accounts for 90% of all deaths from malaria because it is 
becoming more resistant to existing therapeutics.
[58]
 As a result of the increased 
resistance by the malaria parasites, some novel organometallic antimalarial drugs have 
been synthesized.  
 
  
 
                                  39                                          40                                            41 
 
Figure 1.25: Structures of chloroquine 39, quinine 40 and mefloquine 41. 
 
Brocard et al. discovered that the insertion of a ferrocenyl group to chloroquine resulted 
in the chemotherapeutic activity of chloroquine being altered.
[59]
 They showed that for 
ferroquine 42  (figure 1.26) an analogue of chloroquine, the incorporation of a 
ferrocenyl moiety as an integral part of the side chain of chloroquine between the two N 
atoms had superior efficacy to other analogues in which the moiety was terminal on the 
side chain or bonded to the quinoline. In vitro assays showed that ferroquine was more 
potent than chloroquine in the inhibition of the growth of P.  falciparium.    
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Figure 1.26: Structure of ferroquine 42. 
 
To date, the use of ferroquine as a potential antimalarial agent has made it possible to 
avoid the relapse in the long term which is associated with conventional antimalaria 
therapeutics and as a result ferroquine is in phase 1 clinical trials. Biot et al. recently 
demonstrated that the mode of action of ferroquine is similar to that of chloroquine, in 
that ferroquine forms complexes with haematin found in infected red blood cells and 
ferroquine is an even stronger inhibitor of β-haematin formation than chloroquine.[60] 
When chloroquine is administered to chloroquine resistant malaria parasites, the 
chloroquine is expelled rapidly from red blood cells and this is catalyzed by a P. 
falciparum transmembrane protein. However, when ferroquine is administered Biot et 
al. reported that ferroquine may block the P. falciparium transmembrane protein 
through its lipophilic properties, acting like a resistance reversing agent; hence, this 
could be the reason why ferroquine is effective against chloroquine-resistant malaria. 
Biot et al. also have shown the preparation of a series of ferrocenyl mefloquine 
analogues 43 and 44 (figure 1.27).  When tested on P. falciparium strains, the results 
showed that the ferrocenyl analogue compounds exhibited a lower antimalarial activity 
than existing mefloquine and quinine therapeutics.
[61] 
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43                                                                 44 
 
Figure 1.27: Structures of ferrocenyl mefloquine analogues 43 and 44. 
 
Go et al. prepared a series of ferrocenyl chalcones an example of which is compound 
45 (figure 1.28). These antimalarial ferrocene derivatives did not involve any 
incorporation of any of the existing conventional therapeutics previously discussed.
[62]
 
In vitro assays against Plasmodium falciparium showed that the most active compound 
was 1-ferrocenyl-3-(4-nitrophenyl)prop-2-en-1-one and the location of the ferrocene 
moiety and the polarity of the carbonyl linkage influenced the ease of oxidation of Fe
2+
 
in ferrocene which enhanced the antiplasmodial activity. 
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Figure 1.28: Structure of 1-ferrocenyl-3-(4-nitrophenyl)prop-2-en-1-one 45. 
 
Go et al also reported that the incorporation of ferrocene may enhance the antimalarial 
activity through the generation of free radicals from the redox cycling of the ferrocene 
moiety which may contribute to the antiplasmodial activity observed with ferrocenyl 
chalcones. However, the extent to which this property is manifested is also influenced 
by other physicochemical properties such as polarity, planarity and lipophilicity of the 
compounds.
[62]
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1.2.3 Antibacterial therapeutics 
 
Antibiotics have been critical in the fight against infectious diseases caused by bacteria; 
however, bacterial resistance to existing antibiotics continues to develop and poses a 
significant threat. For instance, diseases such as gonorrhoea and tuberculosis have 
become hard to treat with current antibiotics.
[63]
 Antibacterial resistance over the years 
has developed as a result of the natural consequence of the ability of the bacterial cell to 
adapt as a result of the prolonged usage of the existing antibiotics. To complicate 
matters there has been a decline in antibacterial research by many large pharmaceutical 
companies and this has led to a shortfall in the development of new and better 
antibacterial agents to fight the present threat of drug resistance. Penicillin V 46 (figure 
1.29) historically was the first antibacterial drug that was effective against many 
previously serious diseases such as syphilis and staphylococcus infections. Penicillin V 
is still widely used today, although many types of bacteria are now resistant to its 
administration such as Eschericia. coli.
[64-65]
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Figure 1.29: Structure of Penicillin V 46. 
 
Resistance to penicillin V in Eschericia. coli was first reported by Abraham et al. in 
1940 and, later on in 1952, Lederberg et al. reported the ability for bacterial to transfer 
genetic information on antibiotic resistance to other bacterial species.
[64-65]
 
Despite the years of exhaustive medicinal chemical studies on the modification of 
known antibacterial scaffolds, it is becoming increasingly difficult to deliver new leads 
on this approach. The recent focus on antibacterial research has, therefore, moved to the 
identification of novel therapeutics. The use of organometallic compounds as potential 
antibacterial agents is now an active area of research. The first reported antibiotic that 
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contained an organometallic moiety was ferrocenyl penicillin 47 (figure 1.30). In 1975 
Edward et al reported the synthesis of ferrocenyl penicillin.
[66]
 They reported that when 
a ferrocenyl moiety is incorporated into penicillin, the antibacterial properties of the 
penicillin V derivative increased significantly. 
 
47 
 
Figure 1.30: Structure of ferrocenyl penicillin 47. 
 
The observed increased antibacterial activity of ferrocenyl penicillin as a result of the 
incorporation of a ferrocene metal complex and the successful organometallic 
therapeutics that are in clinical use in cancer treatment has prompted the exploration of 
organometallics as antibacterial agents.
[67]
 Dyson et al. have recently reported the 
synthesis of a series of water soluble ruthenium (II) arene complexes, which were 
screened for antibacterial activity,  The ruthenium complex, {Ru(η6-p-cymene)I2(1,3,5-
triaza-7-phosphatricylo[3.3.1.1]decane)} 48 (figure 1.31) showed the highest 
antibacterial  activity against Bacillus subtilis compared to the other water soluble 
ruthenium (II) arene complexes.  
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Figure 1.31: Structure of {Ru(η6-p-cymene)I2(1,3,5-triaza-7-phosphatricylo [3.3.1.1] 
decane)}48.  
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Kabbani et al. have also reported the synthesis of copper and cobalt complexes with 4-
chloro-3-nitrobenzoate (ClNBz) and the nitrogen ligands 1,3-diaminopropane (1,3-
DAP) or o-phenylenediamine (o-PDA) and they have shown that the copper complex 
[Cu(ClNBz)(o-PDA)]Cl 49 (figure 1.32) showed the highest antibacterial activity 
compared to the other complexes studied as indicated by its ability to inhibit the growth 
of Staphylococcus aureus and  Enterococcus faecalis.
[68]
 
 
 
49 
Figure 1.32: Structure of [Cu(ClNBz)(o-PDA)]Cl 49. 
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1.3 Summary 
 
Despite the years of exhaustive medicinal chemistry studies on the modification 
of known therapeutic scaffolds, it is becoming increasingly difficult to deliver 
new leads on this approach and as a result the use of organometallics in 
biomedical applications has become an active area of research. The use of 
organometallics as potential therapeutics commenced with the discovery of 
cisplatin by Rosenberg in 1965 which marked the genesis of bioorganometallic 
chemistry due to the success of cisplatin against various types of cancer. 
Furthermore, the incorporation of organometallics into compounds with 
medicinal applications has resulted in increased efficacy of existing 
therapeutics, for example ferrocifen, the ferrocenyl analogue of tamoxifen, has 
shown antiproliferative effects in both hormone-dependent and hormone-
independent tumours which was not shown by tamoxifen an established 
chemotherapeutic. Furthermore the use of ferroquine, the ferrocenyl analogue of 
chloroquine as a potential antimalarial agent has made it possible to avoid the 
relapse in the long term which is associated with conventional antimalarial 
therapeutics. 
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Chapter 2: Synthesis and structural characterisation of 1-alkyl-1’-N-para, N-meta 
and N-ortho-(ferrocenyl) benzoyl dipeptide esters 
 
2.1 Introduction  
 
 
Organometallic compounds containing transition metals, such as cobalt, copper, iron 
and platinum are known to have antiproliferative (in vitro) and antineoplastic (in vivo) 
activities.
[1]
 Platinum coordination compounds, such as cisplatin and carboplatin are 
currently being used in the treatment of a variety of tumours.
[1]
 However, problems 
with toxicity, harsh side effects during administration, together with acquired drug 
resistance, has lead to increased research, to find alternatives to cisplatin and its 
analogues.  
Ferrocene is a particularly useful organometallic compound for biological applications 
due to its electrochemical properties, its stability and its aromatic nature which allows 
for derivatization. As a result of these factors, ferrocene research has received an 
increased level of interest over the past decade.
[1]
 Ferricenium salts are known to inhibit 
tumour growth through the formation of hydroxyl radicals under physiological 
conditions, leading to the oxidative damage of DNA.
[2] 
Therefore, ferrocenyl 
derivatives that possess redox potentials which fall within the range of biologically 
accessible potentials, offer a desirable and alternative method to target and kill cancer 
cells. The aim of this research is to develop novel ferrocenyl dipeptide bioconjugates 
for use as potential anticancer agents. 
Previous studies within the group have been carried out on the non small cell lung 
cancer (NSCLC) cell line, H1299 to evaluate the in vitro activity of novel ferrocenyl 
benzoyl amino acid and dipeptide esters. The effect of these compounds on H1299 cell 
growth was expressed as IC50 values. The IC50 value is the concentration of a drug 
required for 50% inhibition of cell growth.  N-{ortho-(ferrocenyl) benzoyl} glycine 
ethyl ester was initially tested for its in vitro anti-proliferative activity against H1299 
lung cancer cells.  This compound was found to be cytotoxic and had an IC50 value of 
48 ± 1.01 µM, whereas the starting material, ortho-ferrocenyl ethyl benzoate, was 
completely inactive against the cell line. Therefore, other derivatives were prepared and 
evaluated for their anticancer activity against H1299 lung cancer cells. The dipeptide 
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derivative N-{ortho-(ferrocenyl) benzoyl} glycine glycine ethyl ester was shown to 
have an IC50 value of approximately 20 ± 1.72 µM, while N-{ortho-(ferrocenyl) 
benzoyl} glycine L-alanine ethyl ester had an IC50 value of 5.3 ± 1.23 µM. The N-
{meta-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester 28 and N-{para-(ferrocenyl)-
benzoyl} glycine L-alanine ethyl ester were also tested and gave results of 4.0 ± 0.71 
µM and 6.6 ± 1.03 µM respectively.
[3-7]
  
As an extension of this study we now report the synthesis and structural 
characterization of novel 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl 
dipeptide esters. These compounds (figure 2.1) consist of four key moieties:  
 
(i) A redox active centre 
(ii) A conjugate linker  
(iii) A alkyl chain (further lowers the oxidation potential of the ferrocene 
moiety) 
(iv) A dipeptide chain 
 
These novel derivatives differ from the N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters by having an alkyl moiety on the previously unsubstituted 
cyclopentadiene ring (figure 2.1). The primary objective of this research is to explore a 
structure-activity relationship (SAR) study of the incorporation of alkyl chains moieties 
on the unsubstituted ring of the N-para, N-meta and N-ortho-(ferrocenyl) benzoyl 
dipeptide esters.
[3-7]
 The dipeptides employed in this investigation were Glycine 
Glycine (Gly Gly), Glycine L-Alanine (Gly L-Ala), Glycine L-Leucine (Gly L-Leu) 
and Glycine L-Phenylalanine (Gly L-Phe) ethyl esters. A tripeptide or tetrapeptide 
chain was shown to have a negative effect on biological activity.
[6] 
Thus, a series of 
novel 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters 64–
99 (figure 2.1) were prepared by coupling alkyl ferrocenyl benzoic acids to the 
dipeptide ethyl esters using the conventional N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC) and 1-hydroxybenzotriazole (HOBt) coupling 
protocol. All the compounds were fully characterized using a combination of nuclear 
magnetic resonance techniques (
1
H, 
13
C & DEPT-135), 
1
H-
13
C COSY and electrospray 
ionization mass spectrometry (ESI-MS). 
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64–99 
 
R = CH3 , CH2CH3 , CH2CH2CH3 
R’ = H, CH3 , C4H9, C7H7, 
 
Figure 2.1 General structure of the 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters 64–99. 
 
2.2 The synthesis of the alkylferrocene derivatives 
 
For the synthesis of the alkylferrocenes, three synthetic pathways were considered as 
shown in scheme 2.1. The most direct approach for the preparation of alkylferrocenes 
involves the Friedel Crafts alkylation of ferrocene (scheme 2.1a). However, these 
reactions proceed with a low degree of regiocontrol and invariably produce mixtures of 
mono- and poly-alkylated derivatives in low yields.
[8]
 The reason for such undesired 
polyalkylation is that the introduction of one alkyl group to the ferrocene results in the 
alkylferrocene ring being more activated than the ferrocene starting material resulting 
in further alkylation, leading to the almost inevitable second alkylation and hence, its 
use as a synthetic pathway was not investigated.  
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The synthesis of alkylferrocene utilising catalytic palladium cross coupling using 
ferrocene boronic acid and alkylhalides (Scheme 2.1b) offered a potential synthetic 
pathway which was evaluated in this study.
[9]
 Initial work involved the optimisation of 
the experimental protocol and it was observed that reflux of reactants at 80 
o
C for 144 
hr resulted in the synthesis of alkylferrocene, however, the yields for these reactions 
varied from 15–20%. The reflux period was time consuming and the yields were 
relatively low, hence, other feasible synthetic pathways were considered.  The Friedel 
Crafts acylation reaction of ferrocene and Vilsmeir formylation are well established 
methods and furnish good yields of mono- and di-acylated ferrocenes (scheme 2.1c) 
with a remarkable degree of regioselectivity compared to the direct approach for the 
preparation of alkylferrocenes via Friedel Crafts alkylations.
[10-11] 
Accordingly, a two-
step protocol involving regioselective acylation followed by hydrogenation of the 
acylated ferrocene constituted a method of choice for the preparation of the 
alkylferrocenes. The hitherto reported general methods for the deoxygenation of 
acylferrocenes include Clemmensen reduction and reductive deoxygenation using 
lithium aluminium hydride in the presence of anhydrous aluminium trichloride.
[12-14] 
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Scheme 2.1. Synthesis of alkylferrocene via three pathways (a), (b) and (c).  
 
These methods were both evaluated as potential synthetic pathways for the formation of 
the alkylferrocenes. It was observed that the deoxygenation of acylferrocenes using 
lithium aluminium hydride in the presence of anhydrous aluminium chloride resulted in 
the formation of alkylferrocenes and the yields for these reactions varied from 75-95% 
whilst the Clemmensen reduction protocol was not successful on initial evaluation, 
hence, it was not investigated further.  
 
2.2.1 The synthesis of alkylferrocene derivatives via palladium catalysed cross 
coupling. 
 
The preparation of the alkylferrocene derivatives via palladium catalysed cross 
coupling involved the refluxing of ferrocene boronic acid in dimethoxyethane (DME) 
in the presence of 1,1-bis-(diphenylphosphino)ferrocene dichloropalladium(II) catalyst, 
3M NaOH solution and iodoethane yielded ethylferrocene as shown in scheme 2.2.
[15]
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                                   56 
(i) 1,1-bis-(diphenylphosphino)ferrocene dichloropalladium(II), 
DME, NaOH, Iodoethane 
 
Scheme 2.2: The synthesis of ethylferrocene via palladium catalysed cross coupling. 
 
The catalytic cycle for the formation of alkylferrocene derivatives via palladium cross 
coupling proceeds via three steps, (i) oxidative addition of a carbon electrophile to the 
zero valent palladium followed by (ii) the transmetallation of a nucleophilic carbon 
from boron to the palladium complex. Which is then followed by (iii) the rapid 
reductive elimination of the cross coupled product to regenerate the zero valent 
palladium, Pd(0) as shown in scheme 2.3.
[15] 
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Scheme 2.3: Palladium catalysed cross coupling mechanism for the synthesis of ethyl 
ferrocene.   
 
2.2.2 The synthesis of alkylferrocene derivatives via reductive deoxygenation of 
acylferrocenes derivatives 
 
2.2.2.1 The synthesis of the acylferrocene derivatives 
 
For the synthesis of acylferrocene derivatives two synthetic protocols reported in the 
literature were used. For the preparation of ferrocene carboxyaldehyde, Vilsmeir 
formylation was used.
[11]
 For the synthesis of acetylferrocene and propionyl ferrocene 
Friedel Crafts acylation was the method of choice.
[10]
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2.2.2.1.1 Synthesis of ferrocene carboxaldehyde 
 
                                   48 
(i) POCl3, DMF; (ii) NaOH, H2O 
 
Scheme 2.4: Synthesis of ferrocene carboxaldehyde 48. 
 
In the mechanism for the formation of ferrocene carboxaldehyde the initial step is the 
formation of the Vilsmeir reagent.
[11]
 Today it is well established that the reaction 
proceeds via the formation of a chloromethylene iminium cation from the reaction 
between the DMF and phosphorus oxychloride as shown in scheme 2.5. 
 
Scheme 2.5: Formation of choloromethylene iminium cation. 
 
The chloromethylene iminium cation in the presence of an electron rich species in this 
case ferrocene undergoes iminoalkylation which is essentially an electrophilic 
substitution reaction. Hydrolysis of the iminoalkylation product is carried out using 
NaOH and water. This is a particularly useful method as it removes any acid formed 
and results in the formation of ferrocene carboxyaldehyde as shown in scheme 2.6. 
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Scheme 2.6: Iminoalkylation (i) and base induced hydrolysis (ii). 
 
In the synthesis of ferrocene carboxaldehyde via Vilsmeir formylation, low percentage 
yields of 11% were obtained. These low percentage yields were due to the fact the 
formylation is not substrate specific. Di-formylated ferrocene was formed in the 
reaction and unreacted ferrocene was recovered which showed that the reaction 
conditions employed did not result in the reaction going to completion. As a result of 
these limitations large scale synthesis was employed in order to get sufficient amounts 
of ferrocene carboxylaldehyde required for the reductive deoxygenation reaction to 
obtain methylferrocene. 
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2.2.2.1.2 Synthesis of acetylferrocene  
 
                                                                                                   49 
Scheme 2.7: Synthesis of acetylferrocene 49.  
 
Friedel Crafts acylation is a well known effective synthetic pathway of introducing new 
carbon-carbon bonds into aromatic compounds.
[10]
 The most common catalyst for 
acylation of an aromatic ring is aluminum trichloride. Aluminium trichloride is a strong 
Lewis acid, and it is used in Friedel Crafts acylation. It is often associated with a few 
limitations, for example aluminum trichloride gives off HCl gas upon contact with 
moist air and is required in greater than stoichiometric amounts. This leads to the 
generation of considerable quantities of acidic and aluminum waste. For the Friedel 
Crafts acylation of ferrocene when aluminium trichloride is used, the activation of the 
ferrocene ring, leads to a large amount of disubstitution product being formed.
[10]
 
Therefore for the synthesis of acetyl ferrocene a benign catalyst, phosphoric acid, was 
used instead to catalyze the Friedel Crafts acylation reaction in the presence of acetic 
anhydride. This acylation reaction affords a higher yield of primarily the mono-
substituted product, acetylferrocene. From numerous Friedel Crafts acylation reactions 
carried out, it was observed that slow addition of phosphoric acid over 30 min resulted 
in the generation of high yields of acetylferrocene, greater than 80%, as opposed to 
spontaneous addition of the catalyst which resulted in low yields being obtained. The 
mechanism for the synthesis of acetylferrocene involves the generation of an acylium 
ion electrophile by protonation of the acetic anhydride by phosphoric acid (scheme 
2.8).
[14]
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Scheme 2.8: Formation of acylium ion.  
 
The  electrons on the cyclopentadiene ring of ferrocene act as a nucleophile, attacking 
the positively charge acylium carbon. This step destroys the aromaticity giving rise to a 
ferrocenyl cation intermediate. Removal of the proton from the carbon atom bearing the 
acyl group reforms the aromatic system, generating HCl and regenerating the active 
catalyst (scheme 2.9). 
 
Scheme 2.9: Fridel crafts acylation mechanism for synthesis of acetyl ferrocene. 
 
2.2.2.1.3 Synthesis of propionyl ferrocene  
 
 
                                       50 
Scheme 2.10: Synthesis of propionyl ferrocene 50.  
 
The mechanism for the synthesis of propionyl ferrocene is similar to that used for the 
synthesis of acetylferrocene (scheme 2.8 and 2.9).
[14]
 The only difference is that 
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propionic anhydride is used instead of acetic anhydride. The percentage yield of 
propionyl ferrocene was greater than 50%. These percentage yields were lower than 
those obtained for the acetylferrocene; the reason for the low yield was a result of steric 
hindrance associated with the size of acylium ion electrophile formed in the Friedel 
Crafts acylation reaction. 
 
2.2.2.1.4 Reductive deoxygenation of acylferrocenes derivatives 
 
(i) LiAlH4, AlCl3, diethyl ether 
 
48.R’= H; 49. R’= CH3 : 50. R’= CH2CH3 
51. R’’ = CH3;   56.  R’’= CH2CH3; 60.  R’’= CH2CH2CH3 
 
Scheme 2.11: Reductive deoxygenation of acylferrocenes derivatives. 
 
The reductive deoxygenation of acylferrocenes to the corresponding hydrocarbons via 
the combined action of lithium aluminium hydride and the use of the strong Lewis acid 
aluminium trichloride in diethyl ether, as shown in scheme 2.11 yielded the desired 
alkylated ferrocene derivatives with percentage yields  varying between 75-95%. 
 
2.3 Synthesis of 1-alkyl-1’-para, meta and ortho-(ferrocenyl) benzoic acids 
 
Following already established protocols for the synthesis of  para-(ferrocenyl) benzoic 
acid, the synthesis of 1-alkyl-1’-para, meta and ortho-(ferrocenyl) benzoic acids 
involved the diazonium coupling of the alkylferrocene to 2, 3, 4-ethylamino benzoate 
followed by hydrolysis to yield the desired products (scheme 2.12).
[3-7]
 However, the 
percentage yields were less than 8%. When 2,3,4-amino benzoic acids were used 
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instead of 2,3,4-ethylamino benzoates, yields greater than 15% were obtained for the 1-
alkyl-1’-para, meta and ortho-(ferrocenyl) benzoic acids (scheme 2.13). 
 
        51.                                                               52.                                                      53.  
(i) NaNO2, HCl, (ii) NaOH, MeOH, HCl 
 
 
Scheme 2.12: The synthesis of 1-methyl-1’-para-ferrocenyl benzoic acid via a two step 
reaction scheme. 
 
(i) NaNO2, HCl 
 
51:  R = CH3;   56:  R = CH2CH3; 60: R = CH2CH2CH3 
53, 54, 55:  R = CH3;   57, 58, 59:  R = CH2CH3;   61, 62, 63: R = CH2CH2CH3 
 
Scheme 2.13: The synthesis of 1-alkyl-1’-para, meta and ortho-(ferrocenyl) benzoic 
acids.  
 
The mechanism for the diazonium coupling using 2,3,4-amino benzoic acids is shown 
is shown in scheme 2.14.
 [13]
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R = CH3;  CH2CH3;  CH2CH2CH3 
 
Scheme 2.14: The mechanism for the diazonium coupling reaction.   
 
2.4 The synthesis of 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl 
dipeptide esters 
 
The synthesis of 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide 
esters 64–99 involved the coupling of the dipeptide ethyl ester hydrochloride salts of 
Gly Gly, Gly L-Ala, Gly L-Leu and Gly L-Phe to 1-alkyl-1’-para, meta and ortho- 
(ferrocenyl) benzoic acids using N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimidehydrochloride (EDC), 1-hydroxybenzotriazole (HOBt) and 
triethylamine (TEA) in dichloromethane shown in scheme 2.15.
[3-7] 
The 1-alkyl-1’ 
derivatives were isolated following the coupling procedure and purified by column 
chromatography, using a 1:1 mixture of hexane and ethyl acetate as the eluent. The pure 1-
alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters 64–99 was 
furnished as either an orange solid or a red oil, with yields of 12-28%. All compounds gave 
spectroscopic and analytical data in accordance with their proposed structures. 
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(i) EDC, HOBt, Triethylamine and dipeptides ethyl esters (R3) 
R
1
 R
2
 
 
R
3
 Compound no. 
 
 
 
-CH3 
 
Gly Gly(OEt) 64 
Gly L-Ala(OEt) 65  
Gly L-Leu(OEt) 66 
Gly L-Phe(OEt)  67 
 
Gly Gly(OEt) 68 
Gly L-Ala(OEt) 69 
Gly L-Leu(OEt) 70 
Gly L-Phe(OEt)  71 
 
Gly Gly(OEt) 72 
Gly L-Ala(OEt) 73 
Gly L-Leu(OEt) 74 
Gly L-Phe(OEt)  75 
 
 
 
 
-CH2CH3 
 
Gly Gly(OEt) 76 
Gly L-Ala(OEt) 77 
Gly L-Leu(OEt) 78 
Gly L-Phe(OEt)  79 
 
Gly Gly(OEt) 80 
Gly L-Ala(OEt) 81 
Gly L-Leu(OEt) 82 
Gly L-Phe(OEt)  83 
 
Gly Gly(OEt) 84 
Gly L-Ala(OEt) 85 
Gly L-Leu(OEt) 86 
Gly L-Phe(OEt)  87 
 
 
 
 
-CH2CH2CH3 
 
Gly Gly(OEt) 88 
Gly L-Ala(OEt) 89 
Gly L-Leu(OEt) 90 
Gly L-Phe(OEt)  91 
 
Gly Gly(OEt) 92 
Gly L-Ala(OEt) 93 
Gly L-Leu(OEt) 94 
Gly L-Phe(OEt)  95 
 
Gly Gly(OEt) 96 
Gly L-Ala(OEt) 97 
Gly L-Leu(OEt) 98 
Gly L-Phe(OEt)  99 
 
Scheme 2.15: The synthesis of 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters 64–99. 
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Of the compounds synthesized, the ortho derivatives (72-75, 84-87, 96-99) and meta 
derivatives (68-71, 80-83, 92-95) gave the lowest yields, while the para derivatives  
(64-67, 76-79, 88-91) gave the highest yields. The difference in percentage yield can be 
rationalized by considering the respective orientations of the ortho and meta-ferrocenyl 
benzoic acids. The 1-alkyl-1’- meta and ortho-(ferrocenyl) benzoic acids are more 
sterically hindered than the 1-alkyl-1’-para-(ferrocenyl) benzoic acid starting material 
which give arise to the low yields. This is consistent with previously reported 
observations by Corry et al. for the N-(ferrocenyl) benzoyl dipeptide derivatives.
[3-7]
 
The side chains of the reacting α-amino acids and the alkyl chain incorporated can also 
have an influence on the overall yield. Yields are lower in cases where both the side 
chain of the α-amino acids and alkyl group are large enough to exert steric hindrance. 
This is clearly observed for 1-methyl and 1-propyl-1’–N-{para-(ferrocenyl) benzoyl} 
glycine L-phenylalanine ethyl esters. The increase of the alkyl chain length from a 
methyl (67) to a propyl (91) resulted in a drop of the percentage yield from 16% to 14% 
respectively. 
 In the standard coupling protocol (EDC/HOBt), the first step towards the amide bond 
formation involves the addition of the carboxyl group to the carbodiimide to give an O-
acylisourea ester intermediate. This intermediate is highly reactive and is prone to 
intramolecular acyl transfer to form an N-acylurea by-product (scheme 2.16). The 
formation of this by-product contributes to the low yields observed for compounds 64-
99. Previously reported in the literature, it has been shown that the addition of HOBt 
stabilizes the O-acylisourea ester intermediate, by converting it to an amine-reactive 
HOBt ester. This reduces intramolecular acyl transfer of O-acylisourea to form N-
acylurea.
[7] 
 In comparison to the previously reported N-(ferrocenyl) benzoyl  
dipeptide esters 
[3-7] 
the yields of the compounds synthesized are lower as a result of the 
presences of the alkyl groups. For instance, the 1-methyl-1’–N-{meta-(ferrocenyl) 
benzoyl} glycine L-alanine ethyl (69) had a percentage yield of 22%, whilst the N-
{meta-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester (28) had a yield of 42%. 
[3]
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Scheme 2.16: Intramolecular acyl transfer of O-acylisourea to form N-acylurea. 
 
As depicted in scheme 2.17, the EDC/HOBt mediated coupling of the 1-alkyl-1’-para, 
meta and ortho-(ferrocenyl) benzoic acids (i) with the dipeptide ethyl ester 
hydrochloride salts of Gly Gly, Gly L-Ala, Gly L-Leu and Gly L-Phe (vi), progresses 
through a formation of an unstable intermediate; an O-acylisourea ester (iii). This 
compound is formed by the reaction of the EDC (ii) with the 1-alkyl-1’-para, meta and 
ortho-(ferrocenyl) benzoic acids (i). Due to the instability of this intermediate, it is 
prone to intramolecular acyl transfer. The addition of HOBt (iv) stabilizes the the O-
acylisourea intermediate by converting it to an amine-reactive HOBt ester (v), which is 
a much more stable compound and remains reactive with the amine moiety of the 
dipeptide ethyl ester hydrochloride salts. Upon addition of the dipeptide ethyl ester 
hydrochloride salts of Gly Gly, Gly L-Ala, Gly L-Leu and Gly L-Phe (vi), the HOBt is 
displaced  resulting in the formation of 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters (64–99).[7] 
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R= 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoic acids 
                                                                 R’= H; CH3; C4H9; C7H7 
 
Scheme 2.17: Mechanism of the synthesis of 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters 64–99 using EDC and HOBt. 
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2.5 
1
H NMR spectroscopic studies of 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters 
 
All the 
1
H NMR  experiments were performed in DMSO-d6 as the 1-alkyl-1’-N-para, 
N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters showed limited solubility in 
other deuterated solvents. In DMSO-d6 the two amide protons appear between δ 8.80 
and δ 8.20 (figure 2.2). The appearance of these signals in the downfield region of the 
1
H NMR spectrum is due to hydrogen bond interactions between the amide proton and 
the S=O bond of DMSO-d6. If CDCl3 was used to obtain the spectra, the amide protons 
would most likely appear more upfield since CDCl3 does not possess the same ability to 
form hydrogen bonds.
[7]
 The splitting pattern of the hydrogens on the benzoyl linker 
and the cyclopentadiene rings do not follow first order (n+1) splitting patterns. The 
splitting pattern of the benzoyl linker of the 1-alkyl-1’ derivatives in the literature is 
shown to follow second order splitting pattern.[7] This is due to the extended coupling of 
magnetically inequivalent hydrogens on the benzoyl linker.[7] These signals are reported in 
table 2.1.          
 
Table 2.1: Splitting pattern of the aromatic hydrogens on the benzyol linker. 
 
Orientation of benzoyl 
linker 
Splitting pattern for the four aromatic hydrogens 
para-disubstituted 
derivatives 
2 signals  observed (apparent doublets peaks) 
meta-disubstituted 
derivatives 
3 signals  observed (apparent singlet, multiplet and doublet 
peaks) 
Ortho-disubstituted 
derivatives 
4 signals observed (apparent doublet, triplet, triplet and 
doublet peaks) 
 
In general, the protons on the benzoyl linker appear between δ 8.15 and δ 7.10. For the 
disubstituted ferrocene moiety, three splitting patterns are observed. For the 
cyclopentadiene ring attached to the benzoyl linker (η5C5H4-benzoyl), the protons 
appear as either apparent singlet or triplet signals in the region of δ 4.89 and δ 4.20. 
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This complexity is due to four protons being magnetically inequivalent, thus, following the 
second order splitting pattern. The protons on the alkylated cyclopentadiene ring (η5-
C5H4-alkyl) overlap with the signals of the methylene groups of the glycine moiety, 
resulting in a multiplet being observed between δ 4.05 - 3.79. The typical chemical shifts 
of the 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters that 
follow the (n+1) rule, include the methylene protons of the ethyl ester (-OCH2CH3) 
which appear as a quartet in the region  δ 4.20 - 3.96, whilst the methyl protons (-
OCH2CH3) appear as a triplet in the region δ 1.26 - 1.04.  
 
 
 
Figure 2.2: Typical chemical shifts observed for the 1-alkyl-1’-N-para, N-meta and N-
ortho-(ferrocenyl) benzoyl dipeptide esters 64–99. 
 
 
 
 
 
 
 
 
 55 
 
2.5.1 
1
H NMR spectroscopic study of 1-propyl-1’-N-{para-(ferrocenyl) benzoyl} 
glycine L-phenylalanine ethyl ester 91 
 
91 
 
The 
1
H NMR spectrum of the 1-propyl-1’-N-{para-(ferrocenyl) benzoyl} glycine L-
phenylalanine ethyl ester (91) is shown in figure 2.3. The two amide protons appear as 
a triplet at δ 8.56 and as a doublet at δ 8.27 with coupling constants of 6.0 Hz and 7.6 
Hz respectively. The four aromatic protons present between δ 7.71 and δ 7.51 are 
observed as two apparent doublet signals with coupling constant of 8.0 Hz respectively. 
The protons of the phenyl ring appear as a multiplet between δ 7.18 - 7.12 which 
integrates for 5 protons. The ortho and meta protons on the cyclopentadiene ring 
(η5C5H4-benzoyl) attached to the benzoyl spacer moiety appear as apparent singlets at δ 
4.74 and δ 4.27. The methine group {-CH(CH2Ph)} appears as a multiplet between δ 
4.40 -  4.38. The methylene protons of the ethyl ester (-OCH2CH3) appear as a quartet 
at δ 3.96 with a coupling constant of 7.2 Hz. The protons on the alkylated 
cyclopentadiene ring (η5C5H4-alkyl) overlap with the protons of the methylene groups 
of (-NHCH2CO-), resulting in a multiplet being observed between δ 3.84 - 3.79, which 
has an overall integration of six. The protons of the methylene group {-CH(CH2Ph)} is 
observed as a multiplet between δ 2.92 - 2.85.  For the propyl chain attached to the 
cyclopentadiene ring, the protons of the methylene groups (-CH2CH2CH3) appear as a 
triplet at δ 1.90 and a multiplet between δ 1.30 - 1.29 whilst the protons on the methyl 
group (-CH2CH2CH3) appear as a triplet at δ 0.66. The methyl group of the ethyl ester 
(-OCH2CH3) is observed as a triplet at δ 1.04.  
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Figure 2.3: 
1
H NMR spectrum of 1-propyl-1’-N-{para-(ferrocenyl) benzoyl} glycine 
L-phenylalanine ethyl ester 91.
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2.6 H
1
-H
1 
COSY spectroscopic studies of 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters 
 
The COSY experiment (Correlation Spectroscopy) is a standard technique that provides 
a means of identifying mutually coupled protons in the structure of a compound. The 
experiment presents a two-dimensional contour map, with each dimension representing 
proton chemical shifts and the contours representing signal intensity. In the spectrum 
the diagonal running bottom left to top right shows peaks that correspond with those in 
the usual 1D spectrum. The peaks of interest are the crosspeaks which represent the 
coupling between the protons that are correlated to each other.
[17]
 
 
2.6.1 H
1
-H
1
COSY spectrum of 1-ethyl-1’-N-{para-(ferrocenyl) benzoyl} glycine 
glycine ethyl ester 76 
 
In the H
1
-H
1 
COSY spectrum (figure 2.4) of 1-ethyl-1’-N-{para-(ferrocenyl) benzoyl} 
glycine glycine ethyl ester (76) the two amide protons 8 and 10 (-NHCH2CO-) correlate 
with the adjacent methylene protons 9 and 11 (-NHCH2CO-) of the glycine glycine 
ethyl ester. Correlation is also present between the protons of the para disubstituted 
benzoyl spacer, 6 and 7. The ortho protons 5 and meta protons 4 on the cyclopentadiene 
ring (η5C5H4-benzoyl) attached to the benzoyl spacer, correlate. The methylene of the 
ethyl ester (-OCH2CH3) 12 correlates to the methyl protons 13. These correlations 
observed for this derivative is consistent with previously reported observations for the 
N-(ferrocenyl) benzoyl dipeptide derivatives.
[3-7]  
For the protons on the alkylated cyclopentadiene ring (η5C5H4-alkyl), the methylene 
protons 2 correlate to the methyl protons 1. This correlation is not observed in the N-
(ferrocenyl) benzoyl dipeptide derivatives because the derivatives do not have an 
alkylated cyclopentadiene ring. 
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76 
 
 
 
Figure 2.4: H
1
-H
1 
COSY spectrum of 1-ethyl-1’-N-{para-(ferrocenyl) benzoyl} 
glycine glycine ethyl ester 76.  
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2.7 
13
C NMR and DEPT-135 spectroscopic studies of 1-alkyl-1’-N-para, N-meta 
and N-ortho-(ferrocenyl) benzoyl dipeptide esters 
 
 
13
C and DEPT-135 NMR spectroscopic studies were carried out on all of the 
compounds synthesized. In the 
13
C NMR spectra of 1-alkyl-1’-N-para, N-meta and N-
ortho-(ferrocenyl) benzoyl dipeptide esters, the typical peaks observed include the 
appearance of three carbonyl signals between δ 173.0 - 166.0 (figure 2.5). The aromatic 
region of the spectrum in the 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters is dependent on whether the ferrocenyl moiety and the 
dipeptide chain are in the ortho, meta or para positions. Ortho and meta derivatives 
give rise to six peaks due to the six non-equivalent carbon atoms on the aromatic ring. 
Whilst the para derivatives have four peaks representing four unique carbons. 
Typically the carbon atoms on the benzoyl linker appear between δ 145 and δ 125. The 
two quaternary carbon atoms present on the benzoyl linker appear between δ 145 and δ 
135. These quaternary carbons can be easily identified by their absence in the DEPT-
135 spectrum.  
For the 1-alkyl-1’ derivatives, six unique carbon signals are observed for the 
disubstituted ferrocene moiety with two ipso carbons being present. The ipso carbon 
(η5-C5H4-benzoyl) appears between δ 84.3 - 80.0, whilst the ipso carbon (η
5
-C5H4-
alkyl) appears between δ 95.3 – 88.0.  
The signals of ortho carbons on the substituted cyclopentadiene rings appear more 
downfield compared to the meta carbons due to deshielding by the benzoyl linker and 
the alkyl chain attached. The methylene carbon of the ethyl ester (-OCH2CH3) appears 
between δ 64.0 - 60.0 whilst the methyl carbon appears at δ 14.5 - 14.0. In a DEPT-135 
spectrum, methine and methyl carbons appear as positive peaks, whereas methylene 
carbons appear as negative peaks i.e. below the resonance line. Quaternary carbons are 
absent in a DEPT-135 spectrum.   
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Figure 2.5: Typical chemical shifts observed for the 1-alkyl-1’-N-para, N-meta and N-
ortho-(ferrocenyl) benzoyl dipeptide esters 64–99. 
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2.7.1 
13
C NMR and DEPT-135 spectroscopic studies of 1-methyl-1’-N-{para-
(ferrocenyl) benzoyl} glycine L-leucine ethyl ester 66 
 
 
66 
 
The 
13
C NMR spectrum of 1-methyl-1’-N-{para-(ferrocenyl) benzoyl} glycine L-
leucine ethyl ester displays three carbonyl carbon signals between δ 172.5 and δ 166.2  
(figure 2.6). These are absent in the DEPT-135 spectrum. The aromatic region shows 4 
unique signals between δ 142.4 and δ 125.2. The two quaternary carbon atoms at δ 
142.2 and δ 130.8 from the benzoyl spacer moiety can be easily identified by their 
absence in the DEPT-135 spectrum. The ipso carbon atom on (η5-C5H4-alkyl) ring 
appears at δ 90.4 whilst the ipso on (η5-C5H4-benzoyl) ring appears at δ 84.2. These are 
absent in the DEPT-135 spectrum. The remaining carbon atoms on the cyclopentadiene 
rings are present between δ 70.1 - 66.9. The methylene and methyl carbon atoms of the 
ethyl ester (-OCH2CH3) appear at δ 60.4 and δ 14.0 respectively. The two methylene 
carbon atoms from (-NHCH2CO-) and {-CH2CH(CH3)2} appear at  δ 42.0 and δ 39.4 
respectively and display negative resonances in the DEPT-135 spectrum. The two 
methine carbon atoms from (-NHCHCO-) and {-CH2CH(CH3)2} of the glycine leucine 
ethyl ester appear at  δ 50.3 and δ 24.2 respectively. The two methyl carbon atoms of 
the glycine leucine ethyl ester appear at δ 22.7 and δ 21.4. The carbon atom of the 
methyl group (-CH3) attached to the cyclopentadiene ring appears at δ 13.2.    
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Figure 2.6: 
13
C NMR and DEPT-135 spectra of 1-methyl-1’-N-{para-(ferrocenyl) 
benzoyl} glycine L-leucine ethyl ester 66. 
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2.8 HMQC spectroscopic studies of 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters  
 
HMQC (Heteronuclear Multiple Quantum Coherence) is a 2D NMR technique that 
correlates each carbon atom to the proton to which it is directly attached.
[18]
 Thus, 
HMQC allows the assignment of proton and carbon spectra which aids in structure 
elucidation. This correlation is achieved by using a pulse sequence with a delay time set 
at half the value of the C- H coupling constant, usually in the region of 100 - 200 Hz. 
This results in a correlation between the carbon   atom   and   the proton to which it is 
attached. In the HMQC spectrum (figure 2.7) of 1-ethyl-1’-N-{para-(ferrocenyl) 
benzoyl} glycine glycine ethyl ester (76), the following C-H correlations were 
observed:  
 
(i) Aromatic C-H correlations  
(ii) Cyclopentadiene ring C-H correlations for (η5-C5H4-alkyl) and (η
5
-C5H4-
benzoyl) 
(iii) C-H correlations of methylene groups and C-H correlations of the methyl 
groups on the ethyl alkyl chain moiety and on the ethyl ester 
(iv) C-H correlation of methylene groups on the glycine glycine moiety 
 
The positions of the C-H correlation are listed in (table 2.2). The aromatic C-H 
correlations, C-H correlations of the methylene groups on the glycine moiety and the  
C-H correlations on the (η5-C5H4-benzoyl) are consistent to those observed for the N-
{para-(ferrocenyl) benzoyl} glycine glycine ethyl ester.
[3]
 
However, for the alkylated cyclopentadiene ring (η5-C5H4-alkyl) two C-H correlations 
are observed for the two unique C-H bonds in the ortho and meta positions.  For the 
unsubstituted ring (η5-C5H5) for the N-(ferrocenyl) benzoyl derivatives, one  
C-H correlation signal is observed because the C-H bonds are equivalent giving rise to 
one C-H correction signal.
[3]
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Figure 2.7: HMQC spectrum of 1-ethyl-1’-N-{para-(ferrocenyl) benzoyl} glycine 
glycine ethyl ester 76.  
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Table 2.2: C-H correlation data from HMQC spectrum of 1-ethyl-1’-N-{para-
(ferrocenyl) benzoyl} glycine glycine ethyl ester 76. 
 
Site 
1
H NMR 
13
C NMR 
 
1* 
 
1.02 
 
14.0 
2* 2.12 20.8 
3*  91.3 
(4 and 7)* 4.05 – 3.90 68.5 
(5 and 6)* 4.05 – 3.90 68.8 
(8 and 11)* 4.89 66.9 
(9 and 10)* 4.42 69.9 
12  83.0 
13  130.8 
(14 and 18)* 7.65 125.2 
(15 and 17)* 7.87 127.5 
16  142.6 
19  169.8 
20 8.80  
21* 4.05 – 3.90 42.4 
22  169.7 
23 8.38  
24* 4.05 – 3.90 40.7 
25  166.3 
26* 4.15 60.4 
27* 1.23 14.5 
 
* C-H correlation site  
 
 
 66 
2.9 UV-Vis spectroscopic studies of the 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters  
 
In organic molecules the absorption of ultraviolet and visible radiation is restricted to 
certain functional groups (chromophores) that contain valence electrons of low 
excitation energy.
[20]
 These transitions are usually between a bonding or a lone pair 
orbital and an unfilled non-bonding or anti-bonding orbital. From a molecular orbital 
diagram, the possible electronic transition that occurs, gives rise to absorption bands for 
selective chromophores shown in figure 2.8.
[20]
 The spectrum of a molecule containing 
many chromophores can be limited as dominant absorption bands can overlap with 
weak absorption bands and as a result the use of UV in determination of functional 
groups present is restricted.
[20]
 
 
 
 
Figure 2.8: Electronic transition that occur that give rise to absorption bands for 
selective chromophores. 
 
In this UV-Vis study, the spectra of all compounds were obtained at a concentration of 
4 x 10
-4
 M in ethanol. In the UV spectra of the 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters 64–99, low energy bands observed in the visible 
region, from approximately 390 to 545 nm with a distinct λmax value can be assigned as 
metal to ligand charge transfer (MLCT) band transitions arising from the ferrocene 
moiety. The high energy band between 310 and 390 nm, with distinct λmax values are 
due to the π - π* transitions of the benzoyl moiety (table 2.3).  
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In the literature it is well know that the addition of a conjugate system to ferrocene 
causes the λmax value of ferrocene (400 nm) to shift toward the red region as a result of 
extended conjugation.
[8]
 
In the UV-Vis spectra of the synthesised compounds 64-99, all the derivatives cause the 
ferrocene to undergo a red shift to lower energies as shown for selected compounds in 
table 2.3. In general the para derivatives give rise to lower energy bands compared to 
the meta and ortho derivatives. This is due to the benzoyl linker being coplanar to the 
disubstituted cyclopentadiene rings thus, imposing extended conjugation. These 
observations are in accordance with the observations made for the N-(ferrocenyl) 
benzoyl dipeptide derivatives.
[3-7] 
For the meta and ortho derivatives steric hindrance, contributed by the position of the 
dipeptide derivatives, forces the atoms in these derivatives to adopt a strained conformation 
resulting in a loss of co-planarity of the conjugating groups.[4-5] 
 
From the UV-Vis data for selected 1-methyl-1’-N-para, N-meta and N-ortho 
(ferrocenyl) benzoyl} glycine glycine ethyl esters shown in figure 2.9 and table 2.3 the 
following observations were observed; the para derivatives have maxima at 
approximately 360 nm and 450 nm, corresponding to the π-π* transition of the benzoyl 
moiety and the metal to ligand charge transfer (MLCT) of the ferrocene moiety (figure 
2.9) respectively. For the ortho and meta derivatives the λmax values (table 2.3) are 
lower due to the loss of co-planarity between the ferrocenyl moiety and the benzoyl 
linker. Thus, the ortho derivatives have λmax at 325 nm and 445 nm, while the meta 
derivatives have λmax at 330 nm and 447 nm. From the UV-Vis spectra (figure 2.9) it 
can be seen that the substitution pattern of the benzoyl linker on the ferrocene induces 
the π-π* transition to undergo a red shift to lower energies, compared to the ortho and 
meta derivatives (figure 2.9). 
Extinction coefficient (ε) values were calculated using the Beer-Lambert Law, A = εCl 
where A is absorbance, C is concentration in mol/L and l is the path length of the cell in 
centimetres.
[7]
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Table 2.3: UV-Vis data for selected 1-methyl-1’-N-para, N-meta and N-ortho 
(ferrocenyl) benzoyl} glycine glycine ethyl esters.  
 
 
Compound 
Chromophore 
                  Ferrocene moiety                             Aromatic linker 
  λmax (nm)          ε (L mol
-1
 cm
-1
)  λmax (nm)      ε (L mol
-1
 cm
-1
) 
64           451                     (ε 1075) 360                  (ε 3250) 
68           447                     (ε 1015) 333                  (ε 1750) 
72           445                      (ε 675) 330                  (ε 1063) 
 
 
 
 
 
 
 
Figure 2.9: UV-Vis data for selected 1-methyl-1’-N-para, N-meta and N-ortho 
(ferrocenyl) benzoyl} glycine glycine ethyl esters 64, 68 and 72.   
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2.10 Mass spectrometric studies of 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters   
 
Mass spectrometry enables the determination of the relative molecular mass of many 
different types of compounds. The mass spectrometer is composed of three distinct 
parts, namely the ion source, the analyser and the detector. The sample is introduced 
into the ion source and this allows ionisation to occur. These ions are then extracted 
into the analyser, where they are separated according to their mass (m) to charge (z) 
ratios (m/z). The separated ions are detected and displayed as a mass spectrum. 
Electrospray ionization mass spectrometry (ESI-MS) was employed in the analysis of 
1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters. 
Examination of the mass spectra revealed the presence of sodium ion adducts, 
[M+Na]
+
. In the mass spectra, sequence specific fragment ions were not observed, 
therefore tandem mass spectrometry was employed to determine the fragmentation 
pattern of 1-methyl-1’-N- {para -(ferrocenyl) benzoyl} glycine glycine ethyl ester 64,  
1-ethyl-1’-N-{para-(ferrocenyl) benzoyl} glycine glycine ethyl ester 76 and 1-propyl-
1’-N-{para-(ferrocenyl) benzoyl} glycine glycine ethyl ester 88. 
In the MS/MS spectrum of compound 64, the sequence specific fragment ions are 
present at m/z 275, m/z 303, m/z 331 and m/z 359 (figure 2.10).  The product ions at m/z 
275 and m/z 303 correspond to the 1-methyl-1’-N-{para-(ferrocenyl) benzyl and 1-
methyl-1’-N-{para-(ferrocenyl) benzoyl subunits respectively. However, the expected 
a1 and b1 product ions at m/z 332 and m/z 360 were not observed, instead a1-1 and b1-1 
product ions were observed at m/z 331 and m/z 359 respectively. The formation of a1-1 
and b1–1 ions in the mass spectrum of N-{para-(ferrocenyl) benzoyl} glycine L-alanine 
ethyl ester was investigated previously within the group by tandem mass spectrometry 
and deuterium labelling studies. The results showed that b1-1 product ions arise from 
the loss of a hydrogen atom attached to the nitrogen atom and not to the α-carbon atom 
of the glycine residue.
[22]
 The fragment ion at m/z 434 is due to a loss of C2H4 from the 
ethyl ester group by a McLafferty rearrangement (scheme 2.18).
[23]
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R =1-methyl-1’-N- {para -(ferrocenyl) benzoyl}glycine glycine 
 
Scheme 2.18: McLafferty rearrangement resulting in the m/z 434 fragment ion. 
 
 The sequence specific fragment ions are also observed for derivatives 76 and 88 which 
differ by 14 mass units respectively as shown in figure 2.11 - 2.12. For compound 76 
the sequence specific fragment ions are observed 14 mass units higher at m/z 289, m/z 
317, m/z 345 and m/z 373 (figure 2.11). The product ions at m/z 289 and m/z 317 
correspond to the 1-ethyl-1’-N-{para-(ferrocenyl) benzyl and 1-ethyl-1’-N-{para-
(ferrocenyl) benzoyl subunits respectively whilst the product ion a1-1 and b1-1 are 
observed at m/z 345 and m/z 373 respectively. The fragment ion at m/z 448 is due to a 
loss of C2H4 from the ethyl ester group by McLafferty rearrangement. The sequence 
specific fragment ions for 88 are present at m/z 303, m/z 331, m/z 359 and m/z 387 
(figure 2.12).  The product ions at m/z 303 and m/z 331 correspond to the 1-propyl-1’ -
N-{para-(ferrocenyl) benzyl and 1-propyl-1’-N-{para-(ferrocenyl) benzoyl subunits 
respectively. The product ion a1-1 and b1-1 are observed at m/z 359 and m/z 387 
respectively.  The fragment ion at m/z 462 is due to a loss of C2H4 from the ethyl ester 
group by McLafferty rearrangement. 
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Figure 2.10. Product ions observed in the MS/MS spectrum of 1-methyl-1’ -N- {para-
(ferrocenyl)-benzoyl} glycine glycine ethyl ester 64. 
 
 
Figure 2.11. Product ions observed in the MS/MS spectrum of 1-ethyl-1’ -N- {para-
(ferrocenyl)-benzoyl} glycine glycine ethyl ester 76. 
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Figure 2.12. Product ions observed in the MS/MS spectrum of 1-propyl-1’ -N- {para-
(ferrocenyl) benzoyl} glycine glycine ethyl ester 88. 
   
 
2.11 A comparative study of N-para, N-meta and N-ortho-(ferrocenyl) benzoyl 
dipeptide esters and the novel 1-alkyl-1’ derivatives  
 
 
2.11.1 Introduction 
 
The synthesis and structural characterization of biologically active N-ferrocenyl 
benzoyl dipeptide esters has been previously reported.
[3-7]
 In an extension of that study 
we now report the synthesis and structural characterization of novel 1-alkyl-1’-N-para, 
N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters  
64–99 (figure 2.13). In the literature incorporation of electron donating groups is a well 
know strategy to lower oxidation potentials of ferrocene moieties.
[8]
 Thus, the 
incorporation of the various alkyl chain groups (electron donating groups) to the 
unsubstituted cyclopentadiene ring of the N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters should improve the cytotoxicity of these derivatives. In 
addition, the alkyl chain should also increase the lipophilicity of the reported 
derivatives.
[3-7]
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                                              R = CH3 , CH2CH3 , CH2CH2CH3 
R’ = H, CH3 , C4H9, C7H7, 
 
Figure 2.13 General structures of the N-para, N-meta and N-ortho-(ferrocenyl) benzoyl 
dipeptide esters and the novel 1-alkyl-1’ derivatives. 
 
2.11.2 Synthetic route comparison 
 
For the synthesis of N-para, N-meta and N-ortho-(ferrocenyl) benzoic acid the 
synthetic protocol involved the diazonium coupling of ferrocene to 2,3,4-ethylamino 
benzoate followed by a base hydrolysis.
[3-7]
 However, when this protocol was employed 
in the synthesis of 1-alkyl-1’ benzoic acid derivatives, yields of less than 8% where 
obtained. To improve the selectivity for the synthesis of monoarylferrocene it was 
observed that when 2,3,4-amino benzoic acids were used, yields greater than 15% were 
obtained. For the synthesis of 1-alkyl-1’ dipeptide derivatives (64–99), the yields 
obtained were lower than the N-para, N-meta and N-ortho -ferrocenyl benzoyl 
dipeptide esters previously reported.
[3-7]
 The low yields obtained were due to steric 
hindrance from the incorporation of the alkyl chains and the competing reaction in the 
EDC/HOBt coupling protocol (section 2.4) 
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2.11.3
 1
H NMR, 
13
C NMR and DEPT-135 spectroscopic studies of N-para, N-meta 
and N-ortho-(ferrocenyl) benzoyl dipeptide esters and their 1-alkyl-1’ derivatives.  
 
For the 
1
H NMR spectra of both classes of compounds (figure 2.14)  the two amide 
protons of the dipeptide chain appear between δ 8.89 and δ 8.14. The four aromatic 
protons on the benzyol linker occur between δ 8.15 and δ 7.10 for both classes of 
compounds. The splitting pattern of the benzoyl spacer for both classes follows the 
second order splitting pattern, due to extended coupling of magnetically inequivalent 
hydrogens on the benzoyl linker.
[7]
 Thus, they are reported as apparent signals, as 
shown in table 2 in section 2.5. These typical proton signals do not show any significant 
difference in the chemical shift between the two classes of compounds (figure 2.14).         
The protons on the monosubstituted ferrocene ring in the N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters occur as three signals in the region δ 4.95 and δ 
4.00. For the 1-alkyl-1’derivatives (64–99) the protons on the disubstituted ferrocene 
moiety appear as three signals between δ 4.89 and δ 3.79.  For both classes three 
splitting patterns are observed.
[3-7]
 The cyclopentadiene ring attached to the benzoyl 
linker (η5C5H4-benzoyl) appears as either apparent singlets or triplets for both classes. 
This complexity has already been discussed in Section 2.5. The protons on the 
unsubstituted cyclopentadiene ring of the N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters appear as a singlet due to the hydrogens being magnetically 
equivalent. However the protons on the alkylated cyclopentadiene ring (η5-C5H4-alkyl) 
which are not magnetically equivalent overlap with the signals of the methylene groups 
of the glycine moiety, resulting in a multiplet being observed. The overlapping of the 
cyclopentadiene proton signals is not observed in the monosubstituted ferrocene 
derivatives. For both classes of compounds the methylene protons of the ethyl ester  
(-OCH2CH3) appear between δ 4.20 - 3.96 as a quartet, whilst the methyl protons  
(-OCH2CH3) appear between δ 1.30 - 1.04 as a triplet.  
 
The difference between the two classes of compounds are the presence of the methyl, 
ethyl or propyl groups on the cyclopentadiene ring for the 1-alkyl-1’ derivatives (64–
99). For the methyl (-CH3) group, the proton signals are present between δ 1.46 - 1.70 
as a singlet. The methylene and methyl protons of the ethyl group appear as a quartet 
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between δ 2.15 - 1.96 and as a triplet between δ 1.05 - 0.70 respectively. For the propyl 
group the protons on the methylene groups (-CH2CH2CH3) appear as a triplet between δ 
2.08 - 1.88 and as a multiplet between δ 1.45 - 1.25, whilst the protons on the methyl 
group (-CH2CH2CH3) appear as a triplet between δ 0.76 - 0.66. 
 
 
                                                                                                       64–99 
 
Figure 2.14: Typical chemical shifts observed for N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters and the 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters (64–99). 
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In the 
13
C NMR spectra of N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide 
esters
 
and their 1-alkyl-1’ derivatives (64-99), the typical carbon signals (figure 2.15) 
observed include the presence of carbonyl carbons between δ 172.7 and δ 166.0. The 
carbon atoms on the benzyol linker appear between δ 145 and δ 125 for both classes. 
The methylene and methyl carbon atoms of the ethyl ester (-OCH2CH3) present in both 
classes of compounds appear between δ 64.0 - 60.0, whilst the methyl carbon appears 
between δ 14.5 - 14.0. These typical carbon signals do not show any significant 
difference in the chemical shift between the two classes of compounds.  
However, for the N-(ferrocenyl) benzoyl derivatives, four unique carbon signals are 
observed for a monosubstituted cyclopentadiene ring. The ipso carbon (η5-C5H4-
benzoyl) appears between δ 84.3 - 80.0 and the remaining three unique carbon signals 
on the monosubstituted ring appear between δ 70.5 - 68.5.  
For the 1-alkyl-1’ derivatives, six unique carbon signals are observed for the 
disubstituted ferrocene moiety; two ipso carbons are present, which can be easily 
identified as a difference between the two classes of compounds. The ipso carbon (η5-
C5H4-benzoyl) appears between δ 84.3 - 80.0, whilst the ipso carbon (η
5
-C5H4-alkyl) 
appears between δ 95.3 - 88.0. The remaining four unique carbons on the disubstituted 
cyclopentadiene rings appear between δ 72.0 - 66.0.  
The main difference between the two classes of compounds is the presence of the alkyl 
moieties attached on the cyclopentadiene ring. These alkyl moieties give rise to distinct 
carbon signals which can be easily identified from the 
13
C and DEPT-135 spectra of 
compounds 64-99, which are absent in the N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters.
[3-7]
  
The carbon atom of the methyl group (-CH3) appears between δ 14.0 - 13.2. The 
methylene carbon atoms of the ethyl group (-CH2CH3) appear between δ 24.0 - 20.5, 
whilst the methyl carbon atoms (-CH2CH3) appear between δ 14.0 - 13.8. The two 
methylene carbon atoms of the propyl group (-CH2CH2CH3) appear between δ 36.8 - 
30.0 and between δ 24.0 - 20.5 respectively. The methyl group of the propyl group (-
CH2CH2CH3) appears between δ 14.0 - 13.0.  
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                                                                                               64–99 
Figure 2.16: Typical chemical shifts observed for N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters and the 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters 64–99. 
 
2.12 Conclusion  
 
A series of 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide 
esters 64–99 were prepared and structurally characterized. Each novel compound 
contains an electroactive alkylated ferrocene core,  a conjugated aromatic linker and a 
dipeptide chain  These novel compounds were characterized by a combination of 
1
H 
NMR, 
13
C NMR, DEPT-135 and 
1
H-
13
C COSY (HMQC) spectroscopy, electrospray 
ionization mass spectrometry (ESI-MS). 
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Chapter 3:  Biological evaluation of 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters 
 
3.1 Introduction 
 
Chemotherapy plays a significant role in the control of metastatic cancers that can not 
be cured by surgery. However, cancer is associated with poor prognosis and an increase 
in drug resistance to existing chemotherapy treatments.
[1]
 Hence, there is an urgent need 
for new anticancer therapies. The development of the resistance to a particular or a 
combination of unrelated cancer drugs is a major impediment in the treatment of 
cancer.
[2]
 This multiple drug resistance (MDR) is a result of a variety of changes in the 
cell which result in the increased activity of drug pumps like P-glycoprotein (Pgp) 
which expel the chemotherapeutics out of the cancer cells.
[2] 
In cancer cells there is a 
accumulation of high concentrations of hydrogen peroxide due to the over expression 
of superoxide dismutase (SOD) that transforms superoxide ions into hydrogen 
peroxide.
[3]
 Ferrocene based compounds reported in the literature are well know to 
exploit the overproduction of hydrogen peroxide in cancer cells to produce hydroxyl 
radicals (•OH) which cause oxidative DNA damage.  
In previous studies carried out to evaluate the in vitro anticancer activity of N-para, N-
meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters (figure 3.1) in non small cell 
lung cancer cell line, H1299, the general trend in cytotoxicity was para < ortho < meta. 
The dipeptide derivative N-{ortho-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester 
was shown to have an IC50 value of 5.3 ± 1.23 µM. The N-{para-(ferrocenyl) benzoyl} 
glycine L-alanine ethyl ester and the N-{meta-(ferrocenyl) benzoyl} glycine L-alanine 
ethyl ester had IC50 values of 6.6 ±  1.03 µM and 4.0 ± 0.71 µM respectively.
[3-7]
   
In a further SAR study a series of 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters were synthesised, structurally characterised and biologically 
evaluated. In total, 36 compounds were tested for their anti-proliferative effect on the 
non small cell lung cancer cell line, H1299. These novel derivatives differ from the N-
para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters by having an alkyl 
moiety on the previously unsubstituted ferrocene ring. 
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alkyl moiety (R) = CH3;  CH2CH3; CH2CH2CH3 
R’ = H; CH3; C4H9; C7H7 
 
Figure 3.1: General structure of the N-para, N-meta and N-ortho-(ferrocenyl) benzoyl 
dipeptide esters and the 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl 
dipeptide esters.  
 
3.2 In vitro anti-cancer activity of 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters   
 
The in vitro cytotoxicity of the 1-alkyl-1’ derivatives 64–99 were evaluated by 
performing a comprehensive screen of every compound at a single dose (10 μM) in the 
H1299 cell line and the endpoint of the growth inhibition was evaluated by the acid 
phosphatase assay.
[7] 
The screening of the compounds was performed in collaboration with 
Dr. Norma O’Donovan and James Murphy of the National Institute for Cellular 
Biotechnology (NICB), Dublin City University. The comprehensive screen was performed 
in triplicate by treating individual wells of a 96-well plate containing H1299 cells with a 
10 μM solution of each test compound prepared in DMSO. A reference control N-meta-
(ferrocenyl) benzoyl glycine L-alanine ethyl ester (28), a DMSO control and a control 
for normal (untreated) cell growth were included in the assays. The cells were then 
incubated for 5 days, until cell confluency was reached. At this point, cell survival was 
established through determination of the acid phosphatase activity of surviving cells.  
In the acid phosphatase assay, a solution of the p-nitrophenyl phosphate substrate is 
added at the end-point of the assay. This substrate is dephosphorylated by the acid 
phosphatase enzyme, which is located in the lysosomes of cells, to yield  
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p-nitrophenol.
[8]
 In the presence of strong alkali, the p-nitrophenol chromophore can be 
quantified by measuring the absorbance at 405 nm (figure 3.2).  
 
 
Figure 3.2 Acid phosphatase end-point assay: (i) Phosphatase catalysed reaction (in 
water); (ii) Colour reaction in strong base (NaOH). 
 
This colorimetric end-point assay is an indirect measure of cytotoxicity which evaluates 
the enzyme activity of cells after a given treatment period. The results of the 
comprehensive screens are expressed as the percentage growth inhibition ± standard 
deviation (relative to the DMSO controls). Standard deviations have been calculated using 
data obtained from three independent experiments.  The results for the preliminary screen 
of compounds 64–99 are depicted in figures 3.3-3.5.  
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Alkyl Benzoyl 
 
 
 
 
 
Dipeptide ethyl 
ester 
Compound 
 No. 
% growth 
inhibition at 10 µM 
 
 
 
-CH3 
 
Gly Gly(OEt) 64           83 ± 4.35 
Gly L-Ala(OEt) 65  83 ± 0.97 
Gly L-Leu(OEt) 66 28 ± 1.57 
Gly L-Phe(OEt)  67 20 ± 2.86 
 
Gly Gly(OEt) 68 84 ± 3.80 
Gly L-Ala(OEt) 69 84 ± 1.26 
Gly L-Leu(OEt) 70 41 ± 1.01 
Gly L-Phe(OEt)  71 20 ± 2.92 
 
Gly Gly(OEt) 72 38 ± 2.40 
Gly L-Ala(OEt) 73 48 ± 1.48 
Gly L-Leu(OEt) 74 28 ± 2.61 
Gly L-Phe(OEt)  75 20 ± 3.68 
No alkyl chain 
incorporation  
     
Gly L-Ala(OEt) 
 
 
 
 
              28* 83 ± 0.87 
 
 
Note: 28* Originally prepared by Alan Corry 
[7]
 
 
Figure 3.3: % Growth inhibition at 10 µM on H1299 lung cancer cells for 1-methyl-
1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters 64–75 and 
reference compound 28.  
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Alkyl Benzoyl 
 
 
 
 
 
Dipeptide ethyl 
ester 
Compound 
 no. 
% growth 
inhibition at 
10 µM 
 
 
 
 
-CH2CH3 
 
Gly Gly(OEt) 76 83 ± 1.48 
Gly L-Ala(OEt) 77 84 ± 2.32 
Gly L-Leu(OEt) 78 34 ± 1.55 
Gly L-Phe(OEt)  79 19 ± 3.62 
 
Gly Gly(OEt) 80 70 ± 2.61 
Gly L-Ala(OEt) 81 73 ± 1.65 
Gly L-Leu(OEt) 82 43 ± 0.76 
Gly L-Phe(OEt)  83 30 ± 2.42 
 
Gly Gly(OEt) 84 34 ± 1.94 
Gly L-Ala(OEt) 85 46 ± 1.79 
Gly L-Leu(OEt) 86 20 ± 2.47 
Gly L-Phe(OEt)  87 17 ± 1.33 
No alkyl chain 
incorporation  
     
Gly L-Ala(OEt) 
 
 
 
 
28* 83 ± 0.87 
 
 
Note: 28* Originally prepared by Alan Corry 
[7]
 
 
Figure 3.4: % Growth inhibition at 10 µM on H1299 lung cancer cells for 1-ethyl-1’-
N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters 76-87 and reference 
compound 28.  
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Alkyl Benzoyl 
 
 
 
 
 
Dipeptide ethyl 
ester 
Compound 
 No. 
% growth 
inhibition at 
10 µM 
 
 
 
 
-CH2CH2CH3 
 
Gly Gly(OEt) 88 76 ± 3.42 
Gly L-Ala(OEt) 89 80 ± 4.50 
Gly L-Leu(OEt) 90 55 ± 1.91 
Gly L-Phe(OEt)  91 34 ± 2.50 
 
Gly Gly(OEt) 92 76 ± 3.12 
Gly L-Ala(OEt) 93 80 ± 4.07 
Gly L-Leu(OEt) 94 55 ± 0.91 
Gly L-Phe(OEt)  95 28 ± 2.32 
 
Gly Gly(OEt) 96 32 ± 1.56 
Gly L-Ala(OEt) 97 38 ± 0.58 
Gly L-Leu(OEt) 98 20 ± 2.57 
Gly L-Phe(OEt)  99 14 ± 3.43 
No alkyl chain 
incorporation 
     
Gly L-Ala(OEt) 
 
 
 
 
              28* 83 ± 0.87 
 
 
Note: 28* Originally prepared by Alan Corry 
[7]
 
 
Figure 3.5: % Growth inhibition at 10 µM on H1299 lung cancer cells for 1-propyl-1’-
N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters 88-99 and reference 
compound 28.  
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From the preliminary screen at 10 μM a general trend can be observed, the 1-alkyl-1’- 
N-ortho- derivatives exhibited lower percentage growth inhibition values compared to 
the meta and para derivatives for the dipeptides employed in the SAR study. For 
instance, the 1-methyl-1’-N-{ortho-(ferrocenyl) benzoyl} glycine glycine ethyl ester 72 
showed a percentage growth inhibition value of 38 ± 2.40 whilst the 1-methyl-1’-N-
para and meta-(ferrocenyl) benzoyl} glycine glycine ethyl ester (64 and 68) showed 
percentage growth inhibition values of 84 ± 4.35 and 83 ± 2.86 respectively. The ortho 
derivatives were not investigated further.  
A general trend was also observed in these compounds, that is, the Gly Gly (OEt) and 
Gly L-Ala (OEt) derivatives are more active than the Gly L-Leu and Gly L-Phe ethyl 
esters which display percentage growth inhibition values ≤ 55 %. For instance the  
1-ethyl-1’-N-{para-(ferrocenyl) benzoyl} glycine glycine ethyl ester and glycine L-
alanine ethyl ester displayed percentage growth inhibition values of 83 % ± 1.48 and 84 
% ± 2.32 respectively, whilst the Gly L-Leu(OEt) and Gly L-Phe(OEt) displayed 
percentage growth inhibition values of 34 % ± 1.55 and 19 % ± 3.62 respectively. Thus, 
the Gly L-Leu and Gly L-Phe ethyl ester derivatives were not investigated further. As a 
result, it can be concluded that when chiral α-amino acids with bulky side chains are 
used as the second amino acid in the dipeptide moiety a loss of anti-proliferative 
activity is observed. 
For the 1-alkyl-1’-N-para, N-meta-(ferrocenyl) benzoyl dipeptide esters, 12 lead 
compounds were identified which showed percentage growth inhibition values ≥ 70 % 
and therefore, IC50 values were determined for these compounds. 
 
3.3 IC50 value determination 
 
To determine the IC50 values of the 12 target compounds, individual 96-well plates 
containing H1299 cells were treated with the test compounds at concentrations ranging 
from 0.1 μM to 100 μM. The cells were then incubated for 5-6 days, until cell 
confluency was reached. Cell survival was determined by performing the acid 
phosphatase assay. The IC50 value for each compound was calculated using Calcusyn 
software, and standard deviations have been calculated using data obtained from three 
independent experiments. The values obtained are listed in table 3.1 and figure 3.6.  
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Table 3.1. IC50 values for selected compounds, carboplatin and cisplatin against human 
lung carcinoma cell line H1299. 
Compound Name                                                                                                                            No.          IC50 
Cisplatin 
 
 
8 1.5 ± 0.10 
Carboplatin 
 
N- {meta-(ferrocenyl)-benzoyl} Gly L-Ala(OEt)   
 
 
9 
 
  28* 
 
10 ± 1.60 
 
4.0 ± 0.71 
 
1-methyl- 1’ -N- {para-(ferrocenyl)-benzoyl} Gly Gly(OEt)   
 
64 
 
2.8 ± 1.23 
 
1-methyl-1’ –N- {para-(ferrocenyl)-benzoyl} Gly L-Ala(OEt) 
 
65 4.5 ± 0.40 
 
1-methyl-1’ –N- {meta-(ferrocenyl)-benzoyl} Gly Gly(OEt) 
 
68 2.6 ± 0.62 
 
1-methyl- 1’ -N- {meta-(ferrocenyl)-benzoyl} Gly L-Ala(OEt) 
 
69 6.7 ± 0.31 
 
1-ethyl- 1’ -N- {para-(ferrocenyl)-benzoyl} Gly Gly(OEt)  
 
76 
 
3.5 ± 0.82 
 
1-ethyl-1’ –N- {para-(ferrocenyl)-benzoyl} Gly L-Ala(OEt) 
 
77 5.6 ±1.63 
 
1-ethyl- 1’ -N- {meta-(ferrocenyl)-benzoyl} Gly Gly(OEt) 
 
80 6.1 ± 1.09 
 
1-ethyl- 1’ -N- {meta-(ferrocenyl)-benzoyl} Gly L-Ala(OEt) 
 
81 13.3 ± 1.10 
 
1-propyl-1’ –N- {para-(ferrocenyl)-benzoyl} Gly Gly(OEt)   
 
88 5.4 ±1.21 
 
1-propyl- 1’ -N- {para-(ferrocenyl)-benzoyl}Gly L-Ala(OEt) 
 
89 6.6 ± 2.10 
 
1-propyl- 1’ -N- {meta-(ferrocenyl)-benzoyl} Gly Gly(OEt)   
 
92 11.3 ± 2.10 
 
1-propyl- 1’ -N- {meta-(ferrocenyl)-benzoyl} Gly L-Ala(OEt)   
 
93 20.1 ± 2.46 
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Figure 3.6: IC50 plot for selected compounds in the H1299 cell line. 
 
From the IC50 values (Table 3.1) of the 1-alkyl-1’-N-para, N-meta -(ferrocenyl) 
benzoyl Gly Gly and Gly L-Ala ethyl esters 64, 65, 68, 69, 76, 77, 80, 81, 88, 89, 92 
and 93, it can be seen that the cytotoxicity of the derivatives decreases with the increase 
of the size of the alkyl moiety incorporated (propyl < ethyl < methyl). Indeed, all the 
methyl and ethyl derivatives display IC50 values that are lower than 14 µM. The in vitro 
cytotoxicity of the platinum (II) based anticancer drug carboplatin was also evaluated 
against the H1299 cell line and was found to have an IC50 value of 10.0 ± 1.60 µM 
(Table 3.1). Thus, compounds 64, 65, 68, 69, 76, 77, 80, 88 and 89 are more cytotoxic 
in vitro than the clinically employed anticancer drug carboplatin. In addition, the 1-
methyl-1’-N-{para-(ferrocenyl) benzoyl} glycine glycine ethyl ester 64 displays an 
IC50 value of 2.8 ± 1.23 µM,  the 1-ethyl-1’–N-{para-(ferrocenyl) benzoyl} glycine 
glycine ethyl  ester 76 displays an IC50 value of 3.5 ± 0.82 µM and the 1-methyl- 1’ -N- 
{meta-(ferrocenyl)-benzoyl} glycine glycine ethyl ester 68 shows an IC50 value of 2.6 ± 
0.62 µM. These compounds display improved bioactivity in comparison to the most 
active ferrocenyl benzoyl analogues, the N-{meta-(ferrocenyl) benzoyl} glycine L-
alanine ethyl ester 28 which displayed an IC50 values of 4.0 ± 0.71 µM.
[6]
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From these results incorporation of methyl and ethyl alkyl groups results in an 
improved cytotoxicity of the para derivatives of the glycine glycine ethyl esters and an 
improved cytotoxicity of the methyl meta glycine glycine derivative. However, when 
the size of the chain length increased to ethyl, the 1-ethyl-1’-N-{meta-(ferrocenyl)-
benzoyl} glycine L-alanine ethyl ester displayed an IC50 of 13.3 ± 1.10 µM. This IC50 
value was ca. three times higher than the unsubstituted analogue.
[6]
 Thus, the increase 
in alkyl chain length resulted in a drastic decrease in the cytotoxicity of the 1-alkyl-1’-
N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters. Although 
compounds 64 and 68 are the most active derivatives of the 1-alkyl-1’-N-para, N-meta 
and N-ortho-(ferrocenyl) benzoyl dipeptide esters, they are less active compared to 
cisplatin which displays an IC50 value of 1.5 ± 0.10 µM against human H1299 lung 
cancer cells. 
It was previously shown that the N-(6-ferrocenyl-2-naphthoyl) glycine glycine ethyl 
ester 31, induced DNA damage through the generation of •OH radicals via a Fenton-
type reaction.
[9]
 In the Fenton-type reaction, the ferrocene moiety of the ferrocenyl 
bioconjugates is oxidised to a higher oxidised state, by donating an electron to a hydrogen 
peroxide species, which results in the formation of a hydroxyl radical and a hydroxyl ion 
(scheme 3.1).
[9]
 
 
                         31 
 
Scheme 3.1: Fenton reaction generation of .OH radical species. 
 
The hydroxyl radical (HO
•
) generated oxidises guanine to oxo-8-guanine (scheme 3.2), 
thus altering the base pairing sequence to Adenine which results in DNA damage 
leading to cell apoptosis.
[9]
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        Guanine                                                                                              oxo-8-guanine 
 
Scheme 3.2: Oxidation of guanine to oxo-8-guanine. 
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3.4 Conclusions  
 
Cytotoxicity of the 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl 
dipeptide esters, decreases with the increase of the size of the alkyl group incorporated 
(propyl < ethyl < methyl) on the ferrocene moiety. All the methyl and ethyl derivatives 
have IC50 values that are lower than 14 µM. The order of the amino acids in the 
dipeptide chain is crucial for activity, the trend being Gly Gly > Gly L-Ala > Gly L-Leu 
> Gly L-Phe. The most active derivatives of the 1-alkyl-1’-N-para, N-meta and N-
ortho-(ferrocenyl) benzoyl dipeptide esters are the 1-methyl-1’-N-{para-(ferrocenyl) 
benzoyl} glycine glycine ethyl ester 64 and the 1-methyl-1’-N-{meta-(ferrocenyl) 
benzoyl} glycine glycine ethyl ester 68 which display IC50 values of 2.8 ± 1.23 µM and 
2.6 ± 0.62  µM respectively. These compounds are more active than carboplatin but are 
less effective against cisplatin which are clinically employed anticancer drugs. 
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Chapter 4: Synthesis and structural characterisation of N-{para-(ferrocenyl)    
ethynyl benzoyl}, N-{6-(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) 
ethynyl-2-furanoyl} amino acid and dipeptide esters 
 
 
 4.1 Introduction 
 
To date we have shown that the replacement of the conjugated linker of N-(ferrocenyl) 
benzoyl dipeptide esters with a naphthoyl linker leads to an improvement in 
antiproliferative effect in the non small cell lung cancer (NSCLC) cell line, H1299.
[1-3] 
From the series of N-(ferrocenyl) naphthoyl amino acid and dipeptide ethyl esters 
reported, the N-{6-(ferrocenyl)-2-napthoyl} glycine glycine ethyl ester 31 displayed an 
IC50 value of 0.13 ± 0.01 µM in the H1299 lung cancer cell  line.
[3]
  
From the promising results obtained from the 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters 64–99. It has been clearly demonstrated in the 
SAR study of the 1-alkyl-1’ derivatives that employing the incorporation of a methyl 
derivative to the unsubstituted cyclopentadiene ring enhances the anti-proliferative 
effect of the ferrocenyl dipeptide bioconjugates relative to the N-(ferrocenyl) benzoyl 
dipeptide derivatives in the H1299 lung cancer cell line.
[4-8]
 The most active derivative 
was the 1-methyl-1’-N-{meta-(ferrocenyl) benzoyl} glycine glycine ethyl ester 68 
which displayed an IC50 values of 2.6 ± 0.62 µM.  
In a continuation to this SAR study in search for novel compounds with increased anti-
proliferative effect, a new library of ferrocenyl based bioconjugates 105-138, which 
consist of four key moieties (figure 4.1): 
 
(i) An electroactive core  
(ii) An ethynyl moiety  
(iii) Three different aromatic linkers  
(iv)  A series of amino acid and dipeptide esters  
 
This SAR study involves the biological evaluation of the incorporation of an ethynyl 
moiety between the ferrocene moiety and the conjugate linker. Furthermore, the 
incorporation of L-leucine and L-phenylalanine into the dipeptide chains have been 
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shown in the preliminary screen of the 1-alkyl-1’ derivatives (64-69) (section 3.2)  to 
display low percentage growth inhibition values in H1299 lung cancer cell line. The 
dipeptides and the amino acid employed were Glycine Glycine (Gly Gly), Glycine L-
Alanine (Gly L-Ala), Glycine D-Alanine (Gly D-Ala), Sarcosine Glycine (Sar Gly), 
Sarcosine L-Alanine (Sar L-Ala), L-Proline L-Alanine (L-Pro L-Ala), L-Proline 
Glycine (L-Pro Gly), Glycine L-Leucine (Gly L-Leu) and Glycine L-Phenylalanine 
(Gly L-Phe) and γ-aminobutyric acid (GABA). 
 
                                                                          
Figure 4.1: General structure of the N-(ferrocenyl) benzoyl and naphthoyl 
bioconjugates and N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) ethynyl-2-
naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} amino acid and dipeptide esters. 
 
The synthesis of the new ferrocenyl conjugates involved Sonogashira coupling of an 
ethynyl ferrocene to three bromo acylated acids to generate para-(ferrocenyl) ethynyl 
benzoic acid, naphthoic acid and 2-furanoic acid. A series of amino acid and dipeptide 
esters were coupled to the N-(ferrocenyl) ethynyl acids generating new classes of 
compounds, which were characterized by a combination of 
1
H NMR, 
13
C NMR,  
DEPT-135, 
1
H-
13
C COSY spectroscopy and electrospray ionization mass spectrometry.  
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4.2 Synthesis of ethynyl ferrocene 101 
 
 
       49                                             100                                                      101 
Scheme 4.1: Synthesis of ethynyl ferrocene. 
 
The synthesis of ethynyl ferrocene is well document in the literature.
[9-10]
 Despite being 
commercially available, it is expensive to purchase for use on a large scale. Rosenblum 
et al. have reported the synthesis of ethynyl ferrocene which was prepared via 
formation of (2-formyl-1-chlorovinyl) ferrocene from acetyl ferrocene using N,N-
dimethylformamide and phosphorus oxychloride.
[10]
 Dehalogenation of (2-formyl-1-
chlorovinyl) ferrocene using 1M sodium hydroxide yields ethynyl ferrocene as shown 
in scheme 4.1. The yields obtained from this synthetic protocol are high, but it requires 
aggressive reagents like POCl3; however, this was the protocol chosen to synthesis 
ethynyl ferrocene.  
 
4.2.1 Synthesis of (2-formyl-l-chlorovinyl) ferrocene intermediate 
 
           49                                         100 
Scheme 4.2: Synthesis of (2-formyl-l-chlorovinyl) ferrocene intermediate. 
 
The treatment of a ketone with Vilsmeir reagent leads generally to the formation of 
halovinyl aldehydes and it is referred to as a Vilsmeir haloformylation. For a Vilsmeir 
haloformylation to occur it requires a ketone that can undergo enolisation that is 
(scheme 4.3). 
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Scheme 4.3: Enolisation of ketone.  
 
The treatment of acetylferrocene with a Vilsmeir reagent, prepared by the reaction of 
phosphorus oxychloride in N,N-dimethylformamide as reported by Rosenblum et al., 
leads to the formation of a mixture of (2-formyl-1-chlorovinyl) ferrocene and a 
unwanted unstable (1-chlorovinyl)ferrocene (scheme 4.2. In continuation of this work, 
Polin et al. have shown that the formation of (1-chlorovinyl) ferrocene can be 
suppressed by using excess phosphorus oxychloride, N,N-dimethylformamide and solid 
sodium acetate.
[11]
 From numerous reactions carried out, it was observed that if the 
Vilsmeir reagent was added over 2 hr as opposed to 30 min as reported by Polin et al., 
it favoured the formation of (2-formyl-l-chlorovinyl) ferrocene.  In the mechanism for 
the formation of (2-formyl-l-ch1orovinyl) ferrocene the initial step is the formation of 
the Vilsmeir reagent (i) in scheme 4.4. Once the Vilsmeir reagent (i) is formed it reacts 
with the enolised ketone (ii) to form a β – N-N- dimethylaminovinyl ketone (iii) 
(scheme 4.4). 
 
 
Scheme 4.4: Formation of β – N-N- dimethylaminovinyl ketone (iii). 
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The β – N-N- dimethylaminovinyl ketone (iii) further reacts with a Vilsmeir reagent to 
give rise to a bisiminium chloride (iv). This intermediate is liable and undergoes 
nucleophillic substitution with a chloride ion to give rise to the iminium intermediate 
(v). Base hydrolysis of the intermediate (v) with sodium acetate gives rise to (2-formyl-
l-ch1orovinyl) (vi) as outlined in scheme 4.5.
[11]
 
 
 
Scheme 4.5: Formation of (2-formyl-l-ch1orovinyl) ferrocene. 
 
In the synthesis of (2-formyl-l-ch1orovinyl) ferrocene via Vilsmeier haloformylation 
the spectral data obtained for the isolated (2-formyl-l-ch1orovinyl) ferrocene was in 
agreement with that reported previously for this compound and a yield greater than 
60% was obtained.
[11]
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4.2.2 Dehalogenation of (2-formyl-l-ch1orovinyl) ferrocene to obtain 
ethynylferrocene 
 
100                                                   101 
Scheme 4.6: Dehalogenation of (2-formyl-l-ch1orovinyl) ferrocene to obtain 
ethynylferrocene.  
 
In the base induced dehalogenation of (2-formyl-l-ch1orovinyl) ferrocene to obtain 
ethynylferrocene according to Polin et al., initial attempts were not successful as the 
reaction required anhydrous conditions which could not have been attained. As a result 
an alternative pathway had to be established which did not require adverse anhydrous 
conditions. By using potassium tert-butoxide as an alternative base in dry THF at 0 
o
C 
resulted in the dehalogenation of (2-formyl-l-ch1orovinyl) ferrocene to 
ethynylferrocene with yields greater than 45%.  
 
4.3 Synthesis of para-(ferrocenyl) ethynyl benzoic acid, 6-(ferrocenyl) ethynyl-2-
naphthoic acid and 5-(ferrocenyl) ethynyl-2-furanoic acid via Sonogashira cross 
coupling reaction 
 
(i) TEA, PPh3, Bis(triphenylphosphine)palladium(II) dichloride, THF, Cu(I) 
 
Scheme 4.7: Synthesis of para-(ferrocenyl) ethynyl benzoic acid 102, 6-(ferrocenyl) 
ethynyl-2-naphthoic acid 103 and 5-(ferrocenyl) ethynyl-2-furanoic acid 104 via 
Sonogashira cross coupling reaction.  
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The Sonogashira cross coupling reaction is a transition metal-catalysed cross-coupling 
reaction used in organic synthesis to form carbon-carbon bonds.
[13]
 The coupling 
reaction involves the use of a palladium catalyst, a copper (I) iodine co-catalyst and an 
amine base to form a carbon–carbon bond between a terminal alkyne and an aryl halide. 
Sonogashira cross-coupling of an ethynyl ferrocene to the three bromo acylated acids 
was employed to generate para-(ferrocenyl) ethynyl benzoic acid 102, 6-(ferrocenyl) 
ethynyl-2-naphthoic acid 103 and 5-(ferrocenyl) ethynyl-2-furanoic acid 104 in yields 
greater than 60%. These high yields are largely due to the fact that the Sonogashira 
cross coupling reaction is a substrate specific reaction between an alkyne and an aryl 
halides. The mechanism for the Sonogashira cross coupling consist of two catalytic 
cycles namely a palladium cycle and a copper cycle as shown in scheme 4.8.[14] 
To enhance the formation of activation of bis(triphenylphosphine)palladium(II) 
dichloride, anhydrous conditions are required. It was observed that the incorporation of 
triphenylphosphine enhances Sonogashira reaction because it is oxidised by any oxygen 
in the reaction vessel to triphenylphosphine oxide which enhances the reduction of the 
Pd (II) catalyst to its active form Pd (0).
[15]
 
In the palladium catalytic cycle the active palladium catalyst Pd (0) reacts with the aryl 
bromide in an oxidative addition to form a Pd (ll) intermediate complex (i). The 
generated complex (i) reacts in a transmetallation reaction with the copper acetylide, 
which is produced in the copper catalytic cycle to give rise to complex (ii). In complex 
(ii) both organic ligands are trans-oriented. The ligands undergo a trans-cis 
isomerisation to produce complex (iii). In the final step of the catalytic cycle complex 
(iii) undergoes reductive elimination to produce the required compounds (iv) with 
regeneration of the palladium catalyst.
[15]
 
In the copper catalytic cycle the ethynylferrocene reacts with the copper (I) iodine in 
the presence of triethylamine to produce a copper (I) acetylide, which acts as an 
activated species for the coupling reactions hence the copper (I) iodine acts as a co-
catalyst to increase the rate of the Sonogashira cross-coupling reaction.  
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Scheme 4.8: Catalytic cycles in the Sonogashira coupling reaction.  
 
4.4 Synthesis of N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) ethynyl-
2-naphthoyl}, N-{5-ferrocenyl ethynyl-2-furanoyl} amino acid and dipeptide esters 
 
The synthesis of N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) ethynyl-2-
naphthoyl}, N-{5-ferrocenyl ethynyl-2-furanoyl} amino acid and dipeptide esters was 
carried by coupling of the dipeptide ethyl and methyl ester hydrochloride salts of  
Gly Gly, Gly L-Ala, Gly D-Ala, Gly L-Leu and Gly L-Phe, Sar Gly, Sar L-Ala, L-Pro 
L-Ala, L-Pro Gly and the amino acid GABA,  to N-para-(ferrocenyl) ethynyl benzoic 
acid, N-6-(ferrocenyl) ethynyl-2-naphthoic acid and N-5-(ferrocenyl) ethynyl-2-
furanoic acid using the N-(3-dimethylaminopropyl)-N’-ethylcarbodiimidehydrochloride 
(EDC), 1-hydroxybenzotriazole (HOBt) protocol as shown in scheme 4.9. The 
synthesised pure ethynyl derivatives 105-138 was furnished as either an orange solid or 
a red oil with yields of 8-38%. All compounds gave spectroscopic and analytical data in 
accordance with their proposed structures. 
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(i) EDC, HOBt, triethylamine, dipeptide ethyl esters and free N-terminal γ-
Amino butyric acid esters 
 
R
1
 R
2
 Compound no. 
 
 
 
 
Gly Gly(OMe) 105 
GlyGly(OEt) 106 
Gly L-Ala(OMe) 107 
Gly L-Ala(OEt)  108 
Gly D-Ala(OMe) 109 
Gly D-Ala(OEt)   110 
GABA(OMe) 111 
GABA(OEt)   112 
Gly L-Phe(OEt)   113 
Gly L-Leu(OEt)   114 
Sar Gly(OEt) 115 
Sar Gly(OMe)  116 
Sar L-Ala(OEt)   117 
L-Pro Gly(OEt)   118 
L-Pro L-Ala(Oet)   119 
 
Gly Gly(OEt)   120 
Gly L-Ala(OEt) 121 
Sar L-Ala(OEt)   122 
L-Pro Gly(OEt) 123 
GABA(OEt)   124 
 L-Pro L-Ala(Oet) 125 
Gly L-Leu(OEt) 126 
Sar Gly(OEt) 127 
Gly L-Phe(OEt) 128 
 
 
Gly Gly(OEt) 129 
Gly L-Ala(OEt) 130 
Gly D-Ala(OEt) 131 
Gly L-Phe(OEt) 132 
Gly L-Leu(OEt) 133 
Sar Gly(OEt) 134 
L-Pro Gly(OEt) 135 
L-Pro L-ala(OEt)   136 
Sar L-ala(OEt) 137 
GABA(OEt) 138 
   
Scheme 4.9: Synthesis of N-{para-(ferrocenyl) ethynyl benzoyl} amino acid and 
dipeptide esters 105-138. 
 102 
The carbodiimide-mediated coupling reaction follows the mechanism depicted 
in scheme 2.12 for the synthesis of 1-alkyl-1 derivatives. The yields for the 34 
compounds prepared varied from 8-38%. The reasons for the low yields for the 
compounds 105-138 are similar to those outlined in section 2.4. The low yields can also 
be rationalized by considering the respective orientations of the terminal amine moiety 
on the dipeptide amino acid and ethyl esters. Generally 1
o
 amines are more reactive 
than 2
o
 amines and more reactive than 3
o
 tertiary. Thus in the EDC/HOBt coupling 
reactions when 1
o
 amine dipeptide amino acid and ethyl esters {GABA(OEt), Gly 
Gly(OEt) and Gly L-Ala(OEt)} are used, the yields are generally higher than the 2
o
 
amines dipeptide ethyl esters [Sar Gly(OEt), Sar L-Ala(OEt), L-Pro Gly(OEt) and L-Pro 
L-Ala(OEt)]. For instances the N-{6-(ferrocenyl) ethynyl-2-naphthoyl} glycine glycine 
ethyl ester (120) displayed a percentage yield of 32% whilst the N-{6-(ferrocenyl) 
ethynyl-2-naphthoyl} sarcosine glycine ethyl ester (127) had a percentage yield of 13%. 
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4.5 
1
H NMR spectroscopic studies of N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-
(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} 
amino acid and dipeptide esters  
 
 
4.5.1 
1
H NMR spectroscopic studies of N-{para-(ferrocenyl) ethynyl benzoyl} 
amino acid and dipeptide esters  
 
In CDCl3, typical chemical shifts observed for the N-{para-(ferrocenyl) ethynyl 
benzoyl} amino acid and dipeptide esters (figure 4.2) include the appearance of amide 
protons and four aromatic hydrogens on the benzoyl spacer between δ 8.90 and δ 6.50. 
In the 
1
H NMR spectra of the Sar Gly, Sar L-Ala, L-Pro Gly and L-Pro L-Ala dipeptide 
derivatives, the amide protons and the aromatic hydrogens on the benzoyl spacer 
overlap, resulting in multiplets being observed between δ 8.90 and δ 6.50.   
For the Gly Gly, Gly L-Ala and Gly L-Leu derivatives the splitting pattern of the 
hydrogens on the benzoyl linker follows the second order splitting pattern, which is 
consistent with the alkyl derivatives described in section 2.5 and do not overlap with 
the amide proton signals. 
The protons on the monosubstituted ferrocene ring in the N-{para-(ferrocenyl) ethynyl 
benzoyl derivatives, are expected to occur as three signals between δ 4.70 and δ 4.00.  
However, these signals usually overlap with the hydrogen signals of either the 
methylene groups or the methine groups that may be present in the amino acid and 
dipeptide esters. In the Gly L-Ala derivative (108) no overlapping is observed, hence, 
the ortho and meta protons on the cyclopentadiene ring attached to the ethynyl spacer 
(η5-C5H4-C≡C-) appear as two apparent triplet signals. This complexity of the 
appearance of the apparent singlet or triplet signals has already been discussed in 
section 2.5. The protons on the unsubstituted cyclopentadiene ring appear as a singlet as 
all the hydrogens are magnetically equivalent. The methyl protons (-OCH2CH3) of the 
ethyl ester derivatives appear as a triplet between δ 1.30 and δ 1.15. The methyl protons 
(-OCH3) of the methyl derivatives appear as a singlet between δ 3.70 and δ 3.60. 
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Figure 4.2: Typical chemical shifts observed for the N-{para-(ferrocenyl) ethynyl 
benzoyl} amino acid and dipeptide esters 105-119. 
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4.5.1.1 
1
H NMR spectroscopic studies of N-{para-(ferrocenyl) ethynyl benzoyl} 
glycine D-alanine methyl ester 109 
 
 
109 
 
The 
1
H NMR spectrum of compound 109 is shown in figure 4.3. The four aromatic 
protons present at δ 7.73 and δ 7.46 appear as two apparent doublet signals with a 
coupling constant of 8.4 Hz. The two amide protons (-CONH-) present at δ 7.25 and δ 
7.07 are observed as a triplet and a doublet with constants of 5.6 Hz and 6.8 Hz 
respectively. The methine group -CH(CH3) appears as a multiplet between δ 4.55 and δ 
4.50. The ortho protons (η5-C5H4-C≡C-) on the cyclopentadiene ring attached to the (-
C≡C-) spacer moiety appears as an apparent triplet at δ 4.45 whilst the meta protons 
(η5-C5H4-C≡C-) overlap with the protons on the unsubstituted (η
5
-C5H5) ring, the 
methylene protons of (-NHCH2CO-), resulting in a multiplet appearing between δ 4.21 
and δ 4.14 with an overall intergration of nine. The methyl group of the methyl ester (-
OCH3) is present as a singlet at δ 3.68. The methyl group (-CHCH3) on the alanine 
moiety appears as a doublet at δ 1.38 with a coupling constant of 7.2 Hz. 
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Figure 4.3: 
1
H NMR spectrum of N-{para-(ferrocenyl) ethynyl benzoyl} glycine D-
alanine methyl ester 109. 
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4.5.2 
1
H NMR spectroscopic studies of N-{6-(ferrocenyl) ethynyl-2-naphthoyl} 
amino acid and dipeptide esters  
 
The typical chemical shifts observed for the N-{6-(ferrocenyl) ethynyl-2-naphthoyl} 
amino acid and dipeptide esters in CDCl3 include the appearance of amide protons. 
These signals overlap with the six protons on the naphthoyl spacer group between δ 
8.30 and δ 6.70 (figure 4.4). The protons on the monosubstituted ferrocene ring overlap 
with the hydrogen signals of either the methylene groups or the methine groups that 
may be present in the amino acid and dipeptide esters. Hence, the expected three 
signals for a monosubstituted derivative are not observed. For the L-Pro Gly derivative 
(123), the ortho protons (η5-C5H4-C≡C-) on the cyclopentadiene ring attached to the  
-C≡C- spacer moiety is observed as an apparent singlet signal, whilst the meta protons 
overlap with the protons on the unsubstituted (5-C5H5) ring resulting in a multiplet 
being observed between δ 4.21 - 4.18 which has an overall integration of seven. The 
methyl protons (-OCH2CH3) of the ethyl ester derivatives appear between δ 1.30 and δ 
1.00. Due to the overlapping of signals, other spectroscopic techniques were used to 
provide a more complete picture of the molecular structure of these derivatives. These 
included 
13
C NMR, DEPT-135 and 
1
H-
13
C COSY (HMQC) spectroscopy and 
electrospray ionization mass spectrometry (ESI-MS). 
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Figure 4.4: Typical chemical shifts observed for the N-{6-(ferrocenyl) ethynyl-2-
naphthoyl} amino acid and dipeptide esters 120-128.   
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4.5.2.1 
1
H NMR spectroscopic studies of N-{6-(ferrocenyl) ethynyl-2-naphthoyl} 
glycine glycine ethyl ester 120 
 
 
120 
 
The 
1
H NMR spectrum of compound 120 is shown in figure 4.5. The six protons on the 
naphthoyl spacer group overlap with the amide protons resulting in a multiplet between 
δ 8.13 and δ 7.48 with an overall integration of eight. The ortho and meta protons (η5-
C5H4-C≡C-) on the cyclopentadiene ring attached to the -C≡C- spacer moiety are 
observed as apparent triplet signals at δ 4.61 and δ 4.30. The protons on the 
unsubstituted ( 5-C5H5) ring overlap with the signals of the methylene groups of (-
NHCH2CO-), (-OCH2CH3) resulting in a multiplet appearing between δ 4.19 - 4.15 
with an overall integration of eleven. The methyl group of the ethyl ester (-OCH2CH3) 
is present as a triplet at δ 1.23. 
 
 110 
 
 
Figure 4.5: 
1
H NMR spectrum of N-{6-(ferrocenyl) ethynyl-2-naphthoyl} glycine 
glycine ethyl ester 120. 
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4.5.3 
1
H NMR spectroscopic studies of N-{5-(ferrocenyl) ethynyl-2-furanoyl} 
amino acid and dipeptide esters  
 
In CDCl3, the typical chemical shifts observed for the N-{5-(ferrocenyl) ethynyl-2-
furanoyl} dipeptide esters include the overlap the signals of amide protons and the  
aromatic hydrogens of the furanoyl ring spacer group which appear between δ 7.35 and 
δ 6.50 (figure 4.6). However, for the Sar Gly derivative (134), the two aromatic protons 
on the furanoyl linker appear as two doublets and do not overlap with the amide 
protons. The splitting pattern of the furanoyl linker for this derivative follows the n+1 
splitting pattern which is not observed with the benzoyl and naphthoyl linkers. For the 
ferrocene moiety, the expected three splitting pattern signals between δ 4.60 and δ 4.10 
are usually not seen. These signals usually overlap with the hydrogen signals of either 
the methylene groups or methine groups that may be present in the N-{5-(ferrocenyl) 
ethynyl-2-furanoyl} amino acid and dipeptide esters. 
For the Gly L-Phe derivative (132), the ortho protons (η5-C5H4-C≡C-) on the 
cyclopentadiene ring attached to the -C≡C- spacer moiety is observed as an apparent 
singlet, whilst the meta protons overlap with the protons on the unsubstituted ( 5-
C5H5). This results in a multiplet with an overall integration of seven. The apparent 
singlet for the ortho protons (η5-C5H4-C≡C-) follows the second order splitting pattern 
as described in section 2.5.  The methyl protons (-OCH2CH3) of the ethyl ester in this 
derivative appear between δ 1.30 and δ 1.19. Due to the overlapping of signals, other 
spectroscopic techniques were used to provide a more complete picture of the 
molecular structure of these derivatives as described in section 4.5.2 
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Figure 4.6: Typical chemical shifts observed for the N-{5-(ferrocenyl) ethynyl-2-
furanoyl} amino acid and dipeptide esters 129-138.  
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4.5.3.2 
1
H NMR spectroscopic studies of N-{5-(ferrocenyl) ethynyl-2-furanoyl} L-
proline glycine ethyl ester 135 
 
135 
 
The 
1
H NMR spectrum of compound 135 is shown in figure 4.7. The amide proton 
appears at δ 7.34 as a triplet with coupling constants of 5.2 Hz. The aromatic region 
confirms the presence of two protons which are present as two doublets at δ 7.10 and δ 
6.56. The methine proton (-N(CH2CH2CH2)CHCO-) on the proline moiety is present as 
a broad peak at δ 4.80 - 4.78. The ortho protons (η5-C5H4-C≡C-) on the 
cyclopentadiene ring appear as an apparent singlet at δ 4.47, whilst the meta protons 
(η5-C5H4-C≡C-) overlap with the protons on the unsubstituted (
 5
-C5H5) ring, 
methylene protons of (-OCH2CH3), (-NHCH2CO-) and (-N(CH2CH2CH2)CHCO-) 
resulting in a multiplet between δ 4.14 - 3.95 which has an overall integration of 
thirteen. The remaining two methylene protons signals (-N(CH2CH2CH2)CHCO-) 
overlap with each other,  resulting in a multiplet being observed between δ 2.36 - 1.88 
which has an overall integration of four. The methyl group of the ethyl ester (-
OCH2CH3) appears as a triplet at δ 1.23 with a coupling constant of 6.4 Hz. 
  
 
 
 
 
 114 
 
 
 
Figure 4.7:
 1
H NMR spectrum of N-{5-(ferrocenyl) ethynyl-2-furanoyl} L-proline 
glycine ethyl ester 135. 
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4.6 H
1
-H
1 
COSY spectroscopic studies of N-{para-(ferrocenyl) ethynyl benzoyl}, N-
{6-(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} 
amino acid and dipeptide esters  
 
In the H
1
-H
1 
COSY spectra of N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-
(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} amino 
acid and dipeptide esters, the typical protons that correlate include: 
 
(i) Correlation between the aromatic protons.  
(ii) Correlation between the amide protons and adjacent methylene protons 
(iii) Correlation between the ortho protons and meta protons on the cyclopentadiene 
ring attached to the -C≡C- spacer moiety. 
 
The correlations observed for the ethynyl derivatives is consistent with previously 
reported correlations for the N-(ferrocenyl) benzoyl dipeptide derivatives for the Gly 
Gly, Gly L-Ala, Gly L-Leu and Gly L-Phe dipeptide ethyl esters derivatives.
[4-8]  
 
In the H
1
-H
1 
COSY spectrum (figure 4.8) of N-{5-(ferrocenyl) ethynyl-2-furanoyl} 
glycine glycine ethyl ester 129 the two amide protons 6 and 8 (-NHCH2CO-) correlate 
with the adjacent methylene protons 7 and 9 (-NHCH2CO-) of the glycine glycine ethyl 
ester. Correlation is also present between the protons of the furanoyl spacer, 4 and 5. 
The ortho protons 3 and meta protons 2 on the cyclopentadiene ring attached to the -
C≡C- spacer moiety correlate. The methylene of the ethyl ester (-OCH2CH3) 10 
correlate to the methyl protons (-OCH2CH3) 11.  
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129 
 
 
Figure 4.8: H
1
-H
1 
COSY spectrum of N-{5-(ferrocenyl) ethynyl-2-furanoyl} glycine 
glycine ethyl ester 129. 
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4.7. 
13
C NMR and DEPT-135 spectroscopic studies of N-{para-(ferrocenyl) ethynyl 
benzoyl}, N-{6-(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-
furanoyl} amino acid and dipeptide esters  
 
4.7.1 
13
C NMR and DEPT-135 spectroscopic studies of N-{para-(ferrocenyl) 
ethynyl benzoyl} amino acid and dipeptide esters  
 
In the 
13
C NMR spectra of N-{para-(ferrocenyl) ethynyl benzoyl} amino acid and 
dipeptide esters 105-119, the typical peaks observed include the appearance of carbonyl 
signals between δ 175.0 - 160.0 (figure 4.9). In the amino acid derivatives only two 
carbonyl signals are observed whilst for the dipeptide derivatives three carbonyl signals 
are observed. These carbon signals are absent in the DEPT-135 spectrum. In the 
aromatic region of the spectrum four unique carbons signals are observed between δ 
140.0 - 120.0. The two quaternary carbon atoms present on the benzoyl spacer moiety 
can be easily identified by their absence in the DEPT-135 spectrum and these signals 
appear more downfield than the other aromatic carbons, usually between δ 145-135. 
The carbons on the -C≡C- linker appear between δ 96.0 - 90.0 for (η5-C5H4-C≡C-) and 
between δ 87.0 - 84.0 for (η5-C5H4-C≡C-). These two quaternary carbons can be easily 
identified by their absence in the DEPT-135 spectrum.  
The ipso carbon on the cyclopentadiene ring (η5-C5H4-C≡C-) attached to the -C≡C- 
appears between δ 68.0 – 64.0 and is absent in the DEPT-135 spectrum. The remaining 
three unique carbons on the monosubstituted cyclopentadiene rings appear between δ 
72.0 - 66.0. The ortho carbons on (η5-C5H4-C≡C-) attached to the ipso carbons, appear 
more downfield than the meta carbons (η5-C5H4-C≡C-) on the substituted cyclopentadiene 
ring and the unsubstituted ring carbon signal. This indicates that these carbons have 
become deshielded by the ethynyl moiety attached to the cyclopentadiene rings. The five 
carbon atoms on the unsubstituted ring give rise to one unique carbon signal because 
the carbons are equivalent. The methylene carbon of the ethyl ester (-OCH2CH3) appear 
between δ 64.0 - 60.0 whilst the methyl carbon appears at δ 15.0 - 13.0. In the  
DEPT-135 spectra methylene carbons appear as a negative resonance.  
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Figure 4.9: Typical chemical shifts observed for the N-{para-(ferrocenyl) ethynyl 
benzoyl} amino acid and dipeptide esters 105-119.  
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4.7.1.1 
13
C NMR and DEPT-135 spectroscopic studies of N-{para-(ferrocenyl) 
ethynyl benzoyl} γ-amino butyric acid methyl ester 111 
 
 
111 
The 
13
C NMR spectrum of N-{para-(ferrocenyl) ethynyl benzoyl} γ-aminobutyric acid 
methyl ester displays two carbonyl carbon atoms at δ 174.4 and δ 166.9. These are 
absent in the DEPT-135 spectrum. The aromatic region shows 4 unique signals between 
δ 133.0 and δ 126.9. The two quaternary carbon atoms from the benzoyl spacer moiety 
at δ 133.0 and δ 131.4 can be easily identified by their absence in the DEPT-135 
spectrum. The carbon atoms on the -C≡C- linker appear at δ 91.0 for (η5-C5H4-C≡C-) 
and at δ 85.1 for (η5-C5H4-C≡C-). The ipso ferrocenyl carbon atom (η
5
-C5H4-C≡C-) 
appears at δ 64.6 and is not present in the DEPT-135 spectrum. The remaining carbon 
atoms on the cyclopentadiene rings (η5-C5H4-C≡C-) and (η
5
-C5H5) are present between 
δ 71.6 - 69.1. The methyl carbon atom of the methyl ester (-OCH3) appears at δ 51.9. 
The three methylene carbon atoms (-NHCH2CH2CH2-) of the γ-aminobutyric acid 
appear at δ 39.8, δ 31.8 and δ 24.3 and display negative resonance peaks in the  
DEPT-135 spectrum.   
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Figure 4.10: 
13
C NMR and DEPT-135 spectra of N-{para-(ferrocenyl) ethynyl 
benzoyl} γ-aminobutyric acid methyl ester 111. 
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4.7.2 
13
C NMR and DEPT-135 spectroscopic studies of N-{6-(ferrocenyl) ethynyl-
2-naphthoyl} amino acid and dipeptide esters  
 
In the 
13
C NMR spectra of N-{para-(ferrocenyl) ethynyl-2-naphthoyl} amino acid and 
dipeptide esters, the typical peaks observed include the appearance of carbonyl signals 
between δ 175.0 - 160.0 (figure 4.11). In the amino acid derivatives only two carbonyl 
signals are observed whilst for the dipeptide derivatives three carbonyl signals are 
observed. In the aromatic region of the spectrum of these derivatives, ten unique carbon 
signals are observed which appear between δ 140.0 - 120.0. The two quaternary carbon 
atoms present on the naphthoyl moiety can be easily identified by their absence in the 
DEPT-135 spectrum. 
The two quaternary carbons on the -C≡C- linker appear between δ 92.0 - 89.0 for (η5-
C5H4-C≡C-) and between δ 86.0 - δ 84.0 for (η
5
-C5H4-C≡C-), can be easily identified 
by their absence in the DEPT-135 spectrum.  The ipso carbon on the cyclopentadiene 
ring (η5-C5H4-C≡C-) attached to the -C≡C- appears between δ 68.0 - 63.0 whilst the 
other carbons on the cyclopentadiene rings (η5-C5H4-C≡C-) and (η
5
-C5H5) appear 
between δ 72.5 - 68.0 with the ortho carbons (η5-C5H4-C≡C-) appearing more 
downfield than all the carbon atoms present on the cyclopentadiene rings. The ipso 
carbon is easily identified by its absence in the DEPT-135 spectrum. The methylene 
carbons of the ethyl ester (-OCH2CH3) appear between δ 62.0 - 60.0 whilst the methyl 
carbon appears between δ 16.0 - 13.0. In the DEPT-135 spectra methylene carbons 
appear as a negative resonance.  
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Figure 4.11: Typical chemical shifts observed for the N-{6-(ferrocenyl) ethynyl-2-
naphthoyl} amino acid and dipeptide esters 120-128. 
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4.7.2.1 
13
C NMR and DEPT-135 spectroscopic studies of N-{6-(ferrocenyl) ethynyl-
2-naphthoyl} glycine L-leucine ethyl ester 126 
 
 
126 
 
The 
13
C NMR spectrum of N-{6-(ferrocenyl) ethynyl-2-naphthoyl} glycine L-leucine 
ethyl ester displays three carbonyl carbon atoms between δ 172.9 and δ 167.8. These 
are absent in the DEPT-135 spectrum. The aromatic region shows 10 unique carbon 
signals between δ 135.0 and δ 120.8. The four quaternary carbon atoms from the 
naphthoyl spacer moiety at δ 134.8, δ 133.1, δ 130.7 and δ 130.2 can be easily 
identified by their absence in the DEPT-135 spectrum. The carbon atoms on the -C≡C- 
linker appear a δ 90.1 for (η5-C5H4-C≡C-) and at δ 85.6 for (η
5
-C5H4-C≡C-). The ipso 
ferrocenyl carbon atom (η5-C5H4-C≡C-) appears at δ 67.3 and is not present in the 
DEPT 135 spectrum. The remaining carbon atoms on the cyclopentadiene rings (η5-
C5H4-C≡C-) and (η
5
-C5H5) are present between δ 71.1 -69.7. The methylene carbon 
atom of the ethyl ester (-OCH2CH3) is observed at δ 61.4, whilst the methyl carbon 
atom appears at δ 14.2. The two methylene carbon atoms from (-NHCH2CO-) and {-
CH2CH(CH3)2} of the glycine L leucine ethyl ester are observed at  δ 43.8 and δ 41.2. 
The two methine carbon atoms from (-NHCHCO-) and {-CH2CH(CH3)2} of the glycine 
L leucine ethyl ester appear at  δ 51.2 and δ 24.9 respectively. The two methyl carbon 
atoms (-CH2CH(CH3)2) of the glycine L-leucine ethyl ester appear at δ 22.9 and δ 21.9.  
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Figure 4.12: 
13
C NMR and DEPT-135 spectra of N-{6-(ferrocenyl) ethynyl-2-
naphthoyl} glycine L-leucine ethyl ester 126. 
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4.7.3 
13
C NMR and DEPT-135 spectroscopic studies of the N-{5-(ferrocenyl) 
ethynyl-2-furanoyl} amino acid and dipeptide esters  
 
In the 
13
C NMR spectra of N-{5-(ferrocenyl) ethynyl-2-furanoyl} amino acid and 
dipeptide esters, the typical peaks observed include the appearance of carbonyl signals 
between δ 175.0 - 155.0 which are absent in the DEPT-135 spectrum.  In the amino 
acid derivatives only two carbonyl signals are observed, whilst for the dipeptide 
derivatives three carbonyl signals are observed. In the aromatic region of the spectrum 
four unique carbons signals are observed and these signals appear between δ 147.0 - 
115.0. The two quaternary carbon atoms present on the furanoyl moiety can be easily 
identified by their absence in the DEPT-135 spectrum. The carbons on the -C≡C- linker 
appear between δ 95.0 - 90.0 for (η5-C5H4-C≡C-) and between δ 76.0 - 73.0 for (η
5
-
C5H4-C≡C-). The ipso carbon on the cyclopentadiene ring (η
5
-C5H4-C≡C-) attached to 
the -C≡C- appears between δ 68.0 - 62.0, whilst the other carbons on the 
cyclopentadiene rings (η5-C5H4-C≡C-) and (η
5
-C5H5) appear between δ 72.0 – 68.0. 
The ipso carbon (η5-C5H4-C≡C-) and the two quaternary carbons on the -C≡C- linker 
can be easily identified by their absence in the DEPT-135 spectrum.  The methylene 
carbon of the ethyl ester (-OCH2CH3) appears between δ 62.0 - 60.0, whilst the methyl 
carbon appears between δ 15.0 - 13.0. The methylene carbon appears more downfield 
than the methyl group due to the deshielding effect experienced by the methylene 
carbon attached to the oxygen atom.  
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Figure 4.13: Typical chemical shifts observed for the N-{5-(ferrocenyl) ethynyl-2-
furanoyl} amino acid and dipeptide esters 129-138. 
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4.7.3.1 
13
C NMR and DEPT-135 spectroscopic studies of N-{5-(ferrocenyl) ethynyl-
2-furanoyl} L-proline L-alanine ethyl ester 136 
 
 
136 
The 
13
C NMR spectrum of N-{5-(ferrocenyl) ethynyl-2-furanoyl} L-proline L-alanine 
ethyl ester displays three carbonyl carbon signals between δ 173.4 and δ 158.5. These 
are absent in the DEPT-135 spectrum. The aromatic region shows 4 unique carbon 
atoms present between δ 147.4 and δ 115.7. The two quaternary carbon atoms from the 
furanoyl spacer moiety at δ 147.4 and δ 140.9 can be easily identified by their absence 
in the DEPT-135 spectrum. The carbon atoms on the -C≡C- linker appear at δ 94.2 for 
(η5-C5H4-C≡C-) and at δ 75.7 for (η
5
-C5H4-C≡C-). The ipso ferrocenyl carbon atom 
(η5-C5H4-C≡C-) appears at δ 63.0 and is not present in the DEPT-135 spectrum. The 
remaining carbon atoms on the cyclopentadiene rings (η5-C5H4-C≡C-) and (η
5
-C5H5) 
are present between δ 71.7 - 69.5. The methylene carbon atom of the ethyl ester (-
OCH2CH3) appears at δ 61.4 whilst the methyl carbon atom appears at δ 14.2. The 
methine carbon atoms on the proline moiety (-N(CH2CH2CH2)CHCO-) and (CHCH3) 
on the alanine moiety appear at δ 49.8 and δ 46.3 respectively. The three methylene 
carbon atoms (-N(CH2CH2CH2)CHCO-) of proline moiety are observed at  δ 48.7, δ 
27.7 and δ 25.5. In the DEPT-135 spectrum the three peaks appear as negative 
resonances.  The methyl carbon (CHCH3) on the alanine moiety is observed at δ 18.5. 
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Figure 4.14: 
13
C NMR and DEPT-135 spectra studies of N-{5-(ferrocenyl) ethynyl-2-
furanoyl} L-proline L-alanine ethyl ester 136. 
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4.8 HMQC spectroscopic studies of N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-
(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} 
amino acid and dipeptide esters  
 
In the HMQC spectra of the N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) 
ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} amino acid and 
dipeptide esters, the typical carbon to proton that correlate include (i) correlation 
between the aromatic carbon and protons, (ii) correlation between methylene carbon 
and protons and (iii) correlation between the carbon and protons on the 
cyclopentadiene rings The correlations observed for the ethynyl derivatives are 
consistent with previously reported correlations for the N-(ferrocenyl) benzoyl 
dipeptide derivatives for the Gly Gly, Gly L-Ala, Gly L-Leu and Gly L-Phe dipeptide 
ethyl esters derivatives.
[4-8]  
In the HMQC spectrum (figure 4.15) of N-{para-(ferrocenyl) ethynyl benzoyl} glycine 
D-alanine ethyl ester 110 the following C-H correlations were observed:  
 
(i) Cyclopentadiene ring C-H correlations for (η5-C5H5) and (η
5
-C5H4-C≡C-) 
(ii) Aromatic C-H correlations  
(iii) C-H correlations of methylene groups and C-H correlations of the ethyl groups 
on the ethyl ester 
(iv) C-H correlation of methylene groups on the glycine L-alanine moiety 
 
The positions of the C-H correlation are listed in (table 4.1). The C-H correlations are 
consistent to those observed for the N-{para-(ferrocenyl) benzoyl} glycine glycine 
ethyl ester.
[4]
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Figure 4.15: HMQC spectrum of N-{para-(ferrocenyl) ethynyl benzoyl} glycine D-
alanine ethyl ester 110. 
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Table 4.1: C-H correlation data from HMQC spectrum of N-{para-(ferrocenyl) ethynyl 
benzoyl} glycine D-alanine ethyl ester 110. 
 
Site 
1
H NMR 
13
C NMR 
 
(1-5)* 
 
4.20 – 4.18 
 
70.0 
(6 and 9)* 4.42 71.6 
(7 and 8)* 4.20 – 4.18 69.1 
10  68.5 
11  85.1 
12  91.6 
13  131.4 
(14 and 18)* 7.45 126.5 
(15 and 17)* 7.72 127.7 
16   
19  172.7 
20 7.30  
21* 4.15 – 4.10 43.5 
22  168.7 
23 7.05  
24* 4.53 48.4 
25  167.1 
26* 4.15 – 4.10 61.6 
27* 1.20 18.2 
28* 1.37 14.1 
 
*C-H correlation site 
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4.9 UV-Vis spectroscopic studies of N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-
(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} 
amino acid and dipeptide esters  
 
All the UV-Vis spectra were obtained at a concentration of 4 x 10
-4
 M in ethanol. In the 
UV spectra of the N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) ethynyl-2-
naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} amino acid and dipeptide esters 
105-138, metal to ligand charge transfer (MLCT) band transitions arising from the 
ferrocene moiety are observed at low energy bands between 430 to 560 nm, with 
distinct λmax values. The high energy band between 340 and 450 nm, with distinct λmax 
values are due to the π - π* transitions of aromatic linker (table 2.3). The presence of 
the π - π* transitions and the MLCT band transitions are constistent to those seen in the 
alkyl derivatives (section 2.9) and the previously reported N-(ferrocenyl) benzoyl and 
naphthoyl derivatives.
[1-8]
    
In the literature it is know that the presences of a ethynyl moiety on a ferrocene moiety 
causes the λmax of ferrocene to shift toward the red region as a result of extendend 
conjugation.
[7]  
In the UV-Vis spectra of the synthesised compounds 105-138, all the derivatives cause 
the ferrocene moiety to undergo a red shift to lower energies due to the presence of 
both ethynyl moiety and the aromatic linkers. The ethynyl naphthoyl derivatives gave 
rise to lower energy bands compared to the ethynyl benzoyl and ethynyl furanoyl. This 
is due to the ethynyl naphthoyl linker being more conjugated than the other aromatic 
linkers. 
 
For selected N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) ethynyl-2-
naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} glycine glycine ethyl esters the 
λmax values and their extinction coefficient (ε) values, corresponding to the π-π* 
transition and MLCT band transition are shown in table 4.2.  
  
.   
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Table 4.2: Selected UV-Vis spectroscopic data for N-{para-(ferrocenyl) ethynyl 
benzoyl}, N-{6-(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-
furanoyl} glycine glycine ethyl esters 106, 120 and 129 
 
 
Compound 
Chromophore 
                  Ferrocene moiety                             Aromatic linker 
  λmax (nm)          ε (L mol
-1
 cm
-1
)  λmax (nm)      ε (L mol
-1
 cm
-1
) 
106 490                    (ε 1550) 385           (ε 2500) 
120 500                    (ε 1025)  400           (ε 1550 ) 
129           476                     (ε 525) 370           (ε 1025) 
 
Figure 4.16: The UV-Vis spectra of selected compounds 106, 120 and 129. 
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4.10 Mass spectrometric studies of N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-
(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} 
amino acid and dipeptide esters 105-138. 
 
Electrospray ionization (ESI) mass spectrometry of compounds 105-138 revealed the 
presence of sodium adducts, [M+Na]
+
 whilst tandem mass spectrometry was employed 
to determine the fragmentation pattern of compounds.  
In the MS/MS spectrum of compound 106, the sequence specific fragment ions are 
present at m/z 285, m/z 313, m/z 341 and m/z 369 (figure 4.16a).  The product ions at 
m/z 285 and m/z 313 correspond to the N-para-(ferrocenyl) ethynyl benzyl and N-para-
(ferrocenyl) ethynyl benzoyl subunits respectively. The a1-1 and b1-1 product ions were 
observed at m/z 341 and m/z 369 respectively. The fragment ion at m/z 444 is due to a 
loss of C2H4 from the ethyl ester group by a McLafferty rearrangement as already 
described in section 2.10 in scheme 2.11. 
 In the MS/MS spectrum of 120 the sequence specific fragment ions are present at m/z 
335, m/z 363, m/z 391 and m/z 419 (figure 4.16b).  The product ions at m/z 335 and m/z 
363 correspond to the N-6-(ferrocenyl) ethynyl-2-naphthyl and N-6-(ferrocenyl) 
ethynyl-2-naphthoyl subunits respectively. The a1-1 and b1-1 product ions were 
observed at m/z 391 and m/z 419 respectively. The fragment ion at m/z 494 is due to a 
loss of C2H4 from the ethyl ester group by the McLafferty rearrangement. 
For compound 129 the sequence specific fragment ions are observed at m/z 275, m/z 
303, m/z 331 and m/z 359 (figure 4.16c).  The product ions at m/z 275 and m/z 303 
correspond to the N-5-(ferrocenyl) ethynyl-2-furanyl and N-5-(ferrocenyl) ethynyl-2-
furanoyl subunits respectively. The a1-1 and b1-1 product ions are observed at m/z 331 
and m/z 359 respectively. For compound 129 a unique product ion is observed at m/z 
397, corresponding to the loss of the unsubstituted (η5-C5H5) ring. This product ion is 
not observed in the ethynyl benzoyl or ethynyl-2-naphthoyl analogues. The fragment 
ion at m/z 434 is due to a loss of C2H4 from the ethyl ester group by the McLafferty 
rearrangement. 
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(a) 
 
 
 
 
 
 
(b) 
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 (c)         
 
Figure 4.16. MS/MS spectra of (a) N-{para-(ferrocenyl) ethynyl benzoyl} glycine 
glycine ethyl ester 106 (b) N-{6-(ferrocenyl) ethynyl-2-naphthoyl} glycine glycine 
ethyl ester 120 and (c) N-{5-(ferrocenyl) ethynyl-2-furanoyl} glycine glycine ethyl 
ester 129. 
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4.11 A comparative study of N-para, N-meta and N-ortho-(ferrocenyl) benzoyl 
dipeptide esters and the novel ethynyl analogues 105-138. 
 
4.11.1 Introduction 
 
In a further extension to ferrocenyl benzoyl and naphthoyl bioconjugates reported, a 
new library of ferrocenyl based bioconjugates 105-138, which consist of four key 
moieties (i) an electroactive core (ii) a -C≡C- moiety (iii) three different aromatic 
linkers and (iv) and a series of amino acid and dipeptide esters are now reported here. 
The incorporation of the -C≡C- moiety between the ferrocene moiety and the aromatic 
spacer and the use of three different aromatic rings are attempts to further improve the 
cytotoxicity of the previously prepared N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters.  
 
 
                                                                   
Figure 4.17: General structure of the N-(ferrocenyl) benzoyl and naphthoyl 
bioconjugates and the N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) 
ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} amino acid and 
dipeptide esters. 
 
4.11.2 Synthetic pathways employed  
 
For the synthesis of para, meta and ortho-(ferrocenyl) benzoic acid the synthetic 
protocol involved the diazonium coupling of ferrocene to 2, 3, 4-ethylamino benzoate 
followed by basic hydrolysis.
[4-8]
 The use of the diazonium coupling reaction in the 
preparation of the monoarylferrocenes derivatives proceeds with a low degree of 
regiocontrol and produces intractable mixtures of mono-, di- and poly-arylferrocene 
derivatives with low yields of less than 8% for the desired monoarylferrocene 
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derivatives. For the synthesis of the ethynyl analogues 105-138, the synthetic protocol 
involved the use of Sonogashira cross coupling of ethynyl ferrocene to three bromo 
acylated acids to generate para-(ferrocenyl) ethynyl benzoic acid, 6-(ferrocenyl) 
ethynyl-2-naphthoic acid, and 5-(ferrocenyl) ethynyl-2-furanoic acids. In this coupling 
reaction, yields greater than 60% were obtained. These high yields are largely due to 
the fact that Sonogashira cross coupling is a substrate specific reaction between an 
alkyne and an aryl halides employed in the coupling reaction which involves the use of 
palladium catalyst and copper iodine co catalyst.   
 
4.11.3
 1
H NMR, 
13
C NMR and DEPT-135 studies of N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters and the novel ethynyl analogues 105-138.  
 
In the 
1
H NMR, 
13
C NMR and DEPT-135 studies of the N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters
 
and the novel N-{para-(ferrocenyl) ethynyl 
benzoyl}, N-{6-(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-
furanoyl} amino acid and dipeptide esters, clear similarities and differences can be 
identified. Typical signals observed in the 
1
H NMR spectra in both classes of 
compounds include the appearance of amide protons of the peptide chain which appear 
between δ 8.89 and δ 8.14, whereas the aromatic protons appear between δ 8.00 and δ 
7.00. The protons on the monosubstituted ferrocene ring appear between δ 4.95 and δ 
4.00. However with the ethynyl analogues overlapping of the proton signals occurs 
with these derivatives, which makes the assignment of the proton chemical shift a 
challenge.  For instance the amide proton and aromatic proton overlap resulting in 
mutiplets being observed which is not observed with in the N-para, N-meta and N-
ortho-(ferrocenyl) benzoyl dipeptide esters.
[4-8] 
Furthermore the protons on the 
monosubstituted ferrocene ring of the ethynyl analogues tend to overlap with each other 
or with other signals from methylene groups and the methine groups that may be 
present in the amino acid and dipeptide esters.  Hence, the expected three signals for a 
monosubstituted derivative are not observed. Due to this limited scope of information 
observed from the proton chemical shifts, other spectroscopic techniques where used to 
provide a more complete picture of the molecular structure of these derivatives which 
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included 
13
C NMR, DEPT-135 and 
1
H-
13
C COSY (HMQC) spectroscopy and 
electrospray ionization mass spectrometry (ESI-MS). 
The presence of the -C≡C- unit in the new ethynyl ferrocenyl bioconjugates can be 
identified in the 
13
C NMR spectra. The carbons on the -C≡C- linker for the benzoyl 
derivatives appear between δ 96.0 - 90.0 for (η5-C5H4-C≡C-) and between δ 87.0 - 85.0 
for (η5-C5H4-C≡C-). For the naphthoyl derivatives the -C≡C- linkers appear between δ 
90.0 -89.0 for (η5-C5H4-C≡C-) and between δ 85.0 - 84.0 for (η
5
-C5H4-C≡C-) whilst for 
the furanoyl derivatives it appears between δ 95.0 - 90.0 for (η5-C5H4-C≡C-) and 
between δ 76.0 - 73.0 for (η5-C5H4-C≡C-). The typical carbon signals present in the two 
classes of compounds include the presence of carbonyl atoms present between δ 172.7 
and δ 155.0.  The aromatic carbons occur between δ 145.0 - 115.0. The carbon atoms 
on the ferrocenyl rings appear between δ 71.5 and δ 63.0. In the DEPT-135 spectrum 
the presence of the methylene carbon atoms in both classes can be easily identified as 
they appear as negative resonances.  
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4.12 Conclusions 
 
A series of N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) ethynyl-2-
naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} amino acid and dipeptide esters 
were prepared and structurally characterized. Each novel compound incorporated an 
electroactive ferrocene core, a -C≡C-, a conjugated aromatic linker and a dipeptide 
chain with each part exerting a specific effect on biological activity. The ferrocene 
moiety is required for the possible production of hydroxyl radicals, the -C≡C- and 
conjugated aromatic linkers facilitates this process by lowering the redox potential of 
the ferrocene and the peptide fragment can interact with other molecules via hydrogen 
bonding. These novel compounds were characterized by a combination of 
1
H NMR, 
13
C 
NMR, DEPT-135 and 
1
H-
13
C COSY (HMQC) spectroscopy, electrospray ionization 
mass spectrometry (ESI-MS). 
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Chapter 5: The biological evaluation of N-{para-(ferrocenyl) ethynyl benzoyl}, N-
{6-(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} 
amino acid and dipeptide esters  
 
5.1 Introduction 
 
This research group has reported the anti-proliferative effects of ferrocenyl benzoyl  
and ferrocenyl naphthoyl  bioconjugates (figure 5.1) in the H1299 lung cancer cell 
line.
[1-8]  
In an effort to further improve the cytotoxicity of these derivatives, a series of 
N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) ethynyl-2-naphthoyl} and N-
{5-(ferrocenyl) ethynyl-2-furanoyl} amino acid and dipeptide esters 105-138 (figure 
5.1) were synthesised, structurally characterised and biologically evaluated. In total 34 
compounds were tested for their anti-proliferative effects on the non-small cell, lung 
cancer cell line, H1299. These novel derivatives differ from the ferrocenyl benzoyl and 
ferrocenyl naphthoyl bioconjugates by having an ethynyl linker between the ferrocene 
moiety and the aromatic linkers (benzoyl and naphthoyl) and furthermore, a new 
aromatic linker furanoyl has been incorporated.   
 
 
 
Figure 5.1: General structure of the N-(ferrocenyl) benzoyl and naphthoyl 
bioconjugates and the N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) 
ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} amino acid and 
dipeptide esters. 
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5.2 Preliminary biological evaluation of N-{para-(ferrocenyl) ethynyl benzoyl}, N-
{6-(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} 
amino acid and dipeptide esters  
 
5.2.1 Preliminary biological evaluation of the N-{para-(ferrocenyl) ethynyl 
benzoyl} amino acid and dipeptide esters  
 
The in vitro cytotoxicity of the derivatives 105-119 against the H1299 lung cancer cells 
was evaluated by the acid phosphatase assay as previously described in section 3.1. The 
results for the percentage growth inhibition of the derivatives are depicted in figure 5.2 
and table 5.1.   
 
 
Figure 5.2: % Growth inhibition at 10 µM on H1299 lung cancer cells for N-{para-
(ferrocenyl) ethynyl benzoyl} amino acid and dipeptide esters 105-119 and reference 
compound 28. 
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Table 5.1: % Growth inhibition at 10 µM on H1299 lung cancer cells for N-{para-
(ferrocenyl) ethynyl benzoyl} amino acid and dipeptide esters 105-119 and reference 
compound 28. 
 
Ferrocenyl bioconjugate R Compound no. % growth inhibition at 10 
µM 
 
 
 
 
Gly Gly(OMe) 105 34 ± 2.49 
Gly Gly(OEt) 106 70 ± 2.84 
Gly L-Ala(OMe) 107 22 ± 5.47 
Gly L-Ala(OEt) 108 95 ± 1.62 
Gly D-Ala(OMe) 109 23 ± 4.89 
Gly D-Ala(OEt) 110 72 ± 2.01 
GABA(OMe) 111 55 ± 3.35 
GABA(OEt) 112 85 ± 1.07 
Gly L-Phe(OEt) 113 28 ± 1.74 
Gly L-Leu(OEt) 114 53 ± 3.17 
Sar Gly(OEt) 115 47 ± 4.03 
Sar Gly(OMe) 116 25 ± 4.10 
Sar L-Ala(OEt) 117 82 ± 4.75 
L-Pro Gly(OEt) 118 62 ± 5.06 
L-Pro L-Ala(OEt) 119 87 ± 1.12 
 
 
 
Gly-L-Ala(OEt) 
 
 
28* 
 
84 ± 0.33 
 
 
 
 
 
Note: 28* Originally prepared by Alan Corry 
[5] 
 
From the preliminary screen at 10 μM a general trend can be observed, the methyl ester 
derivatives exhibited lower percentage growth inhibition values between 22 % ± 5.47 to 
55 % ± 3.35 compared to the ethyl ester derivatives which exhibited percentage growth 
inhibition values between 47 % ± 4.03 to 95 % ± 1.62. Generally, the lower the 
percentage growth value, the lower the anti-proliferative activity. Thus, the methyl ester 
derivatives were not investigated further.  
A general trend was also observed in these derivatives, that is, the Gly L-Leu and Gly 
L-Phe ethyl esters display percentage growth inhibition values ≤ 53 %. For instance, the 
N-{para-(ferrocenyl) ethynyl benzoyl} glycine L-phenylalanine ethyl ester 113 
displayed % growth inhibition value of 28 % ± 1.74 whilst the N-{para-(ferrocenyl) 
ethynyl benzoyl} glycine L-leucine ethyl ester 114 displayed a percentage growth 
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inhibition values of 53 % ± 3.17. Thus, the Gly L-Leu and Gly L-Phe ethyl ester 
derivatives were not investigated further. As a result, it can be concluded that when 
chiral α-amino acids with bulky side chains are used as the second amino acid in the 
dipeptide moiety, a loss of anti-proliferative activity is observed. Compounds 106, 108, 
110, 112, 117, 118 and 119, showed percentage growth inhibition values ≥ 60 %. 
Therefore, IC50 values were determined for these compounds. 
 
5.2.2 Preliminary biological evaluation of the N-{6-(ferrocenyl) ethynyl-2-
naphthoyl} amino acid and dipeptide esters  
 
The in vitro anti-proliferative effect of compounds 120-128 were studied at a 
concentration of 10 M in the H1299 lung cancer cells. The results of this biological 
study are shown in figure 5.3 and table 5.2. From the preliminary screen a general trend 
was observed, the Gly L-Leu and Gly L-Phe ethyl esters displayed percentage growth 
inhibition values ≤ 34 %.  Thus, the Gly L-Leu and Gly L-Phe ethyl ester derivatives 
were not investigated further. Compounds 120, 121, 122, 123, 124, 125 and 127 
showed percentage growth inhibition values ≥ 68 %. Therefore, IC50 values were 
determined for these compounds.  
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Figure 5.3: Percentage Growth inhibition at 10 µM on H1299 lung cancer cells for N-
{para-(ferrocenyl) ethynyl naphthoyl} amino acid and dipeptide esters 120-128 and 
reference compound 28. 
 
 
Table 5.2: Percentage Growth inhibition at 10 µM on H1299 lung cancer cells for N-
{para-(ferrocenyl) ethynyl naphthoyl} amino acid and dipeptide esters 120-128 and 
reference compound 28. 
 
Ferrocenyl bioconjugate R Compound no. % growth inhibition 
at 10 µM 
 
Gly Gly(OEt) 114 89 ± 1.23 
Gly L-Ala(OEt) 115 84 ± 5.33 
Sar L-Ala(OEt) 116 94 ± 1.02 
L-Pro Gly(OEt) 117 82 ± 1.92 
GABA(OEt) 118 68 ± 5.81 
L-Pro L-Ala(Oet) 119 94 ± 0.61 
Gly L-Leu(OEt) 120 33 ± 4.72 
Sar Gly(OEt) 121 90 ± 1.40 
Gly L-Phe(OEt) 122 29 ± 2.53 
 
 
 
Gly L-Ala(OEt) 
 
 
28* 
 
84 ± 0.33 
 
 
 
 
Note: 28* Originally prepared by Alan Corry 
[5]
 
 147 
5.2.3 Preliminary biological evaluation of the N-{5-(ferrocenyl) ethynyl-2-
furanoyl} amino acid and dipeptide esters   
 
The in vitro cytotoxicity of the derivatives 129-138 against the human lung carcinoma 
cell line H1299 was evaluated by the acid phosphatase assay and the % growth 
inhibition of the derivatives are depicted in figure 5.4 and table 5.2.   
 
 
Figure 5.4: Percentage Growth inhibition at 10 µM on H1299 lung cancer cells for N-
{para-(ferrocenyl) furanoyl naphthoyl} amino acid and dipeptide esters 129-138 and 
reference compound 28. 
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Table 5.2: Percentage Growth inhibition at 10 µM on H1299 lung cancer cells for N-
{para-(ferrocenyl) furanoyl naphthoyl} amino acid and dipeptide esters 129-138 and 
reference compound 28. 
 
Ferrocenyl bioconjugate R Compound no. % growth 
inhibition at 10 µM 
 
 
Gly Gly(OEt) 129 38 ± 2.62 
Gly L-Ala(OEt) 130 13  ± 3.41 
Gly D-Ala(OEt) 131 13 ± 4.37 
Gly L-Phe(OEt) 132 9  ± 3.30 
Gly L-Leu(OEt) 133 11  ± 3.70 
Sar Gly(OEt) 134 18  ± 5.43 
L-Pro Gly(OEt) 135 17  ± 2.33 
L-Pro L-ala(Oet) 136 22  ± 2.60 
Sar L-ala(OEt) 137 17  ± 1.50 
GABA(OEt) 138 13  ± 1.38 
 
 
 
Gly L-Ala(OEt) 
 
 
28* 
 
84 ± 0.33 
 
 
 
 
Note: 28* Originally prepared by Alan Corry 
[5]
 
 
From the preliminary screen at 10 μM, all derivatives exhibited lower percentage 
growth inhibition values between 9 % ± 3.30 to 38 % ± 2.62. In the case of the N-{5-
(ferrocenyl) ethynyl-2-furanoyl} glycine glycine ethyl ester 129, it exhibited the highest 
percentage growth inhibition value of 38 % ± 2.62 and thus, an IC50 value for 129 was 
determined. For compounds 130-138 no further investigation were carried out. 
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5.3 IC50 value determination of N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-
(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} 
amino acid and dipeptide esters  
 
5.3.1 IC50 value determination of N-{para-(ferrocenyl) ethynyl benzoyl} amino acid 
and dipeptide esters  
 
Further studies were conducted as described in Chapter 3 (Section 3.2), to determine 
IC50 values for in the H1299 cell line. The IC50 value for each compound was 
calculated using Calcusyn software, and standard deviations have been calculated using 
data obtained from three independent experiments. The values obtained are listed in 
figure 5.5 and table 5.3. 
 
 
 Figure 5.5:  IC50 plot for selected compounds in the H1299 cell line. 
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Table 5.3:  IC50 values for selected compounds, reference compound 28, carboplatin 
and cisplatin against human lung carcinoma cell line H1299. 
 
Compound Name                                                                                     No.              IC50  
 
Cisplatin 
 
8 1.5 ± 0.10 
 
Carboplatin 9 10 ± 1.60 
 
N- {meta-(ferrocenyl)-benzoyl} Gly L-Ala(OEt)   
 
28* 4.0 ± 0.71 
 
N-{para-(ferrocenyl) ethynyl benzoyl} Gly Gly(OEt)   106 6.9 ± 2.14 
 
N-{para-(ferrocenyl) ethynyl benzoyl} Gly L-Ala(OEt)   108 3.8 ± 1.92 
 
N-{para-(ferrocenyl) ethynyl benzoyl} Gly D-Ala(OEt)   110 6.1 ± 3.41 
 
N-{para-(ferrocenyl) ethynyl benzoyl} GABA(OEt)    112 4.9 ± 4.12 
 
N-{para-(ferrocenyl) ethynyl benzoyl} Sar L-Ala(OEt)   117 7.1 ± 2.46 
 
N-{para-(ferrocenyl) ethynyl benzoyl} L-Pro Gly(OEt)   118 
 
8.3 ± 3.10 
 
N-{para-(ferrocenyl) ethynyl benzoyl} L-Pro L-Ala(OEt)    119 5.7 ± 2.91 
 
 
From the IC50 values of compounds 106, 108, 110, 112, 117, 118 and 119 all exert a 
cytotoxic effect on the H1299 lung cancer cell line. All seven derivatives have an IC50 
value that is lower than 9 µM and more cytotoxic in vitro than the clinically employed 
anticancer drug carboplatin. In addition, the most active compound was N-{para-
(ferrocenyl) ethynyl benzoyl} glycine L-alanine ethyl ester 108 which had an IC50 value 
of 3.8 ± 1.92 M. This compound displays a slight improvement in biological activity 
in comparison to the most active ferrocenyl benzoyl analogue 28 which displayed an 
IC50 value of 4.0 ± 0.71 µM.
[5]
 
The in vitro cytotoxicity of the platinum (II) based anticancer drug cisplatin was also 
evaluated against the H1299 cell line and was found to have an IC50 value of 1.5 ± 0.10 
M. Thus, compounds 106, 108, 110, 112, 117, 118 and 119 are less cytotoxic in vitro 
than the clinically employed anticancer drug cisplatin.  
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Previously, in vitro cytotoxic effects have shown the N-(ferrocenyl) naphthoyl 
derivatives to be more active than the N-(ferrocenyl) benzoyl derivatives with the most 
active derivative, N-{6-(ferrocenyl)-2-napthoyl} glycine glycine ethyl ester displaying 
an IC50 value of 0.13 ± 0.01 µM.
[8]
 For the N-{para-(ferrocenyl) ethynyl benzoyl} 
glycine glycine ethyl ester, an IC50 value of 6.9 ± 5.14 µM was obtained. Thus, it can 
be concluded that the presence of the ethynyl moiety did not result in any marginal 
increase in the cytoxicity of the N-{para-(ferrocenyl) ethynyl benzoyl} amino acid and 
dipeptide esters, when compared to the N-(ferrocenyl) benzoyl and naphthoyl analogues 
previously reported.
[1-8]
 A potential mechanism by which these compounds induce 
DNA damage is by the catalytic generation of HO
•
 radical as described in section 3.2 in 
scheme 3.1.  
 
5.3.2 IC50 value determination of N-{6-(ferrocenyl) ethynyl-2-naphthoyl} amino 
acid and dipeptide esters  
 
The IC50 values for derivatives 120-128 were determined by the acid phosphatase assay 
as previously described in section 3.3. The IC50 values for derivatives 120-128, 
cisplatin and carboplatin are depicted in figure 5.6 and table 5.4. 
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Figure 5.6: IC50 plot for selected compounds in the H1299 cell line. 
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Table 5.4: IC50 values for selected compounds, reference compound 28, carboplatin 
and cisplatin against human lung carcinoma cell line H1299.  
Compound Name                                                                             No.           IC50 
 
Cisplatin 
 
8 1.5 ± 0.10 
 
Carboplatin 9 10 ± 1.60 
 
N- {meta-(ferrocenyl)-benzoyl} Gly L-Ala(OEt)   
 
28* 4.0 ± 0.71 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} Gly Gly(OEt)   120 5.0 ± 4.12 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} Gly L-Ala(OEt)   121 5.0 ± 3.61 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} Sar L-Ala(OEt)    122 3.2 ± 2.64 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} L-Pro Gly(OEt)    123 5.1 ± 1.35 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} GABA(OEt)    124 7.2 ± 1.51 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} L-Pro L-Ala(OEt)    125 3.8 ± 2.02 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} Sar Gly(OEt)   127 4.7 ± 3.71 
 
 
From the IC50 values of the N-{6-(ferrocenyl) ethynyl-2-naphthoyl} amino acid and 
dipeptide ethyl esters 120, 121, 122, 123, 124, 125 and 127, all exert a cytotoxic effect 
on the H1299 lung cancer cell line. All seven derivatives have an IC50 value that is 
lower than 7.2 µM and more cytotoxic in vitro than the clinically employed anticancer 
drug carboplatin. The most active compound was N-{6-(ferrocenyl) ethynyl-2-
naphthoyl} sarcosine L-alanine ethyl ester 122 which had an IC50 value of 3.2 ± 2.64 
M. However, for compounds 120, 121, 124 and 127 the presence of the ethynyl 
moiety had a negative effect of anti-proliferative effect compared to analogous 
compounds prepared previously lacking the ethynyl group.
[6-8]
 For example for N-{6-
(ferrocenyl) ethynyl-2-naphthoyl} γ-aminobutyric acid ethyl ester 124 the IC50 value is 
7.2 ± 1.51 M, whereas for N-(6-ferrocenyl-2-naphthoyl) γ-aminobutyric acid ethyl 
ester the IC50 value was 0.62 ± 0.17  M.  The in vitro cytotoxicity of the platinum (II) 
based anticancer drug cisplatin was also evaluated against the H1299 cell line, and was 
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found to have an IC50 value of 1.5 ± 0.10 M (Table 4). Thus, compounds 120-128 are 
less cytotoxic in vitro than the clinically employed anticancer drug cisplatin.  A 
potential mechanism by which these novel organometallic anticancer compounds may 
induce DNA damage is by the catalytic generation of ROS. This is possible via a 
Fenton-type reaction, in which HO
•
 radicals are generated from the superoxide 
dismutation product, hydrogen peroxide (H2O2). It was shown that the generation of 8-
oxoGua by a compound prepared in a previous SAR study, N-(6-ferrocenyl-2-
naphthoyl) glycine glycine ethyl ester, that the oxidation was occurring by Fenton 
chemistry and that N-(6-ferrocenyl-2-naphthoyl) glycine glycine ethyl ester is 
generating oxidative damage via a ROS-mediated mechanism. Therefore, guanine 
oxidation studies confirmed that N-(6-ferrocenyl-2-naphthoyl) glycine glycine ethyl 
ester was capable of causing oxidative damage to guanine, and it does so by the 
generation of HO
•
 radicals from H2O2.
[8]
 However, the introduction of the ethynyl 
group reduces the IC50 value from 0.13 ± 0.01 M for N-(6-ferrocenyl-2-naphthoyl) gly 
gly(OEt) to 5.0 ± 4.12 M for N-{6-(ferrocenyl) ethynyl-2-naphthoyl}gly gly(OEt). 
Therefore, it is possible that some other feature of these derivatives may play an 
important role, such as the ability to interact with DNA in other ways. It is plausible 
that these polyaromatic derivatives could intercalate with DNA, as observed for many 
polyaromatic drugs including the anthracycline class of chemotherapeutics. The 
hydrogen bond donor and acceptor atoms present in the peptide side chain, could then 
interact with the nucleotide bases positioned in the centre of the helix. Although the 
bulky ferrocene substituent (10.5 Ǻ) is too large to fit into the major groove of DNA 
(depth = 8.5 Ǻ), the oxidation potentials of these derivatives supports the possibility 
that the ferrocene moiety in its oxidized Fe
3+
 state, could interact with the negatively 
charge phosphate backbone positioned on the outside of the helix.  However, for the N-
{6-(ferrocenyl) ethynyl-2-naphthoyl} amino acid and dipeptide ethyl esters the 
presence of the ethynyl group could disrupt this interaction. Thus, it is possible for the 
naphthoyl ferrocenyl bioconjugates to possess two distinct modes of action: the ability 
to cause oxidative damage to DNA through ROS production and the ability to 
intercalate with DNA, both of which would result in the disruption of cancer cell 
replication. A general trend can be seen between the N-{6-(ferrocenyl) ethynyl-2-
naphthoyl} and N-{para-(ferrocenyl) ethynyl benzoyl} amino acid and dipeptide esters. 
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The Gly Gly, Sar L-Ala, L-Pro Gly, L-Pro L-Ala ethyl esters of the N-{6-(ferrocenyl) 
ethynyl-2-naphthoyl} derivatives are more active than the N-{para-(ferrocenyl) ethynyl 
benzoyl}derivatives whilst the Gly L-Ala and GABA esters of the N-{para-(ferrocenyl) 
ethynyl benzoyl}derivatives are more active than the N-{6-(ferrocenyl) ethynyl-2-
naphthoyl}derivatives. 
 
5.3.3 IC50 value determination of N-{5-(ferrocenyl) ethynyl-2-furanoyl}-glycine-
glycine ethyl ester 129.   
 
The IC50 value for N-{5-(ferrocenyl) ethynyl-2-furanoyl} glycine glycine ethyl ester 
129 was the only derivative evaluated by the acid phosphatase assay. The IC50 value for 
the derivative, cisplatin and carboplatin are depicted in figure 5.7 and table 5.5. 
 
Figure 5.7: IC50 plot for compound 129 in the H1299 cell line. 
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Table 5.5: IC50 values for selected compounds, reference compound 28, carboplatin 
and cisplatin against human lung carcinoma cell line H1299. 
 
Compound Name                                                                                No.               IC50  
 
Cisplatin 
 
8 1.5 ± 0.10 
 
Carboplatin 9 10 ± 1.60 
 
N- {meta-(ferrocenyl)-benzoyl} Gly L-Ala(OEt)   
 
28* 4.0 ± 0.71 
 
N-{5-(ferrocenyl) ethynyl-2-furanoyl} Gly Gly(OEt)   129 23 ± 5.14 
 
 
From the results obtained, compound 129 displayed an IC50 value of  23 ± 5.14 M and 
was less cytotoxic in vitro than the clinically employed cisplatin and carboplatin which 
had IC50 values of 1.50 ± 0.10 M and 10 ± 1.60 M respectively. In addition, when 
compared to the N-{para-(ferrocenyl) ethynyl benzoyl} and N-{6-(ferrocenyl) ethynyl-
2-naphthoyl} glycine glycine ethyl esters with IC50 values of 6.9 ± 2.14 M and 5.0 ± 
4.12 M respectively, compound 129 was also less cytotoxic than the two derivatives. 
As a result it can be concluded that the furanoyl ring is not a bioactive aromatic 
conjugate linker that promotes anti-proliferative effect in H1299 lung cancer line.  
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5.4 Conclusion 
 
The biological evaluation of N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) 
ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} amino acid and 
dipeptide esters was carried out in the H1299 lung cancer cell line. The most active 
derivative N-{6-(ferrocenyl) ethynyl-2-naphthoyl} sarcosine L-alanine ethyl ester 122 
displayed an IC50 value of 3.2 ± 2.64 M. This compound is more active than the 
clinically used carboplatin but is less effective than cisplatin. A general trend can be 
seen between the N-{para-(ferrocenyl) ethynyl benzoyl} and N-{6-(ferrocenyl) 
ethynyl-2-naphthoyl} amino acid and dipeptide esters. The Gly Gly, Sar L-Ala,  
L-Pro Gly, L-Pro L-Ala ethyl esters of the N-{6-(ferrocenyl) ethynyl-2-naphthoyl} 
derivatives are more active than the N-{para-(ferrocenyl) ethynyl benzoyl}derivatives 
whilst the Gly L-Ala and GABA esters of the N-{para-(ferrocenyl) ethynyl benzoyl} 
derivatives are more active than the N-{6-(ferrocenyl) ethynyl-2-naphthoyl} 
derivatives. 
From the SAR studies carried out it has been clearly demonstrated that the presence of 
the ethynyl moiety does not result in any significant enhancement of the anti-
proliferative effect of the N-(ferrocenyl) benzoyl and naphthoyl dipeptide derivatives. 
However, the incorporation of a methyl derivative to the unsubstituted cyclopentadiene 
ring of the N-(ferrocenyl) benzoyl dipeptide derivatives showed an enhancement of the 
anti-proliferative effect. Thus, the incorporation of a methyl group to the most active N-
{6-(ferrocenyl)-2-napthoyl} glycine glycine ethyl ester 31 with an IC50 value of 0.13 ± 
0.01 M could result in the formulation of a potent novel bioorganometallic anticancer 
agent. 
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Chapter 6: Experimental data 
 
Experimental note 
 
Chemicals used were purchased from Sigma-Aldrich and TCI. Commercial grade 
reagents were used without further purification and where necessary solvents were 
dried over magnesium sulphate (MgSO4) prior to use. Nuclear magnetic resonance 
spectra (NMR) were obtained using a Bruker AC 400 NMR spectrometer operating at 
400 MHz for 
1
H NMR and 100 MHz for 
13C NMR. Chemical shifts are reported as δ-
values (ppm) relative to trimethylsilane (δ = 0.00 ppm) and all coupling constants (J) 
are in Hertz. Melting points were determined using a Griffin melting point apparatus 
and are uncorrected. Infrared spectra were recorded on a Nicolet 405 FT-IR 
spectrometer and melting points were determined using a Griffin melting point 
apparatus. The IR spectra for solids were obtained in a potassium bromide matrix, 
spectra for liquids were obtained from thin films between NaCl discs. Column 
chromatography was performed on silica gel (40 mesh, 60Å, Fisher). UV-Vis were 
recorded on a Hewlett-Packard 8452A diode array UV-Vis spectrophotometer. 
Electrospray ionization mass spectra were performed on a Micromass LCT mass 
spectrometer or a Brüker Daltonics Esquire-LC ion trap mass spectrometer. Tandem 
mass spectra were obtained on a Micromass Quattro micro 
TM
. LC-MS/MS triple 
quadrupole mass spectrometer.  
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General procedure for the synthesis of the starting materials  
 
Ferrocene carboxyaldehyde (48) 
[1]
 
 
Ferrocene (50 g, 268.76 mmol) was dissolved with dry dichloromethane (150 ml) at 0 
°C under nitrogen. N,N-dimethylformamide (38 ml) was added slowly over 10 min. 
Phosphorus oxychloride (138 ml) was added slowly over 3 hr and the reaction mixture 
was allowed to reflux at 40 °C for 48 hr under nitrogen. The reaction mixture was 
poured onto ice and neutralised with conc. sodium hydroxide solution. The resulting 
solution was extracted with diethyl ether. The solvent was evaporated to yield the crude 
product which was purified by column chromatography (eluent 9:1 hexane: diethyl 
ether) yielding the title compound as deep purple crystals. (24 g, 42%), mp. 120 -121 
°C (lit. 
1
 120 - 122 °C); 
1
H NMR (400 MHz) δ (DMSO- d6):  9.88 (1H, s, -CHO), 4.73 (2H, s, ortho on η
5
-
C5H4-CHO), 4.54 (2H, s, meta on η
5
-C5H4-CHO), 4.21 (5H, s, η
5
-C5H5); 
13
C NMR (100 MHz) δ (DMSO- d6): 193.5 (C=O), 71.4 (Cipso η
5
-C5H4-CHO), 69.9 
(Cmeta η
5
-C5H4-CHO), 69.7 (Cortho η
5
-C5H4-CHO), 67.8 (η
5
-C5H5). 
 
Acetylferrocene (49) 
[2]
  
 
Ferrocene (50 g, 268.76 mmol) was dissolved in acetic anhydride (180 ml) and the 
reaction mixture was allowed to stir for 10 min. Phosphoric acid (50 ml) was added 
slowly to the reaction mixture over 30 min. Reaction mixture was refluxed at 70 °C for 
15 min. The reaction mixture was poured onto ice and neutralised with conc. sodium 
hydroxide solution. The resulting solution was extracted with diethyl ether. The solvent 
was evaporated to yield the crude product which was purified by column 
chromatography (eluent 9:1 hexane: diethyl ether) yielding the title compound as a red 
solid. (50 g, 82%), mp. 82 - 83 °C (lit. 
2
 81 - 83 °C); 
1
H NMR (400 MHz) δ (DMSO- d6): 4.78 (2H, t, J =1.2 Hz, ortho on η
5
-C5H4-COCH3), 
4.57 (2H, t, J =1.2 Hz, meta on η5-C5H4-COCH3), 4.21 (5H, s, η
5
-C5H5), 2.35 (3H, s, -
COCH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 200.1 (C=O), 71.8 (Cipso η
5
-C5H4-COCH3), 70.1 
(Cmeta η
5
-C5H4-COCH3), 68.7 (Cortho η
5
-C5H4-COCH3), 63.5 (η
5
-C5H5), 27.7 (η
5
-C5H4-
COCH3). 
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Propionyl ferrocene (50) 
 
Ferrocene (50 g, 268.76 mmol) was dissolved with propionic anhydride (150 ml) and 
reaction mixture was allowed to stir for 10 min. Phosphoric acid ( 38 ml) was added 
slowly to the reaction mixture over 30 min. Reaction mixture was refluxed at 80 °C for 
15 min. The reaction mixture was poured onto ice and neutralised with conc. sodium 
hydroxide solution. The resulting solution was extracted with with ethyl acetate. The 
solvent was evaporated to yield the crude product which was purified by column 
chromatography (eluent 9:1 hexane: diethyl ether) yielding the title compound as a dark 
brown oil. (34 g, 52%),  
1
H NMR (400 MHz) δ (DMSO- d6): 4.71 (2H, s, ortho on η
5
-C5H4-COCH2CH3), 4.50 
(2H, s, meta on η5-C5H4-COCH2CH3), 4.19 (5H, s, η
5
-C5H5), 2.78 (2H, q, J = 7.2 Hz, -
COCH2CH3), 1.27 (3H, t, J = 7.2 Hz, -COCH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 200.1 (C=O), 71.8 (Cipso η
5
-C5H4-COCH2CH3), 
70.1 (Cmeta η
5
-C5H4-COCH2CH3), 68.4 (Cortho η
5
-C5H4-COCH2CH3), 65.5 (η
5
-C5H5), 
60.6 (-COCH2CH3, -ve DEPT), 17.7 (-COCH2CH3). 
 
Methylferrocene (51)  
 
Lithium aluminum hydride (1.42 g, 37.38 mmol) was dissolved in dry diethyl ether 
(100 ml) under nitrogen at 0 
o
C. Ferrocene carboxyaldehyde (4.00 g, 18.69 mmol) was 
then added slowly followed by anhydrous aluminum chloride (4.98 g, 37.38 mmol). 
The reaction mixture was than allowed to reflux at 55 
o
C for 12 h. The reaction mixture 
was then quenched in ice. The ether layer was washed with water and dried over 
MgSO4. The solvent was removed in vacuo to yield the crude product which was 
purified by column chromatography {eluent 3:2 hexane: diethyl ether} yielding the title 
product as a red oil (3.20 g, 80%),   
1
H NMR (400 MHz) δ ( DMSO- d6 ): 4.12 (5H, s, η
5
-C5H5), 4.09 (2H, s, meta on η
5
-
C5H4-alkyl),  4.02 (2H, s, ortho on η
5
-C5H4-alkyl), 1.95  ( 3H, s, -CH3);  
13
C NMR (100 MHz) δ (DMSO- d6): 89.5 (Cipso η
5
-C5H4-alkyl), 67.1 (Cmeta η
5
-C5H4-
CH3), 65.1 (Cortho η
5
-C5H4-alkyl), 65.8 (η
5
-C5H5), 14.0 (-CH3). 
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1-methyl-1’-para-ferrocenyl ethyl benzoate (52) 
 
Ethyl-4-aminobenzoate (4.13 g, 25.00 mmol) was dissolved in deionised water (30 ml) 
at 0 
o
C followed by addition of concentrated HCl (7 ml). Sodium nitrite (1.72 g, 25.00 
mmol) was dissolved in deionised water (20 ml) at 0 
o
C and was then added to the 
ethyl-4-aminobenzoate solution with stirring at a temperature less than 5 
o
C. The 
resulting pale yellow diazonium salt was then added to a solution of methylferrocene 
(5.00 g, 25.00 mmol) in dry diethyl ether (100 ml) and the reaction mixture was 
allowed to stir at room temperature for 48 h. The reaction mixture was then washed 
with water and brine and the organic layer was dried over MgSO4.  The solvent was 
removed in vacuo to yield the crude product. The crude product was purified by column 
chromatography {eluent 3:2 hexane: diethyl ether} yielding the title product as a red oil 
(1.45 g, 16%), 
1H NMR (400 MHz) δ (DMSO- d6): 7.87 (2H, d, J = 7.4 Hz, ArH), 7.62 (2H, d, J = 7.4 
Hz, ArH), 4.82 (2H, s, ortho on η5-C5H4-benzoyl), 4.38 (2H, s, meta on η
5
-C5H4-
benzoyl), 4.32 (2H, q, J = 6.8 Hz, -OCH2CH3), 3.90 (4H, dd, η
5
-C5H4-alkyl), 1.60 (3H, 
s,  -CH3),  1.19  (3H, t, J = 6.8 Hz, -OCH2CH3); 
13C NMR (100 MHz) δ (DMSO- d6): 169.0 (C=O), 140.3 (Cq), 128.3 (Cq), 127.0, 
125.4, 90.0 (Cipso η
5
-C5H4-alkyl), 85.7 (Cipso η
5
-C5H4-benzoyl), 71.1 (Cmeta η
5
-C5H4-
benzoyl), 69.8 (Cmeta η
5
-C5H4-alkyl), 68.5 (Cortho η
5
-C5H4-alkyl), 67.0 (Cortho η
5
-C5H4-
benzoyl), 61.3 (-OCH2CH3, -ve DEPT), 14.4 (-OCH2CH3), 13.9 (-CH3). 
 
1-methyl-1’-para-ferrocenyl benzoic acid (53) 
 
1-methyl-1’-para-ferrocenyl ethyl benzoate (1.45 g, 4.00 mmol) was dissolved in 
methanol (50 ml) and a 10% v/v sodium hydroxide solution (50 ml) was then added. 
The reaction mixture was then allowed to reflux at 80 
o
C for 12 h. The reaction mixture 
was then cooled to 0 
o
C and conc. HCl was added until the solution reached pH 2. The 
product was isolated by filtration and recrystallisation from chloroform furnished the 
desired product as an orange solid (0.60 g, 47%),  
1
H NMR (400 MHz) δ (DMSO- d6): 12.85 (1H, s, -COOH), 7.89 (2H, d, J = 7.2 Hz, 
ArH), 7.68 (2H, t, J = 7.2 Hz, ArH), 4.89 (2H, s, ortho on η5-C5H4-benzoyl) , 4.41 (2H, 
s, meta on η5-C5H4-benzoyl), 3.95 (4H, dd, η
5
-C5H4-alkyl), 1.62 (3H, s, -CH3); 
 163 
13
C NMR (100 MHz) δ (DMSO- d6): 169.9 (C=O), 140.3 (Cq), 128.4 (Cq), 127.1, 
125.4,  92.6 (Cipso η
5
-C5H4-alkyl), 82.7 (Cipso η
5
-C5H4-benzoyl), 71.0 (Cmeta η
5
-C5H4-
benzoyl), 68.1 (Cmeta η
5
-C5H4-alkyl), 68.6 (Cortho η
5
-C5H4-alkyl),  67.2 (Cortho η
5
-C5H4-
benzoyl),  14.0 (-CH3). 
 
1-methyl-1’-para-ferrocenyl benzoic acid (53) via diazonium coupling using 4-
amino benzoic acid  
 
4-Aminobenzoic acid (3.43 g, 25.00 mmol) was dissolved in deionised water (30 ml) at 
0 
o
C followed by the addition of concentrated HCl (7 ml). Sodium nitrite (1.72 g, 25.00 
mmol) was dissolved in deionised water (20 ml) at 0 
o
C and was then added to the 
ethyl-4-aminobenzoic solution with stirring at a temperature less than 5 
o
C. The 
resulting pale yellow diazonium salt was then added to a solution of methylferrocene 
(5.00 g, 25.00 mmol) in dry diethyl ether (100 ml) and the reaction mixture was 
allowed to stir at room temperature for 48 h. The reaction mixture was then washed 
with water and brine and the organic layer was dried over MgSO4.  The solvent was 
removed in vacuo to yield the crude product. The crude product was purified by column 
chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title product as a red oil 
(1.65 g, 21%), 
1
H NMR (400 MHz) δ (DMSO- d6): 12.80 (1H, s, -COOH), 7.79 (2H, d, J = 7.2 Hz, 
ArH), 7.67 (2H, d, J = 7.2 Hz, ArH), 4.89 (2H, s, ortho on η5-C5H4-benzoyl), 4.41 (2H, 
s, meta on η5-C5H4-benzoyl), 3.90 (4H, dd, η
5
-C5H4-alkyl), 1.62 (3H, s, -CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 174.3 (C=O), 140.1 (Cq), 132.4 (Cq), 126.5, 
123.9, 91.6 (Cipso η
5
-C5H4-alkyl), 80.7 (Cipso η
5
-C5H4-benzoyl), 73.2 (Cmeta η
5
-C5H4-
benzoyl), 69.8(Cmeta η
5
-C5H4-alkyl), 68.0 (Cortho η
5
-C5H4-alkyl), 67.5 (Cortho η
5
-C5H4-
benzoyl), 13.1(-CH3). 
 
1-methyl-1’-meta-ferrocenyl benzoic acid (54)       
 
3-Aminobenzoic acid (3.43 g, 25.00 mmol) and methylferrocene (5.00 g, 25.00 mmol) 
was used as starting materials. The title product was isolated by filtration and 
recrystallisation from chloroform furnished the desired product as an orange solid (1.46 
g, 18%),  
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1
H NMR (400 MHz) δ (DMSO- d6): 12.85 (1H, s, -COOH), 8.00 (1H, s,  ArH), 7.69 
(2H, m,  ArH), 7.36 (1H, t, J = 7.2 Hz, ArH), 4.87 (2H, s, ortho on η5-C5H4-benzoyl), 
4.41 (2H, s, meta on η5-C5H4-benzoyl), 3.96 (4H, dd, η
5
-C5H4-alkyl), 1.62 ( 3H, s, -
CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 170.3 (C=O), 136.5 (Cq), 135.8 (Cq), 129.4, 
128.2, 127.3, 125.1, 90.0 (Cipso η
5
-C5H4-alkyl), 83.2 (Cipso η
5
-C5H4-benzoyl), 72.2 
(Cmeta η
5
-C5H4-benzoyl), 68.8 (Cmeta η
5
-C5H4-alkyl), 68.0 (Cortho η
5
-C5H4-alkyl),  67.3 
(Cortho η
5
-C5H4-benzoyl),  13.9 (-CH3). 
 
1-methyl-1’-ortho-ferrocenyl benzoic acid (55) 
 
2-Aminobenzoic acid (3.43 g, 25.00 mmol) and methylferrocene (5.00 g, 25.00 mmol) 
was used as starting materials. The title product was isolated by filtration and 
recrystallisation from chloroform furnished the desired product as an orange solid (1.26 
g, 16%),  
1
H NMR (400 MHz) δ (DMSO- d6): 12.85 (1H, s, -COOH), 7.95 (1H, d, J = 7.6 Hz, 
ArH), 7.77 (1H, t, J = 7.2 Hz, ArH), 7.65 (1H, t, J = 6.4 Hz, ArH), 7.40 (1H, d, J = 7.6 
Hz, ArH), 4.89 (2H, s, ortho on η5-C5H4-benzoyl), 4.41 (2H, s, meta on η
5
-C5H4-
benzoyl), 3.95 (4H, dd, η5-C5H4-alkyl), 1.62 ( 3H, s, -CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 171.3 (C=O), 140.3 (Cq), 137.5 (Cq), 130.4, 
128.7, 126.3, 125.9, 92.6 (Cipso η
5
-C5H4-alkyl), 80.7 (Cipso η
5
-C5H4-benzoyl), 73.9 
(Cmeta η
5
-C5H4-benzoyl), 68.2 (Cmeta η
5
-C5H4-alkyl), 67.9 (Cortho η
5
-C5H4-alkyl), 67.0 
(Cortho η
5
-C5H4-benzoyl), 13.5 (-CH3). 
 
Ethylferrocene (56) 
 
For compound 56 acetyl ferrocene (4.00 g, 17.54 mmol) was used as a starting material. 
The crude product was purified by column chromatography {eluent 3:2 hexane: diethyl 
ether} yielding the titled product as a red oil (3.12 g, 83%),   
1H NMR (400 MHz) δ (DMSO- d6):  4.12 (5H, s, η
5
-C5H5), 4.10 (2H, t, J = 1.6 Hz, 
meta on η5-C5H4-alkyl), 4.09 (2H, t, J =1.6 Hz, η
5
-C5H4-alkyl), 2.31 (2H, q, J =7.6 Hz, 
-CH2CH3), 1.14 (3H, t, J = 7.6 Hz, -CH2CH3); 
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13C NMR (100 MHz) δ (DMSO- d6):  90.5 (Cipso η
5
-C5H4-alkyl), 68.1 (Cmeta η
5
-C5H4-
alkyl), 67.1 (Cortho η
5
-C5H4-alkyl), 66.8 (η
5
-C5H5), 21.7 (-CH2CH3, -ve DEPT), 14.5 (-
CH2CH3). 
 
Ethylferrocene (56) via Suzuki cross coupling  
 
Ferroceneboronic acid (0.50 g, 2.17 mmol), iodoethane (0.34 g, 2.17 mmol),  
{1,1-bis-(diphenylphosphino) ferrocene}dichloropalladium(II) (0.08 g) was dissolved 
in dimethoxyethane (40 ml) and 5 ml of 3M NaOH  was added. The reaction was 
refluxed for 72 h. Water (30 ml) was added and the reaction was extracted with 
chloroform (150 ml). The combined organic layers were then washed with water (150 
ml) and dried over MgSO4. The solvent was removed in vacuo to yield the crude 
product. The crude product was purified by column chromatography {eluent 3:2 
hexane: diethyl ether} yielding the titled product as a red oil (0.10 g, 20%)   
 
1-ethyl-1’-para-ferrocenyl benzoic acid (57) 
 
4-Aminobenzoic acid (3.20 g, 23.36 mmol) was dissolved in deionised water (30 ml) at 
0 
o
C followed by the addition of concentrated HCl (7 ml). Sodium nitrite (1.61 g, 23.36 
mmol) was dissolved in deionised water (20 ml) at 0 
o
C and was then added to the 
ethyl-4-aminobenzoic solution with stirring at a temperature less than 5 
o
C. The 
resulting pale yellow diazonium salt was then added to a solution of ethylferrocene 
(5.00 g, 23.36 mmol) in dry diethyl ether (100 ml) and the reaction mixture was 
allowed to stir at room temperature for 48 h. The reaction mixture was then washed 
with water and brine and the organic layer was dried over MgSO4.  The solvent was 
removed in vacuo to yield the crude product. The title product was isolated by filtration 
and recrystallisation from chloroform furnished the desired product as an orange solid 
(1.80 g, 23%),  
1
H NMR (400 MHz) δ (DMSO- d6): 12.85 (1H, s, -COOH), 7.86 (2H, d, J = 7.6 Hz, 
ArH), 7.62 (2H, d, J = 7.6 Hz, ArH), 4.82 (2H, t, J =1.6 Hz, ortho on η5-C5H4-
benzoyl), 4.31 (2H, t, J =1.6 Hz, meta on η5-C5H4-benzoyl), 3.91 (4H, dd, η
5
-C5H4-
alkyl), 2.04 (2H, q, J = 7.2 Hz, -CH2CH3), 0.97 (3H, t, J = 7.2 Hz, -CH2CH3); 
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13C NMR (100 MHz) δ (DMSO- d6): 167.3 (C=O), 144.3 (Cq), 129.4 (Cq), 127.5, 
125.4, 91.6 (Cipso η
5
-C5H4-alkyl), 81.3 (Cipso η
5
-C5H4-benzoyl), 70.2 (Cmeta η
5
-C5H4-
benzoyl), 68.8 (Cmeta η
5
-C5H4-alkyl), 68.6 (Cortho η
5
-C5H4-alkyl), 67.0 (Cortho η
5
-C5H4-
benzoyl), 20.7 (-CH2CH3, -ve DEPT), 14.4 (-CH2CH3). 
 
1-ethyl-1’-meta-ferrocenyl benzoic acid (58) 
 
3-Aminobenzoic acid (3.20 g, 23.36 mmol) and ethylferrocene (5.00 g, 23.36 mmol) 
was used as starting materials. The title product was isolated by filtration and 
recrystallisation from chloroform furnished the desired product as an orange solid (1.48 
g, 19%), 
1H NMR (400 MHz) δ (DMSO- d6): 12.85 (1H, s, -COOH), 8.05 (1H, s,  ArH), 7.70 - 
7.66 (2H, m,  ArH), 7.39 (1H, t, J = 7.2 Hz, ArH), 4.89 (2H, t, J =1.6 Hz, ortho on η5-
C5H4-benzoyl), 4.41 (2H, t, J =1.6 Hz, meta on η
5
-C5H4-benzoyl), 3.95 (4H, dd,  η
5
-
C5H4-alkyl), 2.31 (2H, q, J =7.6 Hz, -CH2CH3),  1.14 (3H, t, J = 7.6 Hz, -CH2CH3); 
13C NMR (100 MHz) δ (DMSO- d6): 169.3 (C=O), 139.5 (Cq), 135.8 (Cq), 132.4, 
128.7, 127.7, 125.9, 91.6 (Cipso η
5
-C5H4-alkyl), 81.7 (Cipso η
5
-C5H4-benzoyl), 71.2 
(Cmeta η
5
-C5H4-benzoyl), 68.8 (Cmeta η
5
-C5H4-alkyl), 68.6 (Cortho η
5
-C5H4-alkyl), 66.9 
(Cortho η
5
-C5H4-benzoyl),  23.0 (-CH2CH3,-ve DEPT), 13.5 (-CH2CH3). 
 
1-ethyl-1’-ortho-ferrocenyl benzoic acid (59) 
 
2-Aminobenzoic acid (3.20 g, 23.36 mmol) and ethylferrocene (5.00 g, 23.36 mmol) 
was used as starting materials. The title product was isolated by filtration and 
recrystallisation from chloroform furnished the desired product as an orange solid (1.29 
g, 17%), 
1
H NMR (400 MHz) δ (DMSO- d6): 12.85 (1H, s, -COOH), 7.97 (1H, d, J = 7.6 Hz, 
ArH), 7.74 (1H, t, J = 7.2 Hz, ArH), 7.62 (1H, t, J = 6.4 Hz, ArH), 7.44 (1H, d, J = 7.6 
Hz, ArH), 4.89 (2H, t, J =1.6 Hz, ortho on η5-C5H4-benzoyl), 4.41 (2H, t, J =1.6 Hz, 
meta on η5-C5H4-benzoyl), 3.95 (4H, dd, η
5
-C5H4-alkyl), 2.32 (2H, q, J =7.6 Hz, -
CH2CH3),  1.13 (3H, t, J = 7.6 Hz, -CH2CH3); 
13C NMR (100 MHz) δ (DMSO- d6):169.3 (C=O), 140.3 (Cq), 135.8 (Cq), 131.4, 127.2, 
126.3, 125.1, 89.6 (Cipso η
5
-C5H4-alkyl), 80.7 (Cipso η
5
-C5H4-benzoyl), 70.2 (Cmeta η
5
-
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C5H4-benzoyl), 68.8 (Cmeta η
5
-C5H4-alkyl), 68.6 (Cortho η
5
-C5H4-alkyl), 67.0 (Cortho η
5
-
C5H4-benzoyl), 22.7 (-CH2CH3, -ve DEPT), 14.0 (-CH2CH3). 
 
Propylferrocene (60) 
 
For compound 60 propionyl ferrocene (4.00 g, 16.53 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 3:2 
hexane: diethyl ether} yielding the titled product as a red oil (3.16 g, 84%),   
1H NMR (400 MHz) δ (DMSO- d6):  4.13 (5H, s, η
5
-C5H5), 4.09 (2H, s, meta on η
5
-
C5H4-alkyl), 4.05 (2H, s, ortho on η
5
-C5H4-alkyl), 2.31 (2H, t, J = 7.6 Hz, -
CH2CH2CH3), 1.54 - 1.45 (2H, m, -CH2CH2CH3),  0.92 (3H, t, J = 7.2 Hz,  -
CH2CH2CH3); 
13C NMR (100 MHz) δ (DMSO- d6):  91.5 (Cipso η
5
-C5H4-alkyl), 69.1 (Cmeta η
5
-C5H4-
alkyl), 68.1 (Cortho η
5
-C5H4-alkyl), 66.8 (η
5
-C5H5), 30.3 (-CH2CH2CH3, -ve DEPT), 
22.7 (-CH2CH2CH3, -ve DEPT), 14.4 (-CH2CH2CH3). 
 
1-propyl-1’-para-ferrocenyl benzoic acid (61) 
 
4-Aminobenzoic acid (3.01 g, 21.93 mmol) was dissolved in deionised water (30 ml) at 
0 
o
C followed by the addition of concentrated HCl (7 ml). Sodium nitrite (1.51 g, 21.93 
mmol) was dissolved in deionised water (20 ml) at 0 
o
C and was then added to the 
ethyl-4-aminobenzoic solution with stirring at a temperature less than 5 
o
C. The 
resulting pale yellow diazonium salt was then added to a solution of propyl ferrocene 
(5.00 g, 21.93 mmol) in dry diethyl ether (100 ml) and the reaction mixture was 
allowed to stir at room temperature for 48 h. The reaction mixture was then washed 
with water and brine and the organic layer was dried over MgSO4.  The solvent was 
removed in vacuo to yield the crude product. The title product was isolated by filtration 
and recrystallisation from chloroform furnished the desired product as an orange solid 
(1.61 g, 21%), 
1
H NMR (400 MHz) δ (DMSO- d6): 12.85 (1H, s, -COOH), 7.86 (2H, d, J = 7.4 Hz, 
ArH), 7.62 (2H, d, J = 7.4 Hz, ArH), 4.82 (2H, s, ortho on η5-C5H4-benzoyl), 4.38 (2H, 
s, meta on η5-C5H4-benzoyl), 3.92 (4H, dd, η
5
-C5H4-alkyl), 1.94 (2H, t, J = 7.6 Hz, -
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CH2CH2CH3), 1.40 - 1.27 (2H, m, -CH2CH2CH3),  0.75 (3H, t, J = 7.6 Hz,  -
CH2CH2CH3); 
13C NMR (100 MHz) δ ( DMSO- d6 ): 167.3 (C=O), 144.3 (Cq), 129.3 (Cq), 127.5, 
125.4, 89.3 (Cipso η
5
-C5H4-alkyl), 81.7 (Cipso η
5
-C5H4-benzoyl),  70.1 (Cmeta η
5
-C5H4-
benzoyl), 68.8 (Cmeta η
5
-C5H4-alkyl), 68.5 (Cortho η
5
-C5H4-alkyl),  67.0 (Cortho η
5
-C5H4-
benzoyl),  32.3 (-CH2CH2CH3, -ve DEPT), 22.0 (-CH2CH2CH3, -ve DEPT), 14.4 (-
CH2CH2CH3). 
 
1-propyl-1’-meta-ferrocenyl benzoic acid (62)  
 
3-Aminobenzoic acid (3.01 g, 21.93 mmol) and propyl ferrocene (5.00 g, 21.93 mmol) 
was used as starting materials. The title product was isolated by filtration and 
recrystallisation from chloroform furnished the desired product as an orange solid (1.48 
g, 19%), 
1H NMR (400 MHz) δ ( DMSO- d6 ): 12.85 (1H, s, -COOH), 8.00 (1H, s,  ArH), 7.65 
(2H, m,  ArH), 7.30 (1H, t, J = 7.2 Hz, ArH),  4.89 (2H, s, ortho on η5-C5H4-benzoyl), 
4.41 (2H, s, meta on η5-C5H4-benzoyl), 3.95 (4H, dd, η
5
 C5H4-alkyl), 2.31 (2H, t, J = 
7.6 Hz, -CH2CH2CH3), 1.54 - 1.45 (2H, m, -CH2CH2CH3), 0.92 (3H, t, J = 7.2 Hz,  -
CH2CH2CH3); 
13C NMR (100 MHz) δ (DMSO- d6): 168.3 (C=O), 139.5 (Cq), 136.8 (Cq), 132.4, 
128.9, 127.5, 125.7, 89.6 (Cipso η
5
-C5H4-alkyl), 82.7 (Cipso η
5
-C5H4-benzoyl), 72.2 
(Cmeta η
5
-C5H4-benzoyl), 68.9 (Cmeta η
5
-C5H4-alkyl), 68.6 (Cortho η
5
-C5H4-alkyl),  67.0 
(Cortho η
5
-C5H4-benzoyl),  31.3 (-CH2CH2CH3, -ve DEPT), 22.7 (-CH2CH2CH3, -ve 
DEPT), 14.4 (-CH2CH2CH3). 
 
1-propyl-1’-ortho-ferrocenyl benzoic acid (63) 
 
2-Aminobenzoic acid (3.01 g, 21.93 mmol) and propyl ferrocene (5.00 g, 21.93 mmol) 
was used as starting materials. The title product was isolated by filtration and 
recrystallisation from chloroform furnished the desired product as an orange solid (1.26 
g, 17%), 
1H NMR (400 MHz) δ (DMSO- d6): 12.85 (1H, s, -COOH), 7.95 (1H, d, J = 7.6 Hz, 
ArH), 7.77 (1H, t, J = 7.2 Hz, ArH), 7.65 (1H, t, J = 6.4 Hz, ArH), 7.40 (1H, d, J = 7.6 
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Hz, ArH), 4.89 (2H, s, ortho on η5-C5H4-benzoyl), 4.41 (2H, s, meta on η
5
-C5H4-
benzoyl), 3.95 (4H, dd, η5-C5H4-alkyl), 2.31 (2H, t, J = 7.6 Hz, -CH2CH2CH3), 1.54 - 
1.45 (2H, m, -CH2CH2CH3),  0.92 (3H, t, J = 7.2 Hz,  -CH2CH2CH3); 
13C NMR (100 MHz) δ (DMSO- d6): 169.3 (C=O), 138.5 (Cq), 135.8 (Cq), 130.4, 
128.2, 126.3, 124.1, 90.6 (Cipso η
5
-C5H4-alkyl), 82.7 (Cipso η
5
-C5H4-benzoyl), 71.2 
(Cmeta η
5
-C5H4-benzoyl), 68.7 (Cmeta η
5
-C5H4-alkyl), 68.2 (Cortho η
5
-C5H4-alkyl), 67.1 
(Cortho η
5
-C5H4-benzoyl), 34.3 (-CH2CH2CH3, -ve DEPT), 22.0 (-CH2CH2CH3, -ve 
DEPT), 14.0 (-CH2CH2CH3). 
 
General procedure for the synthesis of 1-methyl-1’-N-ferrocenyl benzoyl dipeptide 
ethyl esters 
 
1-methyl-1’-N-{para -(ferrocenyl) benzoyl} glycine glycine ethyl ester (64) 
 
1-methyl-1’-N-para ferrocenyl benzoic acid (0.25 g, 0.78 mmol) was dissolved in 
dichloromethane (100 ml) at 0 
o
C. N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.15 g, 0.78 mmol), 1-hydroxybenotriazole (0.11 g, 0.78 mmol), glycine 
glycine ethyl ester hydrochloride (0.13 g, 0.78 mmol) and triethylamine (3 ml) were 
added and the reaction mixture was allowed to stir at 0 
o
C for 45 min. The reaction 
mixture was then allowed to stir at room temperature for 48 h. The reaction mixture 
was then washed with water and brine. The organic layer was then dried over MgSO4. 
The solvent was removed in vacuo to yield the crude product. The crude product was 
purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the 
titled product as an orange solid (0.10 g, 28%), m.p 75 - 77 
o
C; 
Mass spectrum: [M+Na]
+
  found:   485.1289
 
C24H26N2O4FeNa requires:              485.1291                  
I.R. υmax (KBr): 3300 (NH), 1740 (C=Oester), 1630 (C=Oamide), 1608 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 360, 451 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.76 (1H, t, J = 6.0 Hz,  -CONH-), 8.35 (1H, t, J = 
6 Hz,  -CONH-), 7.82 (2H, d, J = 8.4 Hz, ArH), 7.60 (2H, d, J = 8.4 Hz, ArH), 4.80 
(2H, s, ortho on η5-C5H4-benzoyl), 4.35 (2H, s, meta on η
5
-C5H4-benzoyl), 4.09 (2H, q, 
J = 7.2 Hz, -OCH2CH3), 3.90 - 3.80 {8H, m, (η
5
-C5H4-alkyl), (-NHCH2CHO-), (-
NHCH2CHO-)}, 1.58 (3H, s, -CH3), 1.19 (3H, t, J = 7.2 Hz, -OCH2CH3); 
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13
C NMR (100 MHz) δ ( DMSO- d6 ): 171.5 (C=O), 168.2 (C=O), 166.5 (C=O), 142.3 
(Cq), 130.8 (Cq), 127.4, 125.2, 92.3 (Cipso η
5
-C5H4-alkyl), 82.0 (Cipso η
5
-C5H4-benzoyl), 
70.4 (Cmeta η
5
-C5H4-benzoyl), 69.1 (Cmeta η
5
-C5H4-alkyl), 68.4 (Cortho η
5
-C5H4-alkyl), 
66.2 (Cortho η
5
-C5H4-benzoyl), 61.5 (-OCH2CH3, -ve DEPT), 42.6 (-NHCH2CHO-, -ve 
DEPT), 40.7 (-NHCH2CHO-, -ve DEPT), 14.5 (-OCH2CH3), 14.2 (-CH3). 
 
1-methyl-1’-N-{para-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester (65) 
 
Glycine L-alanine ethyl ester hydrochloride (0.14 g, 0.78 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.08 g, 22%),  
[α]D
20
 = -10 
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   499.1394
 
C25H28N2O4FeNa requires:              499.1396                  
I.R. υmax  (KBr): 3295 (NH), 1743 (C=Oester), 1636 (C=Oamide), 1608 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 360, 451 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.67 (1H, t, J = 6.4 Hz,  -CONH-), 8.41 (1H, d, J 
= 7.0 Hz,  -CONH-), 7.80 (2H, d, J = 8.4 Hz, ArH), 7.61 (2H, d, J = 8.4 Hz, ArH), 
4.81 (2H, s, ortho on η5-C5H4-benzoyl), 4.36 (2H, s, meta on η
5
-C5H4-benzoyl), 4.31 - 
4.24 ( 1H, m, -CHCH3), 4.05 (2H, q, J = 6.8 Hz, -OCH2CH3) ,  3.96 - 3.85 {6H, m,  
(η5-C5H4-alkyl), (-NHCH2CO-)}, 1.60 (3H, s, -CH3), 1.31 (3H, t, J = 6.2 Hz, -CHCH3), 
1.18 (3H, t, J = 6.8 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 172.5 (C=O), 169.0 (C=O), 166.5 (C=O), 142.5 
(Cq), 130.8 (Cq), 127.4, 125.2, 92.3 (Cipso η
5
-C5H4-alkyl), 82.0 (Cipso η
5
-C5H4-benzoyl), 
71.0 (Cmeta η
5
-C5H4-benzoyl), 69.8 (Cmeta η
5
-C5H4-alkyl), 68.5 (Cortho η
5
-C5H4-alkyl), 
66.9 (Cortho η
5
-C5H4-benzoyl), 60.9 (-OCH2CH3, -ve DEPT), 47.6 (-CHCH3), 42.0 (-
NHCH2CHO-, -ve DEPT), 17.0 (-CHCH3), 14.5 (-OCH2CH3), 14.0 (-CH3). 
 
 
1-methyl-1’-N-{para-(ferrocenyl) benzoyl} glycine L-leucine ethyl ester (66) 
 
Glycine L-leucine ethyl ester hydrochloride (0.17 g, 0.78 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
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hexane: ethyl acetate} and recrystallisation from hexane: ethyl acetate yield the desired 
product as an orange solid (0.07 g, 17%), m.p 142 - 144 
o
C; 
[α]D
20
 = -17
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   541.1884
 
C28H34N2O4FeNa requires:              541.1888                  
I.R. υmax (KBr): 3267 (NH), 1742 (C=Oester), 1640 (C=Oamide), 1610 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 358, 450 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.65 (1H, t, J = 6.0 Hz,  -CONH-), 8.33 (1H, d, J 
= 7.6 Hz,  -CONH-), 7.80 (2H, d, J = 8.0 Hz, ArH), 7.60 (2H, d, J = 8.0 Hz, ArH), 
4.82 (2H, s, ortho on η5-C5H4-benzoyl), 4.37 - 4.29 {3H, m, (meta on η
5
-C5H4-
benzoyl), ( -CH(CH2CH(CH3)2)}, 4.08 (2H, q, J = 7.2 Hz, -OCH2CH3), 3.96 - 3.85 
{6H, m, (η5-C5H4-alkyl), (-NHCH2CO-)}, 1.63 - 1.40 {6H, m, (-CH3), (-
CH(CH2CH(CH3)2)}, 1.18 (3H, t, J = 7.2 Hz, -OCH2CH3), 0.91- 0.89 {6H, m, -
CH(CH2CH(CH3)2}; 
13
C NMR (100 MHz) δ (DMSO- d6): 172.5 (C=O), 169.2 (C=O), 166.2 (C=O), 142.2 
(Cq), 130.8 (Cq), 127.4, 125.2, 90.4 (Cipso η
5
-C5H4-alkyl), 84.2 (Cipso η
5
-C5H4-benzoyl), 
70.1 (Cmeta η
5
-C5H4-benzoyl), 70.0 (Cmeta η
5
-C5H4-alkyl), 68.4 (Cortho η
5
-C5H4-alkyl), 
66.9 (Cortho η
5
-C5H4-benzoyl), 60.4 (-OCH2CH3, -ve DEPT), 50.3 {-
CH(CH2CH(CH3)2}, 42.0 (-NHCH2CHO-, -ve DEPT), 39.4 {-CH(CH2CH(CH3)2), -ve 
DEPT}, 24.2 {-CH(CH2CH(CH3)2}, 22.7 (-CH(CH2CH(CH3)2}, 21.4 {-
CH(CH2CH(CH3)2}, 14.0 (-OCH2CH3), 13.2 (-CH3). 
 
 
1-methyl-1’-N-{para-(ferrocenyl) benzoyl} glycine L-phenylalanine ethyl ester (67) 
 
Glycine L-phenylalanine ethyl ester hydrochloride (0.20 g, 0.78 mmol) was used as a 
starting material. The crude product was purified by column chromatography {eluent 
1:1 hexane: ethyl acetate} and recrystallisation from hexane: ethyl acetate yield the 
desired product as an orange solid (0.07 g, 16%), m.p 82 - 83 
o
C; 
[α]D
20
 = +6
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   575.1794
 
C31H32N2O4FeNa requires:              575.1796                  
I.R. υmax  (KBr): 3263 (NH), 1735 (C=Oester), 1663 (C=Oamide), 1609 (C=Oamide) cm
-1
;
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UV-Vis λmax EtOH: 358, 448 nm; 
1
H NMR (400 MHz) δ ( DMSO- d6 ): 8.68 (1H, t, J = 6.4 Hz,  -CONH-), 8.34 (1H, d, J 
= 7.6 Hz,  -CONH-), 7.81 (2H, d, J = 8.4 Hz, ArH), 7.60 (2H, d, J = 8.4 Hz, ArH), 
7.27 - 7.21 {5H, m, -CH(CH2Ph)}, 4.80 (2H, s, ortho on η
5
-C5H4-benzoyl), 4.47 - 4.45 
{1H, m, -CH(CH2Ph)}, 4.35 (2H, s, meta on η
5
-C5H4-benzoyl), 4.04 (2H, q, J = 7.2 Hz, 
-OCH2CH3),  3.96 - 3.85 {6H, m, (η
5
-C5H4-alkyl), (-NHCH2CO-)}, 3.06 - 2.93 {2H, m, 
-CH(CH2Ph)}, 1.57 (3H, s,  -CH3),  1.12 ( 3H, t, J = 7.2 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 172.4 (C=O), 169.2 (C=O), 166.3 (C=O), 142.0 
(Cq) 136.9 (Cq), 130.7 (Cq), 129.1, 128.0, 127.4, 126.0, 125.2, 90.2 (Cipso η
5
-C5H4-
alkyl), 82.0 (Cipso η
5
-C5H4-benzoyl), 71.4 (Cmeta η
5
-C5H4-benzoyl), 71.0 (Cmeta η
5
-C5H4-
alkyl), 68.0 (Cortho η
5
-C5H4-alkyl), 66.4 (Cortho η
5
-C5H4-benzoyl), 61.4 (-OCH2CH3, -ve 
DEPT), 53.6 {-CH(CH2Ph)}, 42.9 (-NHCH2CHO-, -ve DEPT), 36.7 {-CH(CH2Ph), -ve 
DEPT}, 14.0 (-OCH2CH3), 13.2 (-CH3). 
 
1-methyl-1’-N-{meta-(ferrocenyl) benzoyl} glycine glycine ethyl ester (68) 
 
Glycine glycine ethyl ester hydrochloride (0.13 g, 0.78 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.09 g, 25%),  
Mass spectrum: [M+Na]
+
  found:   499.1286
 
C24H26N2O4FeNa requires:              485.1291                  
I.R. υmax (KBr): 3350 (NH), 1751 (C=Oester), 1627 (C=Oamide), 1602 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 333, 447 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.65 (1H, t, J = 6.0 Hz,  -CONH-), 8.30 (1H, t, J = 
7.6 Hz,  -CONH-), 8.00 (1H, s,  ArH), 7.69 - 7.67 (2H, m,  ArH), 7.39 (1H, t, J = 7.2 
Hz, ArH), 4.80 (2H, s, ortho on η5-C5H4-benzoyl), 4.31 (2H, s, meta on η
5
-C5H4-
benzoyl), 4.10 (2H, q, J = 7.2 Hz, -OCH2CH3) ,  3.91 - 3.82 {8H, m, (η
5
-C5H4-alkyl), (-
NHCH2CHO-), (-NHCH2CHO-)}, 1.61 (3H, s, -CH3),  1.18  (3H, t, J = 7.2 Hz, -
OCH2CH3);  
13
C NMR (100 MHz) δ (DMSO- d6): 170.5 (C=O), 167.2 (C=O), 166.5 (C=O), 136.5 
(Cq), 135.8 (Cq), 129.4, 128.2, 127.3, 125.1, 92.3 (Cipso η
5
-C5H4-alkyl), 82.0 (Cipso η
5
-
C5H4-benzoyl), 70.4 (Cmeta η
5
-C5H4-benzoyl), 69.1 (Cmeta η
5
-C5H4-alkyl), 68.4 (Cortho 
η5-C5H4-alkyl), 66.2 (Cortho η
5
-C5H4-benzoyl), 61.5 (-OCH2CH3, -ve DEPT), 42.6 (-
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NHCH2CHO-, -ve DEPT), 40.7 (-NHCH2CHO-, -ve DEPT), 14.5 (-OCH2CH3), 14.2 (-
CH3). 
 
1-methyl-1’-N-{meta-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester (69) 
 
Glycine L-alanine ethyl ester hydrochloride (0.14 g, 0.78 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.08 g, 22%),  
[α]D
20
 =  -13
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   499.1391
 
C25H28N2O4FeNa requires:              499.1396                  
I.R. υmax  (KBr):  3311 (NH), 1751 (C=Oester), 1620 (C=Oamide), 1601 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 333, 447 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.65 (1H, t, J = 6.0 Hz,  -CONH-), 8.30 (1H, d, J 
= 7.6 Hz,  -CONH-), 8.05 (1H, s,  ArH), 7.70 - 7.69 (2H, m,  ArH), 7.39 (1H, t, J = 7.2 
Hz, ArH), 4.81 (2H, s, ortho on η5-C5H4-benzoyl), 4.34 (2H, s, meta on η
5
-C5H4-
benzoyl),  4.30 - 4.24 (1H, m, -CHCH3), 4.00 (2H, q, J = 6.6 Hz, -OCH2CH3) ,  3.92 - 
3.84 {6H, m, (η5-C5H4-alkyl), (-NHCH2CO-)}, 1.59 (3H, s,  -CH3), 1.31 (3H, t, J = 6.2 
Hz, -CHCH3), 1.15 (3H, t, J = 6.6 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 170.5 (C=O), 167.0 (C=O), 166.9 (C=O), 136.5 
(Cq), 135.8 (Cq), 129.0, 128.2, 126.3, 125.1, 90.3 (Cipso η
5
-C5H4-alkyl), 81.0 (Cipso η
5
-
C5H4-benzoyl), 70.9 (Cmeta η
5
-C5H4-benzoyl), 68.4 (Cmeta η
5
-C5H4-alkyl), 67.5 (Cortho 
η5-C5H4-alkyl), 66.4 (Cortho η
5
-C5H4-benzoyl), 60.8 (-OCH2CH3, -ve DEPT), 48.5 (-
CHCH3), 42.2 (-NHCH2CHO-, -ve DEPT), 17.0 (-CHCH3), 14.9 (-OCH2CH3), 14.5 (-
CH3). 
 
1-methyl-1’-N-{meta-(ferrocenyl) benzoyl} glycine L-leucine ethyl ester (70) 
 
For compound 62 glycine L-leucine ethyl ester hydrochloride (0.17 g, 0.78 mmol) was 
used as a starting material. The crude product was purified by column chromatography 
{eluent 1:1 hexane: ethyl acetate} yielding the titled product as a red oil (0.07 g, 17%),  
[α]D
20
 = -19
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   541.1883
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C28H34N2O4FeNa requires:              541.1888                  
I.R. υmax (KBr): 3287 (NH), 1742 (C=Oester), 1649 (C=Oamide), 1610 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 330, 445 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.65 (1H, t, J = 6.0 Hz,  -CONH-), 8.30 (1H, d, J 
= 7.6 Hz,  -CONH-), 8.00 (1H, s,  ArH), 7.69 - 7.66 (2H, m,  ArH), 7.39 (1H, t, J = 7.0 
Hz, ArH) 4.83 (2H, s, ortho on η5-C5H4-benzoyl), 4.36 (2H, s, meta on η
5
-C5H4-
benzoyl), 4.35 - 4.27 {1H, m, -CH(CH2CH(CH3)2)}, 4.15  (2H, q, J = 7.2 Hz, -
OCH2CH3) ,  3.92 - 3.86 {6H, m, (η
5
-C5H4-alkyl), (-NHCH2CO-)}, 1.69 - 1.45 {6H, m, 
( -CH3), (-CH(CH2CH(CH3)2)}, 1.15 (3H, t, J = 7.2 Hz, -OCH2CH3), 0.90 - 0.85 {6H, 
m, -CH(CH2CH(CH3)2};  
13
C NMR (100 MHz) δ (DMSO- d6): 171.7 (C=O), 169.2 (C=O), 166.8 (C=O), 136.5 
(Cq), 135.8 (Cq), 129.4, 128.2, 127.3, 126.1, 86.4 (Cipso η
5
-C5H4-alkyl), 82.1 (Cipso η
5
-
C5H4-benzoyl), 71.4 (Cmeta η
5
-C5H4-benzoyl), 70.1 (Cmeta η
5
-C5H4-alkyl), 68.1 (Cortho 
η5-C5H4-alkyl), 66.5 (Cortho η
5
-C5H4-benzoyl), 61.0 (-OCH2CH3, -ve DEPT), 51.0  
{-CH(CH2CH(CH3)2)}, 42.7 (-NHCH2CHO-, -ve DEPT), 39.5 {-CH(CH2CH(CH3)2), -
ve DEPT}, 25.0{-CH(CH2CH(CH3)2)}, 22.7 {-CH(CH2CH(CH3)2)},  21.4 {-
CH(CH2CH(CH3)2)}, 14.9 (-OCH2CH3), 13.0 (-CH3). 
 
1-methyl-1’-N-{meta-(ferrocenyl) benzoyl} glycine L-phenylalanine ethyl ester (71) 
 
Glycine L-phenyalanine ethyl ester hydrochloride (0.20 g, 0.78 mmol) was used as a 
starting material. The crude product was purified by column chromatography {eluent 
1:1 hexane: ethyl acetate} yielding the titled product as a red oil (0.06 g, 14 %),  
[α]D
20
 = +8 
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   575.1774
 
C31H32N2O4FeNa requires:              575.1766                  
I.R. υmax  (KBr): 3273 (NH), 1729 (C=Oester), 1653 (C=Oamide), 1599 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 333, 449 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.68 (1H, t, J = 6.0 Hz,  -CONH-), 8.32 (1H, d, J 
= 7.6 Hz,  -CONH-), 7.99 (1H, s,  ArH), 7.71 - 7.69 (2H, m,  ArH), 7.40 (1H, t, J = 7.0 
Hz,  ArH), 7.20 - 7.17 {5H, m, -CH(CH2Ph)}, 4.83 (2H, s, ortho on η
5
-C5H4-benzoyl), 
4.45 - 4.40 {1H, m, -CH(CH2Ph)}, 4.35 (2H, s, meta on η
5
-C5H4-benzoyl), 4.04 (2H, q, 
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J = 7.2 Hz, -OCH2CH3) ,  3.95 - 3.87 {6H, m, (η
5
-C5H4-alkyl), (-NHCH2CO-)}, 3.06 - 
2.93 {2H, m, -CH(CH2Ph)}, 1.55 (3H, s,  -CH3),  1.12 ( 3H, t, J = 7.2 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 170.4 (C=O), 169.2 (C=O), 166.3 (C=O), 137.2 
(Cq), 134.9 (Cq), 130.3 (Cq), 129.1, 128.4,  127.3, 126.1, 125.5, 124.1, 122.7, 91.2 (Cipso 
η5-C5H4-alkyl), 80.0 (Cipso η
5
-C5H4-benzoyl), 70.4 (Cmeta η
5
-C5H4-benzoyl), 70.0 (Cmeta 
η5-C5H4-alkyl), 68.4 (Cortho η
5
-C5H4-alkyl), 67.9 (Cortho η
5
-C5H4-benzoyl), 60.8 (-
OCH2CH3, -ve DEPT), 53.0 {-CH(CH2Ph)},  42.7 (-NHCH2CHO-, -ve DEPT), 37.7 {-
CH(CH2Ph), -ve DEPT}, 14.1 (-OCH2CH3), 13.0 (-CH3). 
 
1-methyl-1’-N-{ortho-(ferrocenyl) benzoyl} glycine glycine ethyl ester (72) 
 
Glycine glycine ethyl ester hydrochloride (0.13 g, 0.78 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.08 g, 22%),  
Mass spectrum: [M+Na]
+
  found:   485.1289
 
C24H26N2O4FeNa requires:              499.1291                  
I.R. υmax  (KBr): 3310 (NH), 1741 (C=Oester), 1627 (C=Oamide), 1618 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 330, 445 nm; 
1
H NMR (400 MHz) δ (d6  DMSO): 8.74 (1H, t, J = 6.0 Hz,  -CONH-), 8.33 (1H, t, J = 
6 Hz,  -CONH-), 7.99 (1H, d, J = 7.0 Hz, ArH), 7.80 (1H, t, J = 7.2 Hz, ArH), 7.69 
(1H, t, J = 6.4 Hz, ArH), 7.40 (1H, d, J = 7.6 Hz, ArH), 4.83 (2H, s, ortho on η5-C5H4-
benzoyl), 4.36 (2H, s, meta on η5-C5H4-benzoyl), 4.11 (2H, q, J = 7.2 Hz, -OCH2CH3),  
3.96 - 3.85 {8H, m, (η5-C5H4-alkyl), (-NHCH2CHO-), (-NHCH2CHO-)}, 1.60 (3H, s,  -
CH3),  1.19  (3H, t, J = 7.2 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (d6 DMSO): 170.5 (C=O), 169.0 (C=O), 168.3 (C=O), 137.5 
(Cq), 135.8 (Cq), 130.4, 128.2, 127.3, 126.1, 93.3 (Cipso η
5
-C5H4-alkyl), 83.6 (Cipso η
5
-
C5H4-benzoyl), 71.7 (Cmeta η
5
-C5H4-benzoyl), 70.5 (Cmeta η
5
-C5H4-alkyl), 68.9 (Cortho 
η5-C5H4-alkyl), 66.2 (Cortho η
5
-C5H4-benzoyl), 61.5 (-OCH2CH3, -ve DEPT), 43.5 (-
NHCH2CHO-, -ve DEPT), 40.7 (-NHCH2CHO-, -ve DEPT), 14.6 (-OCH2CH3), 14.0 (-
CH3). 
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1-methyl-1’-N-{ortho-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester (73) 
 
Glycine L-alanine ethyl ester hydrochloride (0.14 g, 0.78 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.07 g, 19%),  
[α]D
20
 = -15
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   499.1395
 
C25H28N2O4FeNa requires:              499.1396                  
I.R. υmax  (KBr): 3300 (NH), 1743 (C=Oester), 1630 (C=Oamide), 1600 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 324, 448 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.74 (1H, t, J = 6.0 Hz,  -CONH-), 8.33 (1H, d, J 
= 6 Hz,  -CONH-), 7.99 (1H, d, J = 7.2 Hz, ArH), 7.81 (1H, t, J = 7.0 Hz, ArH), 7.69 
(1H, t, J = 6.4 Hz, ArH), 7.40 (1H, d, J = 7.6 Hz, ArH), 4.80 (2H, s, ortho on η5-C5H4-
benzoyl), 4.35 (2H, s, meta on η5-C5H4-benzoyl),  4.31- 4.24 (1H, m, -CHCH3), 4.11 
(2H, q, J = 6.8 Hz, -OCH2CH3),  3.93 - 3.84 {6H, m, (η
5
-C5H4-alkyl), (-NHCH2CO-)}, 
1.58 (3H, s, -CH3), 1.30 (3H, t, J = 6.2 Hz, -CHCH3), 1.17 (3H, t, J = 6.8 Hz, -
OCH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 171.9 (C=O), 169.0 (C=O), 168.2 (C=O), 137.5 
(Cq), 136.8 (Cq), 130.4, 128.2, 127.3, 126.1, 92.6 (Cipso η
5
-C5H4-alkyl), 84.0 (Cipso η
5
-
C5H4-benzoyl), 71.0 (Cmeta η
5
-C5H4-benzoyl), 68.3 (Cmeta η
5
-C5H4-alkyl), 68.0 (Cortho 
η5-C5H4-alkyl), 66.1 (Cortho η
5
-C5H4-benzoyl), 62.4 (-OCH2CH3, -ve DEPT), 47.3 (-
CHCH3), 42.0 (-NHCH2CHO-, -ve DEPT), 17.1 (-CHCH3), 14.9 (-OCH2CH3), 13.4 (-
CH3). 
 
1-methyl-1’-N-{ortho-(ferrocenyl) benzoyl} glycine L-leucine ethyl ester (74) 
 
Glycine L-leucine ethyl ester hydrochloride (0.17 g, 0.78 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.06 g, 15%),  
[α]D
20
 = -21
o 
(c 0.1, EtOH); 
I.R. υmax (KBr): 3260 (NH), 1742 (C=Oester), 1639 (C=Oamide), 1611 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 322, 449 nm; 
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1
H NMR (400 MHz) δ (DMSO- d6):  8.43 (1H, t, J = 7.6 Hz,  -CONH-), 8.23 (1H, d, J 
= 7.6 Hz,  -CONH-), 7.83 (1H,  d,  J = 7.2 Hz, ArH), 7.50 (1H, t, J = 6.8 Hz, ArH), 
7.27 (1H,  t,  J = 6.8 Hz, ArH), 7.15 (1H, d, J = 7.2 Hz, ArH), 4.82 (2H, s, ortho on η5-
C5H4-benzoyl), 4.37 - 4.20 {3H, m, (meta on η
5
-C5H4-benzoyl), (-CH(CH2CH(CH3)2)}, 
4.07 (2H, q, J = 7.0 Hz, -OCH2CH3), 3.96 - 3.85 {6H, m, (η
5
-C5H4-alkyl), (-
NHCH2CO-)}, 1.63 - 1.49 {6H, m, (-CH3), (-CH(CH2CH(CH3)2)}, 1.18 (3H, t, J = 7.0 
Hz, -OCH2CH3), 0.91 - 0.89 {6H, m, -CH(CH2CH(CH3)2)};  
13
C NMR (100 MHz) δ ( DMSO- d6 ): 172.9 (C=O), 169.4 (C=O), 167.8 (C=O), 136.2 
(Cq), 134.8 (Cq), 133.1, 128.8, 127.4, 126.8, 90.1 (Cipso η
5
-C5H4-alkyl), 85.6 (Cipso η
5
-
C5H4-benzoyl), 71.1 (Cmeta η
5
-C5H4-benzoyl), 70.0 (Cmeta η
5
-C5H4-alkyl), 69.8 (Cortho 
η5-C5H4-alkyl), 67.3 (Cortho η
5
-C5H4-benzoyl), 61.4 (-OCH2CH3, -ve DEPT), 51.2 {-
CH(CH2CH(CH3)2)}, 43.8 (-NHCH2CHO-, -ve DEPT), 41.2 {-CH(CH2CH(CH3)2), -ve 
DEPT}, 24.9 {-CH(CH2CH(CH3)2)}, 22.9 {-CH(CH2CH(CH3)2)}, 21.9  
{-CH(CH2CH(CH3)2)}, 14.2 (-OCH2CH3), 13.1 (-CH3). 
 
1-methyl-1’-N-{ortho-(ferrocenyl) benzoyl} glycine L-phenylalanine ethyl ester 
(75) 
 
Glycine L-phenylalanine ethyl ester hydrochloride (0.20 g, 0.78 mmol) was used as a 
starting material. The crude product was purified by column chromatography {eluent 
1:1 hexane: ethyl acetate} yielding the titled product as a red oil (0.05 g, 12%),  
[α]D
20
 = +10
o 
(c 0.1, EtOH); 
I.R. υmax  (KBr): 3253 (NH), 1755 (C=Oester), 1663 (C=Oamide), 1601 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 323, 449 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.58 (1H, t, J = 6.0 Hz, -CONH-), 8.32 (1H, d, J = 
7.6 Hz,  -CONH-), 8.07 (1H, d, J = 7.0 Hz, ArH), 7.81 (1H, t, J = 7.2 Hz, ArH),  
7.35 (1H, t, J = 7.0 Hz,  ArH ), 7.21 - 7.18 {5H, m, -CH(CH2Ph)}, 4.83 (2H, s, ortho 
on η5-C5H4-benzoyl), 4.45 - 4.43 {1H, m, -CH(CH2Ph)}, 4.35 (2H, s, meta on η
5
-C5H4-
benzoyl), 4.00 (2H, q, J = 7.2 Hz, -OCH2CH3), 3.97 - 3.85 {6H, m, (η
5
-C5H4-alkyl), (-
NHCH2CO-) }, 3.01 - 2.93 {2H, m, -CH(CH2Ph)}, 1.54 (3H, s, -CH3),   1.10 (3H, t, J = 
7.2 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 172.1 (C=O), 169.2 (C=O), 167.3 (C=O), 137.0 
(Cq), 131.0 (Cq), 129.7 (Cq), 128.7, 128.0, 127.4, 126.4, 125.9, 124.7, 123.7, 93.2 (Cipso 
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η5-C5H4-alkyl), 83.9 (Cipso η
5
-C5H4-benzoyl), 70.4 (Cmeta η
5
-C5H4-benzoyl), 70.0 (Cmeta 
η5-C5H4-alkyl), 68.3 (Cortho η
5
-C5H4-benzoyl), 67.9 (Cortho η
5
-C5H4-alkyl), 62.4 (-
OCH2CH3, -ve DEPT), 51.6 {-CH(CH2Ph)},  42.7 (-NHCH2CHO-, -ve DEPT), 35.7 {-
CH(CH2Ph), -ve DEPT}, 13.9 (-OCH2CH3), 13.0 (-CH3). 
 
 
General procedure for the synthesis of 1-ethyl-1’-N-ferrocenyl benzoyl dipeptide 
ethyl esters 
 
 
1-ethyl-1’-N-{para-(ferrocenyl) benzoyl} glycine glycine ethyl ester (76) 
 
Glycine glycine ethyl ester hydrochloride (0.12 g, 0.75 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as an orange solid (0.12 g, 34%), m.p 
108 - 110 
o
C; 
Mass spectrum: [M+Na]
+
  found:   499.1290
 
C25H28N2O4FeNa requires:              499.1296                  
I.R. υmax  (KBr): 3301 (NH), 1740 (C=Oester), 1622 (C=Oamide), 1602 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 360, 450 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.80 (1H, t, J = 6.4 Hz,  -CONH-), 8.38 (1H, t, J = 
6.4 Hz,  -CONH-), 7.87 (2H, d, J = 5.6 Hz, ArH), 7.65 (2H, d, J = 5.6 Hz, ArH), 4.89 
(2H, t, J = 1.2 Hz, ortho on η5-C5H4-benzoyl), 4.42 (2H, t, J = 1.2 Hz, meta on η
5
-
C5H4-benzoyl), 4.15 (2H, q, J = 6.8 Hz, -OCH2CH3), 4.05 - 3.90 {8H, m, (η
5
-C5H4-
alkyl), (-NHCH2CO-), (-NHCH2CO-)}, 2.12 (2H, q, J = 7.6 Hz, -CH2CH3),   1.23 (3H, 
t, J = 6.8 Hz, -OCH2CH3), 1.02 (3H, t, J = 7.6 Hz, -CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 169.8 (C=O), 169.7 (C=O), 166.3 (C=O), 142.6 
(Cq), 130.8 (Cq), 127.5, 125.2, 91.3 (Cipso η
5
-C5H4-alkyl), 83.0 (Cipso η
5
-C5H4-benzoyl), 
69.9 (Cmeta η
5
-C5H4-benzoyl), 68.8 (Cmeta η
5
-C5H4-alkyl), 68.5 (Cortho η
5
-C5H4-alkyl), 
66.9 (Cortho η
5
-C5H4-benzoyl), 60.4 (-OCH2CH3, -ve DEPT), 42.4 (-NHCH2CHO-, -ve 
DEPT), 40.7 (-NHCH2CHO-, -ve DEPT), 20.8 (-CH2CH3, -ve DEPT), 14.5 (-
OCH2CH3), 14.0 (-CH2CH3). 
 
 
 179 
1-ethyl-1’-N- {para-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester (77) 
 
Glycine L-alanine ethyl ester hydrochloride (0.13 g, 0.75 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.09 g, 25%),  
[α]D
20
 = -16
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:    513.1454
 
C26H30N2O4FeNa requires:              513.1453                  
I.R. υmax  (KBr): 3290 (NH), 1753 (C=Oester), 1626 (C=Oamide), 1608 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 359, 449 nm; 
1
H NMR (400 MHz) δ (DMSO- d6):  8.68 (1H, t, J = 6.0 Hz,  -CONH-), 8.40 (1H, t, J 
= 7.2 Hz,  -CONH-), 7.81 (2H, d, J = 7.8 Hz, ArH), 7.60 (2H, d, J = 7.8 Hz, ArH), 
4.82 (2H, t, J = 1.6 Hz, ortho on η5-C5H4-benzoyl), 4.37 (2H, t, J = 1.6 Hz, meta on η
5
-
C5H4-benzoyl),  4.28 - 4.25 (1H, m, -CHCH3), 4.15 (2H, q, J = 6.8 Hz, -OCH2CH3), 
3.90 - 3.85 {6H, m, (η5-C5H4-alkyl), (-NHCH2CO-)}, 2.10 (2H, q, J = 7.6 Hz, -
CH2CH3),  1.31 (3H, t, J = 6.4 Hz, -CHCH3), 1.18 (3H, t, J = 6.8 Hz, -OCH2CH3), 0.98 
(3H, t, J = 7.6 Hz, -CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 171.7 (C=O), 168.7 (C=O), 167.2 (C=O), 142.5 
(Cq), 130.8 (Cq), 127.4, 125.2, 92.3 (Cipso η
5
-C5H4-alkyl), 82.0 (Cipso η
5
-C5H4-benzoyl), 
71.0 (Cmeta η
5
-C5H4-benzoyl), 69.8 (Cmeta η
5
-C5H4-alkyl), 68.7 (Cortho η
5
-C5H4-alkyl), 
66.0 (Cortho η
5
-C5H4-benzoyl), 61.4 (-OCH2CH3, -ve DEPT), 48.0 (-CHCH3), 43.0 (-
NHCH2CHO-, -ve DEPT), 22.8 (-CH2CH3, -ve DEPT), 18.0 (-CHCH3), 14.5 (-
OCH2CH3), 13.9  (-CH2CH3). 
 
1-ethyl-1’-N-{para-(ferrocenyl) benzoyl} glycine L-leucine ethyl ester (78) 
 
Glycine L-leucine ethyl ester hydrochloride (0.16 g, 0.75 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} and recrystallisation from hexane: ethyl acetate yield the desired 
product as an orange solid (0.07 g, 18%), m.p 97 - 99 
o
C; 
[α]D
20
 = -12
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   555.1919
 
C29H36N2O4FeNa requires:              555.1922                  
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I.R. υmax  (KBr): 3280 (NH), 1740 (C=Oester), 1641 (C=Oamide), 1615 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 357, 446 nm; 
1
H NMR (400 MHz) δ (DMSO- d6):  8.68 (1H, t, J = 6.0 Hz,  -CONH-), 8.34 (1H, d, J 
= 7.6 Hz,  -CONH-), 7.82 (2H, d, J = 8.2 Hz, ArH), 7.61 (2H, d, J = 8.2 Hz, ArH), 
4.81 (2H, t, J = 1.6 Hz, ortho on η5-C5H4-benzoyl), 4.36 (2H, t, J = 1.6 Hz, meta on η
5
-
C5H4-benzoyl), 4.30 - 4.25 {1H, m, -CH(CH2CH(CH3)2)}, 4.15 (2H, q, J = 7.2 Hz, - 
OCH2CH3) , 3.97 - 3.87 {6H, m, (η
5
-C5H4-alkyl), (-NHCH2CO-)}, 2.00 (2H, q, J = 7.2 
Hz, -CH2CH3), 1.69 - 1.50 {3H, m, -CH(CH2CH(CH3)2)}, 1.15 (3H, t, J = 7.2 Hz, -
OCH2CH3), 0.90 - 0.85 {6H, m, -CH(CH2CH(CH3)2)}, 0.76 (3H, t, J = 7.2 Hz, -
CH2CH3);  
13
C NMR (100 MHz) δ (DMSO- d6): 173.4 (C=O), 170.0 (C=O), 166.9 (C=O), 140.1 
(Cq), 130.8 (Cq), 127.4, 125.2, 92.1 (Cipso η
5
-C5H4-alkyl), 83.1 (Cipso η
5
-C5H4-benzoyl), 
71.0 (Cmeta η
5
-C5H4-benzoyl), 69.9 (Cmeta η
5
-C5H4-alkyl), 68.1 (Cortho η
5
-C5H4-alkyl), 
67.2 (Cortho η
5
-C5H4-benzoyl), 61.4 (-OCH2CH3, -ve DEPT), 51.3 {-
CH(CH2CH(CH3)2)}, 42.6 (-NHCH2CHO-, -ve DEPT), 39.3 {-CH(CH2CH(CH3)2), -ve 
DEPT}, 28.1 {-CH(CH2CH(CH3)2)}, 23.4 (-CH2CH3, -ve DEPT), 22.9 {-
CH(CH2CH(CH3)2)}, 21.0 {-CH(CH2CH(CH3)2)}, 15.1 (-OCH2CH3), 13.0  (-CH2CH3). 
 
1-ethyl-1’-N- {para-(ferrocenyl) benzoyl} glycine L-phenylalanine ethyl ester (79) 
 
Glycine L-phenylalanine ethyl ester hydrochloride (0.19 g, 0.75 mmol) was used as a 
starting material. The crude product was purified by column chromatography {eluent 
1:1 hexane: ethyl acetate} and recrystallisation from hexane: ethyl acetate yield the 
desired product as an orange solid (0.07 g, 17%), m.p 92 - 94 
o
C; 
[α]D
20
 = +12
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   589.1770
 
C32H34N2O4FeNa requires:              589.1769                  
I.R. υmax  (KBr): 3303 (NH), 1742 (C=Oester), 1629 (C=Oamide), 1608 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 356, 450 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.60 (1H, t, J = 6.0 Hz,  -CONH-), 8.37 (1H, d, J 
= 7.6 Hz,  -CONH-), 7.85 (2H, d, J = 7.4 Hz, ArH), 7.63 (2H, d, J = 7.4 Hz, ArH), 
7.27 - 7.21 {5H, m, -CH(CH2Ph)}, 4.83 (2H, t, J = 1.6 Hz, ortho on η
5
-C5H4-benzoyl), 
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4.48 - 4.46 {1H, m,  -CH(CH2Ph)}, 4.37 (2H, t, J = 1.6 Hz, meta on η
5
-C5H4-benzoyl), 
4.00 (2H, q, J = 6.8 Hz, - OCH2CH3), 3.90 - 3.83 {6H, m, (η
5
-C5H4-alkyl), (-
NHCH2CO-)}, 3.06 - 2.93 {2H, m, -CH(CH2Ph)}, 2.08 (2H, q, J = 7.6 Hz, -CH2CH3), 
1.12 (3H, t, J = 6.8 Hz, -OCH2CH3), 0.98 (3H, t, J = 7.6 Hz, -CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 170.8 (C=O), 168.2 (C=O), 166.7 (C=O), 137.0 
(Cq), 132.7 (Cq), 130.1 (Cq), 128.9, 127.2,  126.9, 124.0, 120.2, 93.1 (Cipso η
5
-C5H4-
alkyl), 84.0 (Cipso η
5
-C5H4-benzoyl), 71.4 (Cmeta η
5
-C5H4-benzoyl), 68.4 (Cmeta η
5
-C5H4-
alkyl), 67.5 (Cortho η
5
-C5H4-alkyl), 66.4 (Cortho η
5
-C5H4-benzoyl), 61.2 (-OCH2CH3, -ve 
DEPT), 51.6 (-CH(CH2Ph)),  43.0 (-NHCH2CHO-, -ve DEPT), 38.0 {-CH(CH2Ph), -ve 
DEPT}, 24.5 (-CH2CH3, -ve DEPT), 13.3 (-OCH2CH3), 13.0 (-CH2CH3). 
 
1-ethyl-1’-N- {meta-(ferrocenyl)-benzoyl}-glycine-glycine ethyl ester (80) 
 
Glycine glycine ethyl ester hydrochloride (0.12 g, 0.75 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.09 g, 25%),  
Mass spectrum: [M+Na]
+
  found:   499.1287
 
C25H28N2O4FeNa requires:              499.1296                  
I.R. υmax  (KBr): 3311 (NH), 1741 (C=Oester), 1622 (C=Oamide), 1601 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 332, 440 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.49 (1H, t, J = 6.0 Hz,  -CONH-), 8.23 (1H, t, J = 
6 Hz,  -CONH-), 7.87 (1H, s,  ArH), 7.67 - 7.63 (2H, m,  ArH), 7.36 (1H, t, J = 7.2 Hz, 
ArH), 4.58 (2H, t, J = 1.6 Hz, ortho on η5-C5H4-benzoyl), 4.20 (2H, t, J = 1.6 Hz, meta 
on η5-C5H4-benzoyl), 4.11 (2H, q, J = 7.2 Hz, - OCH2CH3),  3.98 - 3.87 {8H, m, (η
5
-
C5H4-alkyl), (-NHCH2CO-), (-NHCH2CO-)}, 1.96 (2H, q, J = 7.6 Hz, -CH2CH3),  1.26 
(3H, t, J = 7.2 Hz, -OCH2CH3), 1.03 (3H, t, J = 7.6 Hz, -CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 169.8 (C=O), 168.7 (C=O), 166.3 (C=O), 139.6 
(Cq), 134.1 (Cq), 128.8, 128.5, 124.2, 124.1, 91.2 (Cipso η
5
-C5H4-alkyl), 83.1 (Cipso η
5
-
C5H4-benzoyl), 70.0 (Cmeta η
5
-C5H4-benzoyl), 68.8 (Cmeta η
5
-C5H4-alkyl), 68.5 (Cortho 
η5-C5H4-alkyl), 66.2 (Cortho η
5
-C5H4-benzoyl), 60.3 (-OCH2CH3, -ve DEPT), 42.4 (-
NHCH2CHO-, -ve DEPT), 40.6 (-NHCH2CHO-, -ve DEPT), 20.8 (-CH2CH3, -ve 
DEPT), 14.4 (-OCH2CH3), 14.0 (-CH2CH3). 
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1-ethyl-1’-N-{meta-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester (81) 
 
Glycine L-alanine ethyl ester hydrochloride (0.13 g, 0.75 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.08 g, 22%),  
[α]D
20
 = -18
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   513.1458
 
C25H28N2O4FeNa requires:              513.1453                  
I.R. υmax  (KBr):  3290 (NH), 1739 (C=Oester), 1635 (C=Oamide), 1605 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 333, 444 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.60 (1H, t, J = 6.0 Hz,  -CONH-), 8.40 (1H, d, J 
= 7.0 Hz,  -CONH-), 8.00 (1H, s,  ArH), 7.68 - 7.64  (2H, m,  ArH), 7.40 (1H, t, J = 7.2 
Hz, ArH), 4.68 (2H, t, J = 1.6 Hz, ortho on η5-C5H4-benzoyl), 4.34 (2H, t, J = 1.6 Hz, 
meta on η5-C5H4-benzoyl), 4.30 - 4.24 (1H, m, - CHCH3), 4.00 (2H, q, J = 6.8 Hz, - 
OCH2CH3),  3.96 - 3.82 {6H, m, (η
5
-C5H4-alkyl), (-NHCH2CO-)}, 2.05 (2H, q, J = 7.6 
Hz, -CH2CH3), 1.28 (3H, t, J = 6.4 Hz, -CHCH3), 1.20 (3H, t, J = 6.8 Hz, -OCH2CH3), 
0.96 (3H, t, J = 7.6 Hz, -CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 172.5 (C=O), 169.0 (C=O), 166.2 (C=O), 137.5 
(Cq), 135.8 (Cq), 130.4, 129.2, 127.0, 125.2, 91.0 (Cipso η
5
-C5H4-alkyl), 84.0 (Cipso η
5
-
C5H4-benzoyl), 71.5 (Cmeta η
5
-C5H4-benzoyl), 69.3 (Cmeta η
5
-C5H4-alkyl), 68.1 (Cortho 
η5-C5H4-alkyl), 66.5 (Cortho η
5
-C5H4-benzoyl), 62.4 (-OCH2CH3, -ve DEPT), 47.6 
(CHCH3), 42.8 (-NHCH2CHO-, -ve DEPT), 21.8 (-CH2CH3, -ve DEPT), 19.0 (-
CHCH3), 14.1 (-OCH2CH3), 13.5 (-CH2CH3). 
 
1-ethyl-1’-N-{meta-(ferrocenyl) benzoyl} glycine L-leucine ethyl ester (82) 
 
Glycine L-leucine ethyl ester hydrochloride (0.16 g, 0.75 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.07 g, 18%),  
[α]D
20
 = -13
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   555.1933
 
C29H36N2O4FeNa requires:              555.1922                  
I.R. υmax  (KBr): 3260 (NH), 1737 (C=Oester), 1643 (C=Oamide), 1615 (C=Oamide) cm
-1
;
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UV-Vis λmax EtOH: 333, 445 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.68 (1H, t, J = 6.0 Hz,  -CONH-), 8.34 (1H, d, J 
= 6.8 Hz,  -CONH-), 8.01 (1H, s,  ArH), 7.65 - 7.62  (2H, m,  ArH), 7.45 (1H, t, J = 7.0 
Hz, ArH), 4.78 (2H, t, J = 1.6 Hz, ortho on η5-C5H4-benzoyl), 4.30 (2H, t, J = 1.6 Hz, 
meta on η5-C5H4-benzoyl), 4.34 - 4.26 {1H, m, -CH(CH2CH(CH3)2)}, 4.09 (2H, q, J = 
7.0 Hz, -OCH2CH3), 3.97 - 3.86 {6H, m, (η
5
-C5H4-alkyl), (-NHCH2CO-)}, 2.04 (2H, q, 
J = 7.2 Hz, -CH2CH3), 1.60 - 1.40 {3H, m, -CH(CH2CH(CH3)2)}, 1.10 (3H, t, J = 7.0 
Hz, -OCH2CH3), 0.88 - 0.84 {6H, m, -CH(CH2CH(CH3)2)},  0.74 (3H, t, J = 7.2 Hz, - 
CH2CH3);  
13
C NMR (100 MHz) δ (DMSO- d6): 170.9 (C=O), 168.9 (C=O), 166.4 (C=O), 138.5 
(Cq), 135.8 (Cq), 130.1, 128.2, 127.3, 125.1, 89.9 (Cipso η
5
-C5H4-alkyl), 83.1 (Cipso η
5
-
C5H4-benzoyl), 71.9 (Cmeta η
5
-C5H4-benzoyl), 69.3 (Cmeta η
5
-C5H4-alkyl), 68.0 (Cortho 
η5-C5H4-alkyl), 66.5 (Cortho η
5
-C5H4-benzoyl), 62.5 (-OCH2CH3, -ve DEPT), 50.3  
{-CH(CH2CH(CH3)2)}, 43.0 (-NHCH2CHO-, -ve DEPT), 39.9 {-CH(CH2CH(CH3)2), -
ve DEPT}, 24.4 (-CH2CH3, -ve DEPT), 26.5 {-CH(CH2CH(CH3)2)}, 23.0 {-
CH(CH2CH(CH3)2)}, 22.4 {-CH(CH2CH(CH3)2)}, 14.4 (-OCH2CH3), 13.7 (-CH2CH3). 
 
1-ethyl-1’-N-{meta-(ferrocenyl) benzoyl} glycine L-phenylalanine ethyl ester (83) 
 
Glycine L-phenylalanine ethyl ester hydrochloride (0.19 g, 0.75 mmol) was used as a 
starting material. The crude product was purified by column chromatography {eluent 
1:1 hexane: ethyl acetate} yielding the titled product as a red oil (0.07 g, 18%),  
[α]D
20
 = +16
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   589.1768
 
C32H34N2O4FeNa requires:              589.1769                 
I.R. υmax  (KBr): 3300 (NH), 1739 (C=Oester), 1633 (C=Oamide), 1601 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 332, 444 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.54 (1H, t, J = 6.0 Hz,  -CONH-), 8.30 (1H, d, J 
= 7.4 Hz,  -CONH-), 8.07 (1H, s,  ArH),  7.69 - 7.67 (2H, m,  ArH), 7.35 (1H, t, J = 7.0 
Hz, ArH),  7.22 - 7.19 {5H, m, -CH(CH2Ph)}, 4.83 (2H, t, J = 1.6 Hz, ortho on η
5
-
C5H4-benzoyl), 4.43 - 4.40 {1H, m, -CH(CH2Ph)}, 4.37 (2H, t, J = 1.6 Hz, meta on η
5
-
C5H4-benzoyl), 4.08 (2H, q, J = 7.2 Hz, - OCH2CH3), 3.95 - 3.88 {6H, m, (η
5
-C5H4-
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alkyl), (-NHCH2CO-)}, 3.00 - 2.90 {2H, m, -CH(CH2Ph)}, 2.05 (2H, q, J = 7.6 Hz, -
CH2CH3), 1.10 (3H, t, J = 7.2 Hz, -OCH2CH3), 0.90 (3H, t, J = 7.6 Hz, -CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 172.4 (C=O), 169.7 (C=O), 167.0 (C=O), 135.0 
(Cq), 131.7 (Cq), 130.7 (Cq), 129.7, 128.2,  127.4, 126.0, 124.2, 123.2, 122.7, 89.1 (Cipso 
η5-C5H4-alkyl), 83.0 (Cipso η
5
-C5H4-benzoyl), 73.2 (Cmeta η
5
-C5H4-benzoyl), 69.9 (Cmeta 
η5-C5H4-alkyl), 67.7 (Cortho η
5
-C5H4-alkyl), 66.1 (Cortho η
5
-C5H4-benzoyl), 60.1 (-
OCH2CH3, -ve DEPT), 52.8 {-CH(CH2Ph)},  42.9 (-NHCH2CHO-, -ve DEPT), 37.8 (-
CH(CH2Ph), -ve DEPT), 24.0 (-CH2CH3, -ve DEPT), 14.9 (-OCH2CH3), 14.2 (-
CH2CH3). 
 
1-ethyl-1’-N-{ortho-(ferrocenyl) benzoyl} glycine glycine ethyl ester (84) 
 
Glycine glycine ethyl ester hydrochloride (0.12 g, 0.75 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.08 g, 22%),  
Mass spectrum: [M+Na]
+
  found:   499.1292
 
C25H28N2O4FeNa requires:              499.1296                  
I.R. υmax  (KBr): 3310 (NH), 1739 (C=Oester), 1631 (C=Oamide), 1617 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 325, 444 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.72 (1H, t, J = 6.0 Hz,  -CONH-), 8.34 (1H, t, J = 
6 Hz,  -CONH-), 8.00 (1H, d, J = 7.4 Hz, ArH), 7.81 (1H, t, J = 7.2 Hz, ArH), 7.70 
(1H, t, J = 6.4 Hz, ArH), 7.40 (1H, d, J = 7.6 Hz, ArH), 4.82 (2H, t, J = 1.6 Hz, ortho 
on η5-C5H4-benzoyl), 4.31 (2H, t, J = 2 Hz, meta on η
5
-C5H4-benzoyl), 4.10 (2H, q, J = 
6.8 Hz, - OCH2CH3), 3.97 - 3.85 {8H, m, (η
5
-C5H4-alkyl), (-NHCH2CO-), (-
NHCH2CO-)}, 2.07 (2H, q, J = 7.6 Hz, -CH2CH3),  1.18 (3H, t, J = 6.8 Hz, -
OCH2CH3), 0.98 (3H, t, J = 7.6 Hz, -CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 169.8 (C=O), 168.3 (C=O), 165.2 (C=O), 135.6 
(Cq), 133.8 (Cq), 128.5, 127.2,  126.0, 124.0, 92.3 (Cipso η
5
-C5H4-alkyl), 81.0 (Cipso η
5
-
C5H4-benzoyl), 71.0 (Cmeta η
5
-C5H4-benzoyl), 68.7 (Cmeta η
5
-C5H4-alkyl), 68.0 (Cortho 
η5-C5H4-alkyl), 66.1 (Cortho η
5
-C5H4-benzoyl), 62.4 (-OCH2CH3, -ve DEPT), 43.4 (-
NHCH2CHO-, -ve DEPT), 41.7 (-NHCH2CHO-, -ve DEPT), 22.8 (-CH2CH3, -ve 
DEPT), 14.2 (-OCH2CH3), 13.0 (-CH2CH3). 
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1-ethyl- 1’-N-{ortho-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester (85) 
 
Glycine L-alanine ethyl ester hydrochloride (0.13 g, 0.75 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.07 g, 19%),  
[α]D
20
 = -19
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   513.1447
 
C25H28N2O4FeNa requires:              513.1453                  
I.R. υmax  (KBr):  3289 (NH), 1740 (C=Oester), 1632 (C=Oamide), 1608 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 325, 443 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.48 (1H, t, J = 6.0 Hz,  -CONH-), 8.34 (1H, d, J 
= 7.2 Hz,  -CONH-), 8.01 (1H, d, J = 6.8 Hz, ArH), 7.81 (1H, t, J = 7.2 Hz, ArH), 7.70 
(1H, t, J = 6.4 Hz, ArH), 7.41 (1H, d, J = 7.4 Hz, ArH), 4.72 (2H, t, J = 1.6 Hz, ortho 
on η5-C5H4-benzoyl), 4.38 (2H, t, J = 1.6 Hz, meta on η
5
-C5H4-benzoyl),  4.30 - 4.26 ( 
1H, m, - CHCH3), 4.10 (2H, q, J = 6.8 Hz, - OCH2CH3), 3.92 - 3.80 {6H, m, (η
5
-C5H4-
alkyl), (-NHCH2CO-)}, 2.00 (2H, q, J = 7.6 Hz, -CH2CH3), 1.30 (3H, t, J = 6.4 Hz, - 
CHCH3), 1.15 (3H, t, J = 6.8 Hz, -OCH2CH3), 0.90 (3H, t, J = 7.6 Hz, -CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 172.5 (C=O), 168.0 (C=O), 167.2 (C=O), 138.5 
(Cq), 134.0 (Cq), 129.0, 128.8, 127.5, 124.1, 92.7 (Cipso η
5
-C5H4-alkyl), 81.2 (Cipso η
5
-
C5H4-benzoyl), 70.9 (Cmeta η
5
-C5H4-benzoyl), 69.8 (Cmeta η
5
-C5H4-alkyl), 68.5 (Cortho 
η5-C5H4-alkyl), 66.2 (Cortho η
5
-C5H4-benzoyl), 60.8 (-OCH2CH3, -ve DEPT), 49.6 (-
CHCH3), 42.2 (-NHCH2CHO-, -ve DEPT), 25.8 (-CH2CH3, -ve DEPT), 17.6 (-
CHCH3), 14.8 (-OCH2CH3), 14.0 (-CH2CH3). 
 
1-ethyl-1’-N-{ortho-(ferrocenyl) benzoyl} glycine leucine ethyl ester (86) 
 
Glycine L-leucine ethyl ester hydrochloride (0.16 g, 0.75 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.06 g, 15%), 
[α]D
20
 = -11
o 
(c 0.1, EtOH); 
I.R. υmax  (KBr): 3275 (NH), 1747 (C=Oester), 1649 (C=Oamide), 1614 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 360, 451 nm; 
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1
H NMR (400 MHz) δ(DMSO- d6): 8.68 (1H, t, J = 6.0 Hz,  -CONH-), 8.34 (1H, d, J = 
7.6 Hz,  -CONH-), 8.11 (1H, d, J = 6.6 Hz, ArH), 7.80 (1H, t, J = 7.2 Hz, ArH), 7.70 
(1H, t, J = 6.4 Hz, ArH), 7.40 (1H, d, J = 7.6 Hz, ArH), 4.83 (2H, t, J = 1.6 Hz, ortho 
on η5-C5H4-benzoyl), 4.33 (2H, t, J = 1.6 Hz, meta on η
5
-C5H4-benzoyl), 4.32 - 4.28 
{1H, m, -CH(CH2CH(CH3)2)}, 4.20 (2H, q, J = 7.0 Hz, - OCH2CH3), 3.96 - 3.87 {6H 
m, (η5-C5H4-alkyl), (-NHCH2CO-)}, 2.02 (2H, q, J = 7.2 Hz, -CH2CH3), 1.65 - 1.40 
{3H, m, -CH(CH2CH(CH3)2)}, 1.07 (3H, t, J = 7.0 Hz, -OCH2CH3), 0.92 - 0.88 {6H, 
m, -CH(CH2CH(CH3)2)},  0.70 (3H, t, J = 7.2 Hz, - CH2CH3);  
13
C NMR (100 MHz) δ (DMSO- d6): 170.4 (C=O), 169.6 (C=O), 166.4 (C=O), 136.6 
(Cq), 135.8 (Cq), 131.4, 128.2, 127.7, 124.1, 92.4 (Cipso η
5
-C5H4-alkyl), 82.1 (Cipso η
5
-
C5H4-benzoyl), 71.0 (Cmeta η
5
-C5H4-benzoyl), 70.4 (Cmeta η
5
-C5H4-alkyl), 68.5 (Cortho 
η5-C5H4-alkyl), 66.9 (Cortho η
5
-C5H4-benzoyl), 61.4 (-OCH2CH3, -ve DEPT), 52.3 {-
CH(CH2CH(CH3)2)}, 43.1 (-NHCH2CHO-, -ve DEPT), 40.1 {-CH(CH2CH(CH3)2), -ve 
DEPT}, 27.9 {-CH(CH2CH(CH3)2)}, 24.4 (-CH2CH3, -ve DEPT), 21.7  
{-CH(CH2CH(CH3)2)}, 20.4 {-CH(CH2CH(CH3)2)}, 14.7 (-OCH2CH3), 13.0 (-
CH2CH3). 
 
1-ethyl-1’-N- {ortho-(ferrocenyl) benzoyl} glycine L-phenylalanine ethyl ester (87) 
 
Glycine L-phenylalanine ethyl ester hydrochloride (0.19 g, 0.75 mmol) was used as a 
starting material. The crude product was purified by column chromatography {eluent 
1:1 hexane: ethyl acetate} yielding the titled product as a red oil (0.06 g, 14%), 
[α]D
20
 = +14
o 
(c 0.1, EtOH); 
I.R. υmax  (KBr): 3303 (NH), 1744 (C=Oester), 1629 (C=Oamide), 1608 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 325, 444 nm; 
1
H NMR (400 MHz) δ (DMSO- d6):  8.68 (1H, t, J = 6.0 Hz,  -CONH-), 8.32 (1H, d, J 
= 7.6 Hz,  -CONH-), 8.03 (1H, d, J = 7.0 Hz, ArH), 7.81 (1H, t, J = 7.2 Hz, ArH), 7.79 
(1H, t, J = 6.4 Hz, ArH), 7.38 (1H, d, J = 6.8 Hz,  ArH), 7.23 - 7.19 (5H, m,  
-CH(CH2Ph)), 4.83 (2H, t, J = 1.6 Hz, ortho on η
5
-C5H4-benzoyl), 4.49 - 4.47 {1H, m, 
-CH(CH2Ph)}, 4.37 (2H, t, J = 1.6 Hz, meta on η
5
-C5H4-benzoyl), 4.04 (2H, q, J = 6.4 
Hz, -OCH2CH3),  3.89 - 3.80 {6H, m, (η
5
-C5H4-alkyl), (-NHCH2CO-)}, 3.08 - 2.95 
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{2H, m, -CH(CH2Ph)}, 2.02 {2H, q, J = 7.6 Hz, -CH2CH3), 1.16 (3H, t, J = 6.4 Hz, -
OCH2CH3), 0.94 (3H, t, J = 7.6 Hz, -CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 171.5 (C=O), 169.1 (C=O), 168.2 (C=O), 139.0 
(Cq), 130.9 (Cq), 129.1 (Cq), 128.5, 128.4,  127.1, 126.6, 125.2, 124.2, 121.7, 92.1 (Cipso 
η5-C5H4-alkyl), 81.1 (Cipso η
5
-C5H4-benzoyl), 71.4 (Cmeta η
5
-C5H4-benzoyl), 69.9 (Cmeta 
η5-C5H4-alkyl), 68.9 (Cortho η
5
-C5H4-alkyl), 67.9 (Cortho η
5
-C5H4-benzoyl), 62.8 (-
OCH2CH3, -ve DEPT), 53.6 {-CH(CH2Ph)},  42.2 (-NHCH2CHO-, -ve DEPT), 39.8 {-
CH(CH2Ph), -ve DEPT}, 23.0 (-CH2CH3, -ve DEPT), 15.0 (-OCH2CH3), 14.1 (-
CH2CH3). 
 
 
General procedure for the synthesis of 1-propyl-1’-N-ferrocenyl benzoyl dipeptide 
ethyl esters 
 
1-propyl-1’-N-{para-(ferrocenyl) benzoyl} glycine glycine ethyl ester (88) 
 
Glycine glycine ethyl ester (0.12 g, 0.72 mmol) was used as a starting material.  The 
crude product was purified by column chromatography {eluent 1:1 hexane: ethyl 
acetate} and recrystallisation from hexane: ethyl acetate yield the desired product as an 
orange solid (0.09 g, 26%), m.p 118 - 120 
o
C; 
Mass spectrum: [M+Na]
+
  found:   513.1464
 
C26H30N2O4FeNa requires:              513.1453                  
I.R. υmax  (KBr): 3389 (NH), 1735 (C=Oester), 1626 (C=Oamide), 1609 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 361, 450 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.76 (1H, t, J = 5.6 Hz,  -CONH-), 8.40 (1H, t, J = 
5.6 Hz, -CONH-), 7.82 (2H, d, J = 8.0 Hz, ArH), 7.60 (2H, d, J = 8.0 Hz, ArH), 4.85 
(2H, s, ortho on η5-C5H4-benzoyl), 4.38 (2H, s, meta on η
5
-C5H4-benzoyl), 4.11 (2H, q, 
J = 6.8 Hz, -OCH2CH3), 3.90 - 3.80 {8H, m, (η
5
-C5H4-alkyl), (-NHCH2CO-), (-
NHCH2CO-)}, 2.07 (2H, t, J = 7.6 Hz, -CH2CH2CH3), 1.38 - 1.28 (2H, m, -
CH2CH2CH3), 1.18 (3H, t, J = 6.8 Hz, -OCH2CH3), 0.76 (3H, t, J = 7.2 Hz, - 
CH2CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 169.8 (C=O), 168.3 (C=O), 166.9 (C=O), 142.5 
(Cq), 130.8 (Cq), 127.5, 125.2, 90.1 (Cipso η
5
-C5H4-alkyl), 83.0 (Cipso η
5
-C5H4-benzoyl), 
71.7 (Cmeta η
5
-C5H4-benzoyl), 69.8 (Cmeta η
5
-C5H4-alkyl), 68.5 (Cortho η
5
-C5H4-alkyl), 
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66.7 (Cortho η
5
-C5H4-benzoyl), 62.4 (-OCH2CH3, -ve DEPT), 42.8 (-NHCH2CHO-, -ve 
DEPT), 41.9 (-NHCH2CHO-, -ve DEPT), 32.8 (-CH2CH2CH3, -ve DEPT),  25.0 (-
CH2CH2CH3, -ve DEPT), 14.5 (-OCH2CH3), 14.0 (-CH2CH2CH3). 
 
1-propyl-1’-N- {para-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester (89) 
 
 
Glycine L-alanine ethyl ester hydrochloride (0.13 g, 0.72 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.08 g, 22%),  
[α]D
20
 = -14
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   527.1632
 
C26H30N2O4FeNa requires:              527.1609                  
I.R. υmax  (KBr):  3295 (NH), 1743 (C=Oester), 1636 (C=Oamide), 1608 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 360, 451 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.68 (1H, t, J = 6.0 Hz,  -CONH-), 8.41 (1H, d, J 
= 7.0 Hz,  -CONH-), 7.78 (2H, d, J = 7.4 Hz, ArH), 7.64 (2H, d, J = 7.4 Hz, ArH), 
4.82 (2H, s, ortho on η5-C5H4-benzoyl), 4.37 (2H, s, meta on η
5
-C5H4-benzoyl),  4.30 - 
4.25 (1H, m, - CHCH3), 4.08 (2H, q, J = 6.8 Hz, - OCH2CH3),  3.95 - 3.88 {6H, m, (η
5
-
C5H4-alkyl), (-NHCH2CO-)}, 2.07 (2H, t, J = 7.6 Hz, -CH2CH2CH3), 1.40 - 1.27 {5H, 
m, (-CH2CH2CH3), (-CHCH3)}, 1.18 (3H, t, J = 6.8 Hz, -OCH2CH3), 0.74 (3H, t, J = 
7.2 Hz, - CH2CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 171.0 (C=O), 169.2 (C=O), 168.6 (C=O), 141.5 
(Cq), 132.8 (Cq), 128.4, 124.2, 90.3 (Cipso η
5
-C5H4-alkyl), 83.0 (Cipso η
5
-C5H4-benzoyl), 
71.5 (Cmeta η
5
-C5H4-benzoyl), 68.7 (Cmeta η
5
-C5H4-alkyl), 68.2 (Cortho η
5
-C5H4-alkyl), 
67.9 (Cortho η
5
-C5H4-benzoyl), 62.4 (-OCH2CH3, -ve DEPT), 49.6 (-CHCH3), 43.0 (-
NHCH2CHO-, -ve DEPT), 32.0 (-CH2CH2CH3, -ve DEPT),  22.8 (-CH2CH2CH3, -ve 
DEPT), 17.6 (-CHCH3), 14.8 (-OCH2CH3), 13.9 (-CH2CH2CH3). 
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1-propyl-1’-N-{para-(ferrocenyl) benzoyl} glycine L-leucine ethyl ester (90) 
 
Glycine L-leucine ethyl ester hydrochloride (0.16 g, 0.72 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} and recrystallisation from hexane: ethyl acetate yield the desired 
product as an orange solid (0.06 g, 15%), m.p 76 - 78 
o
C; 
[α]D
20
 = -15
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   569.2197
 
C30H38N2O4FeNa requires:              569.2181                  
I.R. υmax  (KBr): 3275 (NH), 1749 (C=Oester), 1629 (C=Oamide), 1613 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 360, 451 nm; 
1
H NMR (400 MHz) δ (DMSO- d6):  8.67 (1H, t, J = 6.0 Hz,  -CONH-), 8.33 (1H, d, J 
= 7.6 Hz,  -CONH-), 7.85 (2H, d, J = 7.6 Hz, ArH), 7.66 (2H, d, J = 7.6 Hz, ArH), 
4.88 (2H, s, ortho on η5-C5H4-benzoyl), 4.37 (2H, s, meta on η
5
-C5H4-benzoyl), 4.33 - 
4.27 {1H, m, -CH(CH2CH(CH3)2)}, 4.14 (2H, q, J = 7.2 Hz, - OCH2CH3), 3.97 - 3.86 
{6H m, (η5-C5H4-alkyl), (-NHCH2CO-)}, 2.00 (2H, t, J = 7.6 Hz, -CH2CH2CH3), 1.69 - 
1.45 {3H, m, -CH(CH2CH(CH3)2)}, 1.40 - 1.27 (2H, m, -CH2CH2CH3), 1.15 (3H, t, J = 
7.2 Hz, -OCH2CH3), 0.91 - 0.83 {6H, m, -CH(CH2CH(CH3)2)}, 0.72 (3H, t, J = 7.2 Hz, 
- CH2CH2CH3);  
13
C NMR (100 MHz) δ (DMSO- d6): 171.4 (C=O), 169.4 (C=O), 168.1 (C=O), 140.1 
(Cq), 131.8 (Cq), 129.4, 126.2, 89.8 (Cipso η
5
-C5H4-alkyl), 84.1 (Cipso η
5
-C5H4-benzoyl), 
71.2 (Cmeta η
5
-C5H4-benzoyl), 69.9 (Cmeta η
5
-C5H4-alkyl), 68.5 (Cortho η
5
-C5H4-alkyl), 
67.9 (Cortho η
5
-C5H4-benzoyl), 62.8 (-OCH2CH3, -ve DEPT), 52.1  
{-CH(CH2CH(CH3)2)}, 42.5 (-NHCH2CHO-, -ve DEPT), 40.0 {-CH(CH2CH(CH3)2), -
ve DEPT}, 32.0 (-CH2CH2CH3, -ve DEPT), 26.4 {-CH(CH2CH(CH3)2)}, 23.5 (-
CH2CH2CH3, -ve DEPT), 23.7 {-CH(CH2CH(CH3)2)}, 22.4 {-CH(CH2CH(CH3)2)}, 
14.9 (-OCH2CH3), 14.0 (-CH2CH2CH3). 
 
1-propyl-1’-N-{para-(ferrocenyl) benzoyl} glycine L-phenylalanine ethyl ester (91) 
 
Glycine L-phenyalanine ethyl ester hydrochloride (0.18 g, 0.72 mmol) was used as a 
starting material. The crude product was purified by column chromatography {eluent 
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1:1 hexane: ethyl acetate} and recrystallisation from hexane: ethyl acetate yield the 
desired product as an orange solid (0.06 g, 14%), m.p 74 - 75 
o
C; 
[α]D
20
 = +11
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   603.2046
 
C33H36N2O4FeNa requires:              603.2034                  
I.R. υmax  (KBr): 3292 (NH), 1737 (C=Oester), 1630 (C=Oamide), 1609 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 360, 452 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.56 (1H, t, J = 6.0 Hz,  -CONH-), 8.27 (1H, d, J 
= 7.6 Hz,  -CONH-), 7.71 (2H, d, J = 8.0 Hz, ArH), 7.51 (2H, d, J = 8.0 Hz, ArH), 
7.18 - 7.12 {5H, m, -CH(CH2Ph)}, 4.74 (2H, s, ortho on η
5
-C5H4-benzoyl), 4.40 - 4.38 
{1H, m, -CH(CH2Ph)}, 4.27 (2H, s, meta on η
5
-C5H4-benzoyl), 3.96 (2H, q, J = 7.2 Hz, 
- OCH2CH3), 3.84 - 3.79 {6H, m, (η
5
-C5H4-alkyl), (-NHCH2CO-)}, 2.92 - 2.85  {2H, 
m, -CH(CH2Ph)}, 1.90 (2H, t, J = 7.6 Hz, -CH2CH2CH3), 1.30 - 1.29 (2H, m, -
CH2CH2CH3), 1.04 (3H, t, J = 7.2 Hz, -OCH2CH3), 0.66 (3H, t, J = 7.2 Hz, - 
CH2CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 169.8 (C=O), 168.7 (C=O), 166.3 (C=O), 140.6 
(Cq), 137.0 (Cq), 134.1 (Cq), 128.8, 128.5, 126.2, 124.2, 124.1, 91.5 (Cipso η
5
-C5H4-
alkyl), 83.1 (Cipso η
5
-C5H4-benzoyl), 70.0 (Cmeta η
5
-C5H4-benzoyl), 68.8 (Cmeta η
5
-C5H4-
alkyl), 68.0 (Cortho η
5
-C5H4-alkyl), 66.2 (Cortho η
5
-C5H4-benzoyl), 60.1 (-OCH2CH3, -ve 
DEPT), 52.8 (-CH(CH2Ph),  42.8 (-NHCH2CHO-, -ve DEPT), 36.4 {-CH(CH2Ph), -ve 
DEPT}, 31.0 (-CH2CH2CH3, -ve DEPT), 20.6 (-CH2CH2CH3, -ve DEPT), 14.4 (-
OCH2CH3), 14.0 (-CH2CH2CH3). 
 
 
1-propyl-1’-N-{meta-(ferrocenyl) benzoyl} glycine glycine ethyl ester (92) 
 
Glycine glycine ethyl ester hydrochloride (0.12 g, 0.72 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.08 g, 23 %),  
Mass spectrum: [M+Na]
+
  found:   513.1454
 
C26H30N2O4FeNa requires:              513.1453                  
I.R. υmax  (KBr): 3295 (NH), 1737 (C=Oester), 1631 (C=Oamide), 1609 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 334, 445 nm; 
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1
H NMR (400 MHz) δ (DMSO- d6): 8.74 (1H, t, J = 6.0 Hz,  -CONH-), 8.30 (1H, t, J = 
6 Hz,  -CONH-), 8.08 (1H, s,  ArH), 7.69 - 7.66 (2H, m,  ArH), 7.40 (1H, t, J = 7.0 Hz, 
ArH), 4.80 (2H, s, ortho on η5-C5H4-benzoyl), 4.34 (2H, s, meta on η
5
-C5H4-benzoyl), 
4.01 (2H, q, J = 6.8 Hz, -OCH2CH3), 3.95 - 3.85 {8H, m, (η
5
-C5H4-alkyl), (-
NHCH2CO-), (-NHCH2CO-)}, 2.00 (2H, t, J = 7.6 Hz, -CH2CH2CH3), 1.40 - 1.30 (2H, 
m, -CH2CH2CH3), 1.12 (3H, t, J = 7.2 Hz, -OCH2CH3), 0.70 (3H, t, J = 7.2 Hz, - 
CH2CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 170.8 (C=O), 169.1 (C=O), 165.5 (C=O), 138.5 
(Cq), 135.8 (Cq), 128.2, 127.9, 127.0, 123.2, 92.5 (Cipso η
5
-C5H4-alkyl), 83.0 (Cipso η
5
-
C5H4-benzoyl), 71.7 (Cmeta η
5
-C5H4-benzoyl), 69.8 (Cmeta η
5
-C5H4-alkyl), 68.4 (Cortho 
η5-C5H4-alkyl), 66.7 (Cortho η
5
-C5H4-benzoyl), 62.4 (-OCH2CH3, -ve DEPT), 42.8 (-
NHCH2CHO-, -ve DEPT), 41.9 (-NHCH2CHO-, -ve DEPT), 32.8 (-CH2CH2CH3, -ve 
DEPT),  25.0 (-CH2CH2CH3, -ve DEPT), 14.5 (-OCH2CH3), 14.0 (-CH2CH2CH3). 
 
1-propyl-1’-N-{meta-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester (93) 
 
Glycine L-alanine ethyl ester hydrochloride (0.13 g, 0.72 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.08 g, 22%),  
[α]D
20
 = -16
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   527.1621
 
C27H32N2O4FeNa requires:              527.1609                  
I.R. υmax  (KBr): 3290 (NH), 1739 (C=Oester), 1635 (C=Oamide), 1605 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 330, 449 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.65 (1H, t, J = 6.0 Hz,  -CONH-), 8.41 (1H, d, J 
= 7.2 Hz,  -CONH-), 8.10 (1H, s,  ArH), 7.71 - 7.69 (2H, m,  ArH), 7.42 (1H, t, J = 7.0 
Hz, ArH), 4.80 (2H, s, ortho on η5-C5H4-benzoyl), 4.35 (2H, s, meta on η
5
-C5H4-
benzoyl),  4.30 - 4.25 (1H, m, -CHCH3), 4.10 (2H, q, J = 6.8 Hz, -OCH2CH3),  3.97 - 
3.85 {6H, m, (η5-C5H4-alkyl), (-NHCH2CO-)}, 2.00 (2H, t, J = 7.6 Hz, -CH2CH2CH3), 
1.35 - 1.25 {5H, m, (-CH2CH2CH3), (-CHCH3)}, 1.10 (3H, t, J = 6.8 Hz, -OCH2CH3), 
0.72 (3H, t, J = 7.2 Hz, -CH2CH2CH3); 
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13
C NMR (100 MHz) δ ( DMSO- d6 ): 170.0 (C=O), 169.5 (C=O), 168.2 (C=O), 135.5 
(Cq), 132.8 (Cq), 130.4, 129.2,  126.4, 123.9, 92.3 (Cipso η
5
-C5H4-alkyl), 82.6 (Cipso η
5
-
C5H4-benzoyl), 71.6 (Cmeta η
5
-C5H4-benzoyl), 68.9 (Cmeta η
5
-C5H4-alkyl), 68.4 (Cortho 
η5-C5H4-alkyl), 67.9 (Cortho η
5
-C5H4-benzoyl), 61.4 (-OCH2CH3, -ve DEPT), 48.6 (-
CHCH3), 41.0 (-NHCH2CHO-, -ve DEPT), 31.9 (-CH2CH2CH3, -ve DEPT),  21.0 (-
CH2CH2CH3, -ve DEPT), 18.0 (-CHCH3), 14.2 (-OCH2CH3), 13.9 (-CH2CH2CH3). 
 
1-propyl- 1’-N-{meta-(ferrocenyl) benzoyl} glycine L-leucine ethyl ester (94) 
 
Glycine L-leucine ethyl ester hydrochloride (0.16 g, 0.72 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.07 g, 18%),  
[α]D
20
 = -18
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   569.2193
 
C30H38N2O4FeNa requires:              569.2181                  
I.R. υmax  (KBr): 3260 (NH), 1736 (C=Oester), 1643 (C=Oamide), 1612 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 331, 448 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.65 (1H, t, J = 6.0 Hz,  -CONH-), 8.30 (1H, d, J 
= 7.6 Hz,  -CONH-), 8.00 (1H, s,  ArH), 7.72 - 7.70 (2H, m,  ArH), 7.39 (1H, t, J = 7.0 
Hz, ArH), 4.83 (2H, s, ortho on η5-C5H4-benzoyl), 4.35 (2H, t, J = 1.6 Hz, meta on η
5
-
C5H4-benzoyl), 4.30 - 4.28 {1H, m, -CH(CH2CH(CH3)2)}, 4.19 (2H, q, J = 7.2 Hz, - 
OCH2CH3) , 3.95 - 3.88 {6H, m, (η
5
-C5H4-alkyl), (-NHCH2CO-)}, 2.08 (2H, t, J = 7.6 
Hz, -CH2CH2CH3), 1.69 - 1.45 {3H, m, -CH(CH2CH(CH3)2)}, 1.35 - 1.25 (2H, m, -
CH2CH2CH3), 1.19 (3H, t, J = 7.2 Hz, -OCH2CH3), 0.89 - 0.83 {6H, m, -
CH(CH2CH(CH3)2)},  0.70 (3H, t, J = 7.2 Hz, - CH2CH2CH3);  
13
C NMR (100 MHz) δ (DMSO- d6): 171.9 (C=O), 169.6 (C=O), 166.1 (C=O), 139.1 
(Cq), 137.8 (Cq), 132.4, 129.7, 127.2, 125.7, 89.4 (Cipso η
5
-C5H4-alkyl), 83.3 (Cipso η
5
-
C5H4-benzoyl), 71.0 (Cmeta η
5
-C5H4-benzoyl), 70.4 (Cmeta η
5
-C5H4-alkyl), 68.4 (Cortho 
η5-C5H4-alkyl), 66.1 (Cortho η
5
-C5H4-benzoyl), 61.4 (-OCH2CH3, -ve DEPT), 51.3 (-
CH(CH2CH(CH3)2), 42.9 (-NHCH2CHO-, -ve DEPT), 40.0 {-CH(CH2CH(CH3)2), -ve 
DEPT}, 31.0 (-CH2CH2CH3, -ve DEPT), 27.4 (-CH(CH2CH(CH3)2) 24.7 (-
CH2CH2CH3, -ve DEPT), 23.2 {-CH(CH2CH(CH3)2)}, 22.4 -CH(CH2CH(CH3)2), 14.6 
(-OCH2CH3), 13.6 (-CH2CH2CH3). 
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1-propyl-1’-N-{meta-(ferrocenyl) benzoyl} glycine L-phenylalanine ethyl ester (95) 
 
Glycine L-phenylalanine ethyl ester hydrochloride (0.18 g, 0.72 mmol) was used as a 
starting material. The crude product was purified by column chromatography {eluent 
1:1 hexane: ethyl acetate} yielding the titled product as a red oil (0.07 g, 17%),  
[α]D
20
 = -13
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   603.2032
 
C33H36N2O4FeNa requires:              603.2034                  
I.R. υmax  (KBr): 3300 (NH), 1745 (C=Oester), 1633 (C=Oamide), 1612 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 330, 447 nm; 
1
H NMR (400 MHz) δ (  DMSO- d6 ): 8.68 (1H, t, J = 6.0 Hz,  -CONH-), 8.30 (1H, d, J 
= 7.6 Hz,  -CONH-), 8.00 (1H, s,  ArH), 7.69 - 7.68 (2H, m,  ArH), 7.40 (1H, t,  J = 7.6 
Hz, ArH), 7.25 - 7.21 (5H, m, -CH(CH2Ph)}, 4.80 (2H, s, ortho on η
5
-C5H4-benzoyl), 
4.49 - 4.47 {1H, m, -CH(CH2Ph)}, 4.29 (2H, s, meta on η
5
-C5H4-benzoyl), 4.00 (2H, q, 
J = 7.2 Hz, -OCH2CH3),  3.95 - 3.83 {6H, m, (η
5
-C5H4-alkyl), (-NHCH2CO-)}, 3.06 - 
2.90 {2H, m, -CH(CH2Ph)}, 1.99 (2H, t, J = 7.6 Hz, -CH2CH2CH3), 1.40 - 1.27 (2H, m, 
-CH2CH2CH3), 1.11 (3H, t, J = 7.2 Hz, -OCH2CH3), 0.70 (3H, t, J = 7.2 Hz, - 
CH2CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 171.9 (C=O), 169.2 (C=O), 166.9 (C=O), 137.0 
(Cq), 132.7 (Cq), 130.1 (Cq), 128.7, 127.2,  126.8, 126.1, 125.2, 124.9, 123.7, 89.1 (Cipso 
η5-C5H4-alkyl), 84.0 (Cipso η
5
-C5H4-benzoyl), 71.4 (Cmeta η
5
-C5H4-benzoyl), 69.4 (Cmeta 
η5-C5H4-alkyl), 67.5 (Cortho η
5
-C5H4-alkyl), 66.3 (Cortho η
5
-C5H4-benzoyl), 62.4 (-
OCH2CH3, -ve DEPT), 53.7 (-CH(CH2Ph)), 43.2 (-NHCH2CHO-, -ve DEPT), 39.2 {-
CH(CH2Ph), -ve DEPT}, 33.8 (-CH2CH2CH3, -ve DEPT), 20.6 (-CH2CH2CH3, -ve 
DEPT), 14.9 (-OCH2CH3), 13.1 (-CH2CH2CH3). 
 
1-propyl- 1’-N- {ortho-(ferrocenyl) benzoyl} glycine glycine ethyl ester (96) 
 
 
Glycine-glycine ethyl ester hydrochloride (0.12 g, 0.72 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.08 g, 23%),  
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Mass spectrum: [M+Na]
+
  found:   513.1464
 
C26H30N2O4FeNa requires:              513.1453                  
I.R. υmax  (KBr): 3387 (NH), 1735 (C=Oester), 1629 (C=Oamide), 1609 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 325, 443 nm; 
1
H NMR (400 MHz) δ( DMSO- d6): 8.76 (1H, t, J = 5.6 Hz,  -CONH-), 8.34 (1H, t, J = 
5.6 Hz, -CONH-), 7.98 (1H, d, J = 7.4 Hz, ArH), 7.86 (1H, t, J = 7.2 Hz, ArH), 7.70 
(1H, t, J = 6.8 Hz, ArH), 7.39 (1H, d, J = 7.6 Hz, ArH), 4.83 (2H, s, ortho on η5-C5H4-
benzoyl), 4.36 (2H, s, meta on η5-C5H4-benzoyl), 4.12 (2H, q, J = 6.8 Hz, - OCH2CH3) 
,  3.96 - 3.85 {8H, m, (η5-C5H4-alkyl), (-NHCH2CO-), (-NHCH2CO-)}, 2.05 (2H, t, J = 
7.6 Hz, -CH2CH2CH3), 1.35 - 1.27 (2H, m, -CH2CH2CH3), 1.10 (3H, t, J = 6.8 Hz, -
OCH2CH3), 0.72 (3H, t, J = 7.2 Hz, - CH2CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 168.8 (C=O), 168.3 (C=O), 167.9 (C=O), 142.5 
(Cq), 137.8 (Cq), 130.2, 129.5, 128.9, 126.7, 91.8 (Cipso η
5
-C5H4-alkyl), 81.9 (Cipso η
5
-
C5H4-benzoyl), 71.7 (Cmeta η
5
-C5H4-benzoyl), 69.1 (Cmeta η
5
-C5H4-alkyl), 67.0 (Cortho 
η5-C5H4-alkyl), 66.2 (Cortho η
5
-C5H4-benzoyl), 61.9 (-OCH2CH3, -ve DEPT), 44.4 (-
NHCH2CHO-, -ve DEPT), 42.8 (-NHCH2CHO-, -ve DEPT), 32.8 (-CH2CH2CH3, -ve 
DEPT),  24.5 (-CH2CH2CH3, -ve DEPT), 14.3 (-OCH2CH3), 13.1 (-CH2CH2CH3). 
 
1-propyl- 1’-N-{ortho-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester (97) 
 
Glycine L-alanine ethyl ester hydrochloride (0.13 g, 0.72 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.07 g, 19%),  
[α]D
20
 = -19
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   527.1617
 
C27H32N2O4FeNa requires:              527.1609                  
I.R. υmax  (KBr):  3291 (NH), 1740 (C=Oester), 1639 (C=Oamide), 1618 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 325, 446 nm; 
1
H NMR (400 MHz) δ ( DMSO- d6): 8.68 (1H, t, J = 6.0 Hz,  -CONH-), 8.41 (1H, d, J 
= 7.0 Hz,  -CONH-), 8.01 (1H, d, J = 7.6 Hz, ArH), 7.80 (1H, t, J = 7.2 Hz, ArH), 7.79 
(1H, t, J = 6.0 Hz, ArH), 7.38 (1H, d, J = 7.6 Hz, ArH), 4.85 (2H, s, ortho on η5-C5H4-
benzoyl), 4.37 (2H, s, meta on η5-C5H4-benzoyl),  4.33 - 4.28 (1H, m, - CHCH3), 4.11 
(2H, q, J = 6.4 Hz, - OCH2CH3) ,  3.92 - 3.85 {6H, m, (η
5
-C5H4-alkyl), (-NHCH2CO-)}, 
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2.05 (2H, t, J = 7.6 Hz, -CH2CH2CH3), 1.38 - 1.29 {5H, m, (-CH2CH2CH3), (-
CHCH3)}, 1.14 (3H, t, J = 6.4 Hz, -OCH2CH3), 0.70 (3H, t, J = 7.2 Hz, - 
CH2CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 172.9 (C=O), 169.0 (C=O), 166.2 (C=O), 137.2 
(Cq), 135.8 (Cq), 130.4, 128.6,  127.4, 124.8, 91.3 (Cipso η
5
-C5H4-alkyl), 81.2 (Cipso η
5
-
C5H4-benzoyl), 72.0 (Cmeta η
5
-C5H4-benzoyl), 68.8 (Cmeta η
5
-C5H4-alkyl), 68.5 (Cortho 
η5-C5H4-alkyl), 67.9 (Cortho η
5
-C5H4-benzoyl), 60.4 (-OCH2CH3, -ve DEPT), 47.6 (-
CHCH3), 42.0 (-NHCH2CHO-, -ve DEPT), 31.0 (-CH2CH2CH3, -ve DEPT),  22.8 (-
CH2CH2CH3, -ve DEPT), 17.4 (-CHCH3), 15.0 (-OCH2CH3), 14.0 (-CH2CH2CH3). 
 
1-propyl- 1’-N-{ortho-(ferrocenyl) benzoyl} glycine L-leucine ethyl ester (98) 
 
Glycine L-leucine ethyl ester hydrochloride (0.12 g, 0.72 mmol) was used as a starting 
material. The crude product was purified by column chromatography {eluent 1:1 
hexane: ethyl acetate} yielding the titled product as a red oil (0.05 g, 14%),  
[α]D
20
 = -17
o 
(c 0.1, EtOH); 
I.R. υmax  (KBr): 3272 (NH), 1751 (C=Oester), 1633 (C=Oamide), 1610 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 324, 446 nm; 
1
H NMR (400 MHz) δ( DMSO- d6): 8.67 (1H, t, J = 6.0 Hz,  -CONH-), 8.33 (1H, d, J 
= 7.6 Hz,  -CONH-), 8.03 (1H, d, J = 7.2 Hz, ArH), 7.81 (1H, t, J = 7.0 Hz, ArH), 7.79 
(1H, t, J = 6.4 Hz, ArH), 7.31 (1H, d, J = 7.6 Hz, ArH), 4.79 (2H, s, ortho on η5-C5H4-
benzoyl), 4.35 (2H, s, meta on η5-C5H4-benzoyl), 4.30 - 4.27 {1H, m, -
CH(CH2CH(CH3)2)}, 4.17 (2H, q, J = 7.2 Hz, - OCH2CH3), 3.95 - 3.84 {6H, m, (η
5
-
C5H4-alkyl), (-NHCH2CO-)}, 2.07 (2H, t, J = 7.6 Hz, -CH2CH2CH3), 1.69 - 1.45 {3H, 
m, -CH(CH2CH(CH3)2)}, 1.38 - 1.23 (2H, m, -CH2CH2CH3), 1.17 (3H, t, J = 7.2 Hz, -
OCH2CH3), 0.90 - 0.85 {6H, m, -CH(CH2CH(CH3)2)}, 0.74 (3H, t, J = 7.2 Hz, - 
CH2CH2CH3);  
13
C NMR (100 MHz) δ (DMSO- d6): 170.9 (C=O), 168.5 (C=O), 167.1 (C=O), 139.5 
(Cq), 135.8 (Cq), 129.4, 127.9,  125.2, 124.9, 91.4 (Cipso η
5
-C5H4-alkyl), 82.9 (Cipso η
5
-
C5H4-benzoyl), 71.0 (Cmeta η
5
-C5H4-benzoyl), 70.4 (Cmeta η
5
-C5H4-alkyl), 69.2 (Cortho 
η5-C5H4-alkyl), 66.8 (Cortho η
5
-C5H4-benzoyl), 61.4 (-OCH2CH3, -ve DEPT), 51.3 {-
CH(CH2CH(CH3)2)}, 43.9 (-NHCH2CHO-, -ve DEPT), 41.0 {-CH(CH2CH(CH3)2), -ve 
DEPT}, 31.0 (-CH2CH2CH3, -ve DEPT), 27.7 {-CH(CH2CH(CH3)2)}, 24.4 (-
 196 
CH2CH2CH3, -ve DEPT), 22.7 {-CH(CH2CH(CH3)2)}, 21.4 {-CH(CH2CH(CH3)2)}, 
14.6 (-OCH2CH3), 13.6 (-CH2CH2CH3). 
 
1-propyl-1’-N-{ortho-(ferrocenyl) benzoyl} glycine L-phenylalanine ethyl ester (99) 
 
Glycine L-phenylalanine ethyl ester hydrochloride (0.18 g, 0.72 mmol) was used as a 
starting material. The crude product was purified by column chromatography {eluent 
1:1 hexane: ethyl acetate} yielding the titled product as a red oil (0.06 g, 13%), 
[α]D
20
 = +17
o 
(c 0.1, EtOH); 
I.R. υmax  (KBr): 3288 (NH), 1730 (C=Oester), 1629 (C=Oamide), 1615 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 324, 445 nm; 
1
H NMR (400 MHz) δ(  DMSO- d6 ): 8.50 (1H, t, J = 6.0 Hz,  -CONH-), 8.26 (1H, d, J 
= 7.0 Hz,  -CONH-), 7.91 (1H, d, J = 7.0 Hz, ArH), 7.78 (3H, t, J = 7.2 Hz, ArH), 7.49 
(1H, t, J = 7.2 Hz, ArH), 7.30 (1H, d, J = 7.0 Hz, ArH) 7.16 - 7.10 {5H, m,  
-CH(CH2Ph)}, 4.73 (2H, s, ortho on η
5
-C5H4-benzoyl), 4.40 - 4.38 {1H, m,  -
CH(CH2Ph)}, 4.27 (2H, s, meta on η
5
-C5H4-benzoyl), 3.96 (2H, q, J = 7.2 Hz, - 
OCH2CH3),  3.83 - 3.79 {6H, m, (η
5
-C5H4-alkyl), (-NHCH2CO-)}, 2.84 - 2.80 {3H, m, 
-CH(CH2Ph)}, 1.88 (2H, t, J = 7.6 Hz, -CH2CH2CH3), 1.39 - 1.33 (2H, m, -
CH2CH2CH3), 1.14 (3H, t, J = 7.2 Hz, -OCH2CH3), 0.76 (3H, t, J = 7.2 Hz, - 
CH2CH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 169.6 (C=O), 168.6 (C=O), 166.3 (C=O), 136.0 
(Cq), 134.1 (Cq), 128.8 (Cq), 128.5, 126.2,  125.1, 124.2, 123.1, 122.2, 120.8, 91.2 (Cipso 
η5-C5H4-alkyl), 83.1 (Cipso η
5
-C5H4-benzoyl), 69.9 (Cmeta η
5
-C5H4-benzoyl), 68.8 (Cmeta 
η5-C5H4-alkyl), 68.5 (Cortho η
5
-C5H4-alkyl), 66.2 (Cortho η
5
-C5H4-benzoyl), 60.3 (-
OCH2CH3, -ve DEPT), 50.0 {-CH(CH2Ph)},  42.4 (-NHCH2CHO-, -ve DEPT), 36.2 (-
CH(CH2Ph), -ve DEPT), 31.1 (-CH2CH2CH3, -ve DEPT), 20.8 (-CH2CH2CH3, -ve 
DEPT), 14.3 (-OCH2CH3), 14.1 (-CH2CH2CH3). 
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General procedure for the preparation of starting materials for ethynyl ferrocenyl 
dipeptide derivatives 
 
(2-Formyl-1-chlorovinyl) ferrocene (100) 
[3]
 
 
Acetylferrocene (22.8 g, 99.96 mmol) was dissolved in N, N-dimethylformamide (25 
ml) at 0 °C under nitrogen. Phosphorus oxychloride (25 ml) was added to 
dimethylformamide (25 ml) at 0 °C under nitrogen and stirred for 25 min resulting in a 
viscous red complex. The viscous complex was added to the acetylferrocene mixture 
over 2 hr and further stirred for 3 hr at 0 °C. Diethyl ether (80 ml), sodium acetate (116 
g, mmol) and deionised water (20 ml) were added to reaction mixture. The reaction 
mixture was stirred at room temperature for 12 hr and then conc. sodium bicarbonate 
solution was added. The resulting solution was extracted with ethyl acetate. The solvent 
was evaporated to yield the crude product which was purified by column 
chromatography (eluent 9:1 hexane: diethyl ether) yielding the title compound as deep 
purple crystals. (17 g, 62%), mp. 76 - 77 °C (lit. 
3
 76 - 77 °C); 
1
H NMR (400 MHz) δ (DMSO- d6):  10.03 (1H, d, J = 7.2 Hz, -CHO), 6.32 {1H, d, J = 
7.2 Hz, η5-C5H4-C=CH(Cl)-}. 4.68 {2H, t, J = 2.0 Hz, ortho on η
5
-C5H4-C=CH(Cl)-}, 
4.49 {2H, t, J = 2.0 Hz, meta on η5-C5H4-C=CH(Cl)-}, 4.17 (5H, s, η
5
-C5H5); 
13C NMR (100 MHz) δ (DMSO- d6): 190.8 (C=O), 155.4 (η
5
-C5H4-C=CH(Cl)-), 120.4 
(η5-C5H4-C=CH(Cl)-), 80.1 (Cortho η
5
-C5H4-C=CH(Cl)-), 72.3 (η
5
-C5H5), 70.1 (Cmeta η
5
-
C5H4-C=CH(Cl)-), 68.9 (Cipso η
5
-C5H4-C=CH(Cl)-).   
 
Ethynyl ferrocene (101) 
[4]
 
 
Potassium tert-butoxide (10.24 g, 91.25 mmol) was added to dry tetrahydrofuran (100 
ml) at 0 °C under nitrogen and stirred for 25 min. (2-Formyl-1-chlorovinyl) ferrocene 
(5 g, 18.25 mmol)  was added slowly over 10 min and the reaction mixture was stirred 
at 0°C for 30 min and refluxed at 80 °C for 4 hr. The reaction mixture was poured into 
ice then neutralised with conc. hydrochloric acid. The resulting solution was extracted 
with hexane and the solvent was evaporated to yield the crude product which was 
purified by column chromatography (eluent 9:1 hexane: diethyl ether) yielding the title 
compound as a red solid. (1.87 g, 49%) m.p 52 -53 °C, (lit. 
4
 52 - 53 °C); 
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1H NMR (400 MHz) δ (DMSO- d6):  4.68 (2H, t, J = 2.0 Hz, ortho on η
5
-C5H4-C≡CH), 
4.25 - 4.15 {7H, m, (meta on η5-C5H4-C≡CH), (η
5
-C5H5)}, 2.74  
(1H, s, η5-C5H4-C≡CH); 
13C NMR (100 MHz) δ (DMSO- d6): 82.5 (η
5
-C5H4-C≡CH), 73.5 (η
5
-C5H4-C≡CH), 
71.8 (Cortho η
5
-C5H4-C≡CH), 70.1 (η
5
-C5H5), 68.7 (Cmeta η
5
-C5H4-C≡CH), 63.5 (Cipso η
5
-
C5H4-C≡CH). 
 
para-(ferrocenyl) ethynyl benzoic acid (102) 
 
Ethynyl ferrocene (2.00 g, 9.52 mmol) and 4-bromobenzoic acid (1.91 g, 9.52 mmol) 
were mixed together and dissolved in 50 ml of a 1:1 mixture of dry triethylamine and 
tetrahydrofuran under nitrogen for 10 min.  Triphenylphosphine (0.20 g, 0.76 mmol), 
bis(triphenylphosphine)palladium(II) dichloride (0.28 g, 0.38 mmol) and copper(I) 
iodide (0.07 g, 0.38 mmol)  were mixed together and added to the reaction mixture. The 
reaction mixture was stirred for 10 min and refluxed at 80 
o
C for 12 hr. The reaction 
mixture was vacuum filtered. The solvent was removed in vacuo to yield the crude 
product. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) yielding the title compound as a red solid (2.53 g, 81%), mp 147 
- 149 
o
C; 
1
H NMR (400 MHz) δ (DMSO- d6): 12.83 (1H, s, -COOH), 7.90 (2H, d, J = 9.2 Hz, 
ArH), 7.58 (2H, d, J = 9.2 Hz, ArH), 4.61 (2H, t, J = 2.0 Hz, ortho on η5-C5H4-C≡C-), 
4.38 (2H, t, J = 2.0 Hz, meta on η5-C5H4-C≡C-), 4.29 (5H, s, η
5
-C5H5);  
13
C NMR (100 MHz) δ (DMSO- d6): 171.0 (C=O), 138.2 (Cq), 136.1(Cq), 133.0, 131.0, 
96.4 (η5-C5H4-C≡C-), 87.0 (η
5
-C5H4-C≡C-), 71.4 (Cortho η
5
-C5H4-C≡C-), 70.1 (η
5
-
C5H5), 69.7 (Cmeta η
5
-C5H4-C≡C-), 64.0 (Cipso η
5
-C5H4-C≡C-). 
 
6-(Ferrocenyl) ethynyl-2-naphthoic acid (103) 
 
Ethynyl ferrocene (2.00 g, 9.52 mmol) and 6-bromo-2-naphthoic acid (2.39 g, 9.52 
mmol) were used as starting materials. The crude product was purified by column 
chromatography (eluent 1:1 hexane: ethyl acetate) to yield the desired product as a red 
solid. (2.34 g, 64%), mp 167- 169 
o
C; 
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1
H NMR (400 MHz) δ (DMSO- d6):  12.87 (1H, s, -COOH), 8.13 (1H, s, ArH), 7.95 -
7.48 (5H, m,  (ArH), 4.60 (2H, t, J = 2.0 Hz,  ortho on η5-C5H4-C≡C-), 4.27 (2H, t, J = 
2.0 Hz meta on η5-C5H4-C≡C-), 4.19 (5H, s, η
5
-C5H5); 
13
C NMR (100 MHz) δ (DMSO- d6): 172.7 (C=O), 134.9 (Cq), 134.6 (Cq), 134.0 (Cq), 
132.2 (Cq), 131.6, 130.3, 128.1, 128.0, 127.8, 120.8, 90.3 (η
5
-C5H4-C≡C-), 85.7 (η
5
-
C5H4-C≡C-), 71.4 (Cortho η
5
-C5H4-C≡C-), 69.9 (η
5
-C5H5), 68.7 (Cmeta η
5
-C5H4-C≡C-), 
65.8 (Cipso η
5
-C5H4-C≡C-).  
 
5-(Ferrocenyl) ethynyl-2-furanoic acid (104) 
 
Ethynyl ferrocene (2.00 g, 9.52 mmol) and 5-bromo-2-furanoic acid (1.82 g, 9.52 
mmol) was used as starting materials. The crude product was purified by column 
chromatography (eluent 1:1 hexane: ethyl acetate) to yield the desired product as a red 
oil (2.10 g, 69%);  
1
H NMR (400 MHz) δ (DMSO- d6): 11.5 (1H, s, COOH), 7.06 (1H, d, J = 3.6 Hz, 
ArH), 6.56 (1H, d, J = 3.6 Hz, ArH), 4.48 (2H, s, ortho on η5-C5H4-C≡C-) , 4.24 (2H, s, 
meta on η5-C5H4-C≡C-), 4.16 (5H, s, η
5
-C5H5); 
 13
C NMR (100 MHz) δ (DMSO- d6): 167.9 (C=O), 146.5 (Cq), 139.3 (Cq), 116.1, 
116.0, 94.5 (η5-C5H4-C≡C-), 75.0 (η
5
-C5H4-C≡C-), 71.7 (Cortho η
5
-C5H4-C≡C-), 70.2 
(η5-C5H5), 69.5 (Cmeta η
5
-C5H4-C≡C-), 65.1 (Cipso η
5
-C5H4-C≡C-). 
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General procedure for the preparation of N-{para-(ferrocenyl) ethynyl benzoyl} 
amino acids and dipeptide esters 
 
N-{para-(ferrocenyl) ethynyl benzoyl} glycine glycine methyl ester (105) 
 
N-para-(ferrocenyl) ethynyl benzoic acid (1.00 g, 3.03 mmol) was dissolved in 
dichloromethane (100 ml) at 0 
o
C. N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.58 g, 3.03 mmol), 1-hydroxybenzotriazole (0.35 g, 3.03 mmol), 
glycine glycine methyl ester hydrochloride (0.44 g, 3.03 mmol) and triethylamine (6 
ml) were added and the reaction mixture was allowed to stir at 0 
o
C for 45 min. The 
reaction mixture was then allowed to stir at room temperature for 48 h, and washed 
with water and brine. The organic layer was dried over MgSO4. The solvent was 
removed in vacuo to yield the crude product, that was purified by column 
chromatography (eluent 1:1 hexane: ethyl acetate) yielding the title compound as an 
orange solid (0.35 g, 25%), m.p 169 - 171 
o
C;  
Mass spectrum: [M+Na]
+
  found:   481.0814
 
C24H22N2O4FeNa requires:              481.0827                    
I.R. υmax (KBr): 3261 (NH), 2204 (-C≡C-), 1736 (C=Oester), 1658 (C=Oamide), 1603 
(C=Oamide) cm
-1
; 
UV-Vis λmax EtOH:  385, 490 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.91 (1H, t, J = 6.0 Hz,  -CONH-), 8.40 (1H, t, J = 
6.0 Hz,  -CONH-), 7.90 (2H, d, J = 8.0 Hz, ArH), 7.58 (2H, d, J = 8.0 Hz, ArH), 4.60 
(2H, s, ortho on η5-C5H4-C≡C-), 4.37 (2H, s, meta on η
5
-C5H4-C≡C-), 4.29 (5H, s, η
5
-
C5H5), 3.93 ( 2H, d, J = 5.6 Hz, -NHCH2CO-), 3.86 (2H, d, J = 5.6 Hz, -NHCH2CO-), 
3.63 (3H, s, - OCH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 170.2 (C=O), 168.9 (C=O), 167.8  (C=O), 131.9 
(Cq), 130.0 (Cq), 127.7, 126.0, 91.2 (η
5
-C5H4-C≡C-), 84.1 (η
5
-C5H4-C≡C-), 71.8 (Cortho 
η5-C5H4-C≡C-), 69.8 (η
5
-C5H5),  68.2 (Cmeta η
5
-C5H4-C≡C-),  64.9 (Cipso η
5
-C5H4-C≡C-
),  51.7 (-OCH3), 48.7, (-NHCH2CO-, -ve DEPT), 40.5 (-NHCH2CO-, -ve DEPT). 
 
N-{para-(ferrocenyl) ethynyl benzoyl} glycine glycine ethyl ester (106) 
 
Glycine glycine ethyl ester hydrochloride (0.48 g, 3.03 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
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hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.32 g, 22%), m.p 178 - 180 
o
C;  
Mass spectrum: [M+Na]
+
  found:    495.0972
 
C25H24N2O4FeNa requires:               495.0983              
I.R. υmax (KBr): 3261(NH), 2204 (-C≡C-), 1736 (C=Oester), 1658 (C=Oamide), 1603 
(C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 385, 490 nm; 
1
H NMR (400 MHz) δ (DMSO- d6): 8.89 (1H, t, J = 6.4 Hz,  -CONH-), 8.36 (1H, t, J = 
6.4 Hz,  -CONH-), 7.90 (2H, d, J = 9.2 Hz, ArH), 7.58 (2H, d, J = 9.2 Hz, ArH), 4.61 
(2H, t, J = 2.0 Hz, ortho on η5-C5H4-C≡C-), 4.38 (2H, t, J = 2.0 Hz, meta on η
5
-C5H4-
C≡C-), 4.29 (5H, s, η5-C5H5), 4.10 (2H, q, J = 7.2 Hz, -OCH2CH3), 3.91 (2H, d, J = 6.0 
Hz, -NHCH2CO-), 3.84 (2H, d, J = 6.0 Hz, -NHCH2CO-), 1.19 (3H, t, J = 7.2 Hz, - 
OCH2CH3); 
13
C NMR (100 MHz) δ (DMSO- d6): 170.0 (C=O), 169.3 (C=O), 168.2 (C=O), 132.2 
(Cq), 130.7 (Cq), 127.7, 126.0, 90.9 (η
5
-C5H4-C≡C-), 84.3 (η
5
-C5H4-C≡C-), 72.0 (Cortho 
η5-C5H4-C≡C-), 70.5 (η
5
-C5H5), 69.1 (Cmeta η
5
-C5H4-C≡C-), 67.6 (Cipso η
5
-C5H4-C≡C-), 
62.0 (-OCH2CH3, -ve DEPT), 49.6 (-NHCH2CO-, -ve DEPT), 42.3, (-NHCH2CO-, -ve 
DEPT), 13.9 (-OCH2CH3). 
 
N-{para-(ferrocenyl) ethynyl benzoyl} glycine L-alanine methyl ester (107)  
 
Glycine L-alanine methyl ester hydrochloride (0.48 g, 3.03 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.25 g, 17%), m.p 112 - 114 
o
C;  
[α]D
20
 = -25 
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   495.0965
 
C25H24N2O4FeNa requires:              495.0983                  
I.R. υmax (KBr): 3336 (NH), 2205 (-C≡C-), 1734 (C=Oester), 1660 (C=Oamide), 1604 
(C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 391, 488 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.73 (2H, d, J = 8.4 Hz, ArH), 7.48 (1H, t, J = 6.8 Hz, 
-CONH-), 7.45 ( 2H, d, J = 8.4 Hz, ArH), 7.33 (1H, d, J = 7.2 Hz, -CONH-), 4.55 (1H, 
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quin, J = 7.2 Hz, -CHCH3),  4.44 (2H, t, J = 2 Hz, ortho on η
5
-C5H4-C≡C-), 4.21 - 4.13 
{9H, m, (meta on η5-C5H4-C≡C-), (η
5
-C5H5), (-NHCH2CO-)}, 3.66 (3H, s, -OCH3), 
1.36 (3H, d, J = 7.2 Hz, -CHCH3); 
13
C NMR (100 MHz) δ (CDCl3): 173.2 (C=O), 168.6 (C=O), 167.2 (C=O), 132.0 (Cq), 
131.4 (Cq), 127.8, 127.2, 91.7 (η
5
-C5H4-C≡C-), 85.1 (η
5
-C5H4-C≡C-), 70.7 (Cortho η
5
-
C5H4-C≡C-), 69.2 (η
5
-C5H5), 68.2 (Cmeta η
5
-C5H4-C≡C-), 66.5 (Cipso η
5
-C5H4-C≡C-), 
52.4 (-OCH3), 48.3 (-CHCH3), 43.5 (-NHCH2CO-, -ve DEPT), 18.1 (-CHCH3 ). 
 
N-{para-(ferrocenyl) ethynyl benzoyl} glycine L-alanine ethyl ester (108) 
 
Glycine L-alanine ethyl ester hydrochloride (0.52 g, 3.03 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.30 g, 20%), m.p 115 - 117 
o
C;  
[α]D
20
 = -23 
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:  509.1127
 
C26H26N2O4FeNa requires:             509.1140 
I.R. υmax (KBr): 3275 (NH), 2204 (-C≡C-), 1739 (C=Oester), 1652 (C=Oamide), 1604 
(C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 389, 489 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.81 (2H, d, J = 8.0 Hz, ArH ), 7.54 - 7.51 {3H, m,  
(ArH), (-CONH-)} 7.33 (1H, t, J = 7.2 Hz,  -CONH-), 4.54 (1H, quin, J = 6.8 Hz, - 
CHCH3),  4.53 (2H, t, J = 1.6 Hz, ortho on η
5
-C5H4-C≡C-), 4.28 (2H, t, J = 1.6 Hz, 
meta on η5-C5H4-C≡C-), 4.26 (5H, s, η
5
-C5H5), 4.23 - 4.10 {4H, m,  (-OCH2CH3), (-
NHCH2CO-)}, 1.44 (3H, d, J = 7.2 Hz, -CHCH3), 1.28 (3H, t, J = 7.2 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 172.8 (C=O), 168.9 (C=O), 165.2 (C=O), 132.0 (Cq), 
130.4 (Cq), 127.5, 126.9, 91.0 (η
5
-C5H4-C≡C-), 84.9 (η
5
-C5H4-C≡C-), 71.6 (Cortho η
5
-
C5H4-C≡C-), 70.1 (η
5
-C5H5), 69.2 (Cmeta η
5
-C5H4-C≡C-), 66.0 (Cipso η
5
-C5H4-C≡C-), 
61.6 (-OCH2CH3, -ve DEPT), 48.4 (-CHCH3), 42.0 (-NHCH2CO-, -ve DEPT), 18.7 (-
CHCH3), 14.2 (-OCH2CH3). 
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N-{para-(ferrocenyl) ethynyl benzoyl} glycine D-alanine methyl ester (109) 
 
Glycine D-alanine methyl ester hydrochloride (0.48 g, 3.03 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.21 g, 15%), m.p 129 - 131 
o
C;  
[α]D
20
 = +25 
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   495.0978
 
C25H24N2O4FeNa requires:             495.0983              
I.R. υmax (KBr): 3354 (NH), 2207 (-C≡C-), 1735 (C=Oester), 1621 (C=Oamide), 1604 
(C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 387, 492 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.73 (2H, d, J = 8.4 Hz, ArH ), 7.45 ( 2H, d, J = 8.4 
Hz, ArH),  7.25 (1H, t, J = 5.6 Hz, -CONH-), 7.07 (1H, d, J = 6.8 Hz, -CONH-), 4.55 - 
4.50 (1H, m, -CHCH3 ),  4.45 (2H, t, J = 1.6 Hz, ortho on η
5
-C5H4-C≡C-), 4.21 - 4.14 
{9H, m, (meta on η5-C5H4-C≡C-), (η
5
-C5H5), (-NHCH2CO-)}, 3.68 (3H, s, -OCH3), 
1.38 ( 3H, d, J = 7.2 Hz, -CHCH3); 
13
C NMR (100 MHz) δ (CDCl3): 173.2 (C=O), 168.6 (C=O), 167.2 (C=O), 132.0 (Cq), 
131.4 (Cq), 127.8, 127.2, 90.7 (η
5
-C5H4-C≡C-), 84.2 (η
5
-C5H4-C≡C-), 70.9 (Cortho η
5
-
C5H4-C≡C-), 69.2 (η
5
-C5H5), 68.0 (Cmeta η
5
-C5H4-C≡C-), 65.9 (Cipso η
5
-C5H4-C≡C-), 
52.0 (-OCH3), 47.9 (-CHCH3), 42.9 (-NHCH2CO-, -ve DEPT), 18.9 (-CHCH3 ). 
 
N-{para-(ferrocenyl) ethynyl benzoyl} glycine D-alanine ethyl ester (110) 
 
Glycine D-alanine ethyl ester hydrochloride (0.52 g, 3.03 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.27 g, 18%), m.p 69 - 71 
o
C;  
[α]D
20
 = +23 
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found: 509.1154
 
C26H26N2O4FeNa requires:            509.1140      
I.R. υmax (KBr): 3307 (NH), 2205 (-C≡C-), 1734 (C=Oester), 1651 (C=Oamide), 1604 
(C=Oamide) cm
-1
;
 
 204 
UV-Vis λmax EtOH: 387, 494 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.72 (2H, d, J = 8.0 Hz, ArH), 7.45 (2H, d, J = 8.0 Hz, 
ArH), 7.30 (1H, t, J = 7.2 Hz,  -CONH-), 7.05 (1H, d, J = 6.8 Hz,  -CONH-), 4.53 (1H, 
quin, J = 6.8 Hz, -CHCH3 ),  4.42 (2H, t, J = 1.6 Hz, ortho on η
5
-C5H4-C≡C-), 4.20 - 
4.18 {5H, m, (meta on η5-C5H4-C≡C-), (η
5
-C5H5)}, 4.15 - 4.10 {4H, m,  (-OCH2CH3), 
(-NHCH2CO-)}, 1.37 ( 3H, d, J = 7.2 Hz, -CHCH3), 1.20 (3H, t, J = 7.2 Hz, -
OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 172.7 (C=O), 168.2 (C=O), 167.9 (C=O), 132.1 (Cq), 
130.4 (Cq), 127.0, 126.5, 91.0 (η
5
-C5H4-C≡C-), 84.7 (η
5
-C5H4-C≡C-), 71.6 (Cortho η
5
-
C5H4-C≡C-), 70.5 (η
5
-C5H5), 69.1 (Cmeta η
5
-C5H4-C≡C-), 66.7 (Cipso η
5
-C5H4-C≡C-), 
61.6 (-OCH2CH3, -ve DEPT), 48.4 (-CHCH3), 42.0 (-ve DEPT), 18.2 (-CHCH3), 14.1 
(-OCH2CH3). 
 
N-{para-(ferrocenyl) ethynyl benzoyl} γ-aminobutyric acid methyl ester (111)  
 
γ-Amino butyric acid methyl ester hydrochloride (0.35 g, 3.03 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.41 g, 32%), m.p 88 - 90 
o
C;  
Mass spectrum: [M+Na]
+
  found: 452.0937
 
C24H23NO3FeNa requires:             452.0925                  
I.R. υmax (KBr): 3343 (NH), 2207 (-C≡C-), 1731 (C=Oester), 1606 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 385, 485 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.76 (2H, d, J = 8.4 Hz, ArH ), 7.55 (2H, d,  J = 8.4 
Hz, ArH ),  6.65 (1H, t, J = 4.2 Hz,  -CONH-), 4.53 (2H, t, J = 2.0 Hz, ortho on η5-
C5H4-C≡C-), 4.29 - 4.27 {7H, m, (meta on η
5
-C5H4-C≡C-), (η
5
-C5H5)}, 3.70 (3H, s, -
OCH3), 3.54 {2H, q, J = 6.4 Hz, (-NHCH2CH2CH2-)}, 2.49 {2H, t, J = 6.8 Hz, (-
NHCH2CH2CH2-)}, 2.00 {2H, quin, J = 6.4 Hz, (-NHCH2CH2CH2-)}; 
13
C NMR (100 MHz) δ (CDCl3): 174.4 (C=O), 166.9 (C=O), 133.0 (Cq), 131.4 (Cq), 
127.3, 126.9, 91.0 (η5-C5H4-C≡C-), 85.1 (η
5
-C5H4-C≡C-), 71.6 (Cortho η
5
-C5H4-C≡C-), 
70.0 (η5-C5H5), 69.1 (Cmeta η
5
-C5H4-C≡C-), 64.8 (Cipso η
5
-C5H4-C≡C-), 51.9 (-OCH3), 
39.8 (-NHCH2CH2CH2-, -ve DEPT), 31.8 (-NHCH2CH2CH2-, -ve DEPT), 24.3 (-
NHCH2CH2CH2-, -ve DEPT).  
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N-{para-(ferrocenyl) ethynyl benzoyl} γ-aminobutyric acid ethyl ester (112) 
 
γ-Amino butyric acid ethyl ester hydrochloride (0.40 g, 3.03 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.51 g, 38%), m.p 64 - 66 
o
C; 
Mass spectrum: [M+Na]
+
 found: 466.1101
 
C25H25NO3FeNa requires:            466.1082              
I.R. υmax  (KBr): 3283 (NH), 2205 (-C≡C-), 1726 (C=Oester), 1605 (C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 385, 490 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.73 - 7.67  (4H, m, ArH), 6.65 (1H, t, J = 4.4 Hz,  -
CONH-), 4.55 (2H, t, J = 3.2 Hz, ortho on η5-C5H4-C≡C-), 4.28 (2H, t, J = 3.2 Hz, 
meta on η5-C5H4-C≡C-), 4.16 (5H, s, η
5
-C5H5), 4.07 (2H, q, J = 7.2 Hz,  -OCH2CH3), 
3.45{2H, q, J = 6.4 Hz, -NHCH2CH2CH2-), 2.38 (2H, t, J = 6.8 Hz, -NHCH2CH2CH2-), 
1.91 (2H, quin, J = 6.4 Hz, -NHCH2CH2CH2-), 1.19 ( 3H, t, J= 7.2 Hz,  -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 173.0 (C=O), 167.0 (C=O), 132.7 (Cq), 131.8 (Cq), 
127.2, 126.9, 90.8 (η5-C5H4-C≡C-), 85.4 (η
5
-C5H4-C≡C-), 70.5 (Cortho η
5
-C5H4-C≡C-), 
68.8 (η5-C5H5), 68.2 (Cmeta η
5
-C5H4-C≡C-), 67.1 (Cipso η
5
-C5H4-C≡C-), 60.7 (-
OCH2CH3, -ve DEPT), 39.8 (-NHCH2CH2CH2-, -ve DEPT), 32.1 (-NHCH2CH2CH2-, -
ve DEPT), 24.3 (-NHCH2CH2CH2-, -ve DEPT), 14.8 (-OCH2CH3).  
 
N-{para-(ferrocenyl) ethynyl benzoyl} glycine L-phenylalanine ethyl ester (113) 
 
Glycine L-phenylalanine ethyl ester hydrochloride (0.76 g, 3.03 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.20 g, 12%), m.p 118 - 120 
o
C;  
 [α]D
20
 = -17 
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found: 585.1442
 
C32H30N2O4FeNa requires:            585.1453  
I.R. υmax (KBr): 3359 (NH), 2205 (-C≡C-), 1743 (C=Oester), 1631 (C=Oamide), 1605 
(C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 390, 492 nm; 
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1
H NMR (400 MHz) δ (CDCl3): 7.81 (2H, d, J = 8.0 Hz, ArH), 7.54 (2H, d, J = 8.0 Hz, 
ArH ), 7.25 - 7.19 {6H, m,  (-CONH-), (-CHCH2Ph)}, 6.87 (2H, d, J = 8.0 Hz, -CONH-
),  4.86 - 4.84 (1H, m, -CHCH2Ph),  4.54 (2H, t, J = 1.6 Hz, ortho on η
5
-C5H4-C≡C-), 
4.30 - 4.29 {7H, m, (meta on η5-C5H4-C≡C-), (η
5
-C5H5)}, 4.18 (2H, q, J = 7.2 Hz, -
OCH2CH3), 4.23 (2H, d, J = 4.8 Hz, -NHCH2CO-), 3.20 - 3.08 ( 2H, m, -CHCH2Ph), 
1.26 (3H, t, J = 7.2 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3):171.2 (C=O), 168.1(C=O), 167.0 (C=O), 133.7 (Cq), 
132.0 (Cq), 130.1, 129.3, 128.6, 127.8, 127.2, 126.1, 91.7 (η
5
-C5H4-C≡C-), 84.9 (η
5
-
C5H4-C≡C-), 71.1 (Cortho η
5
-C5H4-C≡C-), 70.4 (η
5
-C5H5), 69.2 (Cmeta η
5
-C5H4-C≡C-), 
67.5 (Cipso η
5
-C5H4-C≡C-), 62.7 (-OCH2CH3, -ve DEPT), 53.0 (-CHCH2Ph), 42.6 (-
NHCH2CO-, -ve DEPT), 38.0 (-CHCH2Ph, -ve DEPT), 13.7 (-OCH2CH3).  
 
N-{para-(ferrocenyl) ethynyl benzoyl} glycine L-leucine ethyl ester (114) 
 
Glycine L-leucine ethyl ester hydrochloride (0.65 g, 3.03 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.19 g, 12%), m.p 132 - 134 
o
C; 
 [α]D
20
 = -18 
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found: 551.1617
 
C29H32N2O4FeNa requires:            551.1609              
I.R. υmax (KBr): 3275 (NH), 2206 (-C≡C-), 1727 (C=Oester), 1640 (C=Oamide), 1605 
(C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 396, 489 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.72 (2H, d, J = 8.4 Hz, ArH), 7.45 {2H, d,  J = 8.4 
Hz, ArH), 7.30 (1H, t, J = 5.2 Hz, -CONH-) 7.00 (1H, d, J = 8.0 Hz,  -CONH-), 4.57 -
4.51 {1H, m, -CHCH2CH(CH3)2)}, 4.45 (2H, t, J = 2.0 Hz,  ortho on η
5
-C5H4-C≡C-), 
4.20 - 4.15 { 9H, m, (meta on η5-C5H4-C≡C-), (-NHCH2CO-), (η
5
-C5H5)}, 4.13 (2H, q, 
J = 7.2 Hz, -OCH2CH3), 1.57 - 1.45 {3H, m, -CHCH2CH(CH3)2)},  1.18 (3H, t, J = 7.2 
Hz, -OCH2CH3 ), 0.88 - 0.86 ( 6H, m, -CHCH2CH(CH3)2);  
13
C NMR (100 MHz) δ (CDCl3): 171.8 (C=O), 168.9 (C=O), 167.1(C=O), 132.0 (Cq), 
131.7 (Cq), 127.3, 126.8, 90.7 (η
5
-C5H4-C≡C-), 84.1 (η
5
-C5H4-C≡C-), 71.7 (Cortho η
5
-
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C5H4-C≡C-), 70.5 (η
5
-C5H5), 68.2 (Cmeta η
5
-C5H4-C≡C-), 66.1 (Cipso η
5
-C5H4-C≡C-), 
61.0 (-OCH2CH3, -ve DEPT), 50.1 (-CHCH2CH(CH3)2), 42.9 (-NHCH2CO-, -ve 
DEPT), 41.3 (-CHCH2CH(CH3)2, -ve DEPT), 25.8 (-CHCH2CH(CH3)2), 22.0 (-
CHCH2CH(CH3)2), 21.9 (-CHCH2CH(CH3)2), 14.0 (-OCH2CH3). 
 
N-{para-(ferrocenyl) ethynyl benzoyl} sarcosine glycine ethyl ester (115) 
 
Sarcosine glycine ethyl ester hydrochloride (0.53 g, 3.03 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.23 g, 16%), m.p 79 - 81 
o
C;  
Mass spectrum: [M+Na]
+
  found: 509.1152
 
C26H26N2O4FeNa requires:           509.1140              
I.R. υmax (KBr): 3284 (NH), 2205 (-C≡C-), 1744 (C=Oester), 1676 (C=Oamide), 1620 
(C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 389,  495 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.65 - 7.35 {5H, m, (-CONH-), (ArH)}, 4.43 (2H, s, 
ortho on η5-C5H4-C≡C-), 4.30 - 3.85 {13H, m, (meta on η
5
-C5H4-C≡C-), (η
5
-C5H5), (-
N(CH3)CH2CO-), (-NHCH2CO-) (-OCH2CH3)}, 3.15 (3H, s, -N(CH3)CH2CO-), 1.17 
(3H, t, J = 7.2 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 173.1 (C=O), 169.3 (C=O), 168.2 (C=O), 132.1 (Cq), 
130.7 (Cq), 127.1, 125.9, 90.9 (η
5
-C5H4-C≡C-), 85.7 (η
5
-C5H4-C≡C-), 72.0 (Cortho η
5
-
C5H4-C≡C-), 70.1 (η
5
-C5H5), 69.1 (Cmeta η
5
-C5H4-C≡C-), 67.6 (Cipso η
5
-C5H4-C≡C-), 
62.0 (-OCH2CH3, -ve DEPT), 49.6 (-N(CH3)CH2CO-, -ve DEPT), 42.3 (-NHCH2CO-, -
ve DEPT), 38.5 (-N(CH3)CH2CO-), 14.3 (-OCH2CH3). 
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N-{para-(ferrocenyl) ethynyl benzoyl} sarcosine glycine methyl ester (116) 
 
Sarcosine glycine methyl ester hydrochloride (0.49 g, 3.03 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.23 g, 16%), m.p 124 - 126 
o
C;  
Mass spectrum: [M+Na]
+
  found: 495.1297
 
C25H24N2O4FeNa requires:           495.0983           
I.R. υmax (KBr): 3286 (NH), 2206 (-C≡C-), 1746 (C=Oester), 1674 (C=Oamide), 1620 
(C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 397, 486 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.45 - 7.35 {5H, m, (-CONH-), (ArH)}, 4.44 (2H, s, 
ortho on η5-C5H4-C≡C-), 4.30 - 3.85 {11H, m, (meta on η
5
-C5H4-C≡C-), (η
5
-C5H5),  
(-N(CH3)CH2CO-), (-NHCH2CO-)}, 3.70 (3H, s, -OCH3), 3.04 (3H, s, -
N(CH3)CH2CO-); 
13
C NMR (100 MHz) δ (CDCl3): 172.1 (C=O), 168.9 (C=O), 167.2 (C=O), 131.7 (Cq), 
130.0 (Cq), 126.9, 125.7, 91.2 (η
5
-C5H4-C≡C-), 84.1 (η
5
-C5H4-C≡C-), 71.8 (Cortho η
5
-
C5H4-C≡C-), 69.9 (η
5
-C5H5), 68.2 (Cmeta η
5
-C5H4-C≡C-), 65.9 (Cipso η
5
-C5H4-C≡C-), 
51.7 (-OCH3), 46.2 (-N(CH3)CH2CO-, -ve DEPT), 41.2 (-NHCH2CO-, -ve DEPT), 38.1 
(-N(CH3)CH2CO-). 
 
N-{para-(ferrocenyl) ethynyl benzoyl} sarcosine L-alanine ethyl ester (117) 
 
Sarcosine L-alanine ethyl ester hydrochloride (0.57 g, 3.03 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.21 g, 14%), m.p 99 - 101 
o
C; 
 [α]D
20
 = -22 
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found: 523.1292
 
C27H28N2O4FeNa requires:            523.1296                
I.R. υmax (KBr): 3270 (NH), 2205 (-C≡C-), 1745 (C=Oester), 1675 (C=Oamide), 1614 
(C=Oamide) cm
-1 
;
 
 
UV-Vis λmax EtOH: 389, 486 nm; 
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1
H NMR (400 MHz) δ (CDCl3): 7.60 - 7.35 {5H, m, (-CONH-), (ArH)}, 4.51- 4.40  
{3H, m,  (ortho on η5-C5H4-C≡C-), (-CHCH3)}, 4.19 - 3.90 {11H, m, (meta on η
5
-
C5H4-C≡C-), (η
5
-C5H5), (-N(CH3)CH2CO-), (-OCH2CH3)}, 3.01 (3H, s, -
N(CH3)CH2CO-), 1.36 (2H, d, J = 7.2 Hz, -CHCH3), 1.21 (3H, t, J = 7.2 Hz, -
OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 172.7 (C=O), 169.0 (C=O), 168.2 (C=O), 133.8 (Cq), 
132.0 (Cq), 128.3, 127.4, 90.6 (η
5
-C5H4-C≡C-), 85.0 (η
5
-C5H4-C≡C-), 71.5 (Cortho η
5
-
C5H4-C≡C-), 70.0 (η
5
-C5H5), 69.1 (Cmeta η
5
-C5H4-C≡C-), 64.6 (Cipso η
5
-C5H4-C≡C-), 
61.6 (-OCH2CH3, -ve DEPT), 48.2 (-CHCH3), 40.1(-N(CH3)CH2CO-, -ve DEPT), 38.3 
(-N(CH3)CH2CO-), 18.3 (-CHCH3), 14.2 (-OCH2CH3). 
 
N-{para-(ferrocenyl) ethynyl benzoyl} L-proline glycine ethyl ester (118) 
 
L-Proline glycine ethyl ester hydrochloride (0.61 g, 3.03 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.27 g, 17%), m.p 58 - 60 
o
C; [α]D
20
 = 17 
o 
; 
Mass spectrum: [M+Na]
+
  found: 535.1282
 
C28H28N2O4FeNa requires:           535.1296          
I.R. υmax (KBr): 3313 (NH), 2205 (-C≡C-), 1735 (C=Oester), 1652 (C=Oamide), 1604 
(C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 395, 499 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.50 - 7.36 {5H, m, (-CONH-), (ArH)}, 4.74 (1 H, t, J 
= 5.2 Hz,  -N(CH2CH2CH2)CHCO-), 4.45 (2H, s, ortho on η
5
-C5H4-C≡C-), 4.19 - 4.10 
{9H, m, (meta on η5-C5H4-C≡C-), (η
5
-C5H5), (-OCH2CH3)}, 3.95 (2H, d, J = 4.0 Hz, -
NHCH2CO-), 3.51 - 3.40 (2H, m, -N(CH2CH2CH2)CHCO-), 2.40 - 1.70 ( 4H, m, -
N(CH2CH2CH2)CHCO-), 1.20 (3H, t, J = 7.2 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 171.5 (C=O), 170.6 (C=O), 169.7 (C=O), 133.8 (Cq), 
131.2 (Cq), 127.4, 126.0, 90.7 (η
5
-C5H4-C≡C-), 84.9 (η
5
-C5H4-C≡C-), 71.9 (Cortho η
5
-
C5H4-C≡C-), 70.4 (η
5
-C5H5), 68.1 (Cmeta η
5
-C5H4-C≡C-), 65.9 (Cipso η
5
-C5H4-C≡C-), 
62.4 (-OCH2CH3, -ve DEPT), 59.8  (-N(CH2CH2CH2)CHCO-), 50.4  
(-N(CH2CH2CH2)CHCO, -ve DEPT), 41.5 (-NHCH2CO-, -ve DEPT),  
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27.5 (-N(CH2CH2CH2)CHCO-, -ve DEPT), 25.4 (-N(CH2CH2CH2)CHCO-, -ve DEPT), 
13.7 (-OCH2CH3). 
 
N-{para-(ferrocenyl) ethynyl benzoyl} L-proline L-alanine ethyl ester (119) 
 
L-Proline L-alanine ethyl ester hydrochloride (0.65 g, 3.03 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.21 g, 13%), m.p 52 - 54 
o
C;  
[α]D
20
 = -69 
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found: 549.1467
 
C29H30N2O4FeNa requires:            549.1453                 
I.R. υmax (KBr): 3285 (NH), 2202 (-C≡C-), 1736 (C=Oester), 1672 (C=Oamide), 1608 
(C=Oamide) cm
-1
;
 
UV-Vis λmax EtOH: 392, 493 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.69 - 7.48 {5H, m, (ArH), (-CONH-)}, 4.68 (1H, t, J 
= 6.4 Hz, -N(CH2CH2CH2)CHCO-), 4.57 (2H, s, ortho on η
5
-C5H4-C≡C-), 4.46 (1H, 
quin, J = 6.8 Hz, -CHCH3), 4.28 (2H, s, meta on η
5
-C5H4-C≡C-), 4.16 - 4.12 {7H, m, 
(η5-C5H5), (-OCH2CH3)}, 3.60 - 3.40 (2H, m, (-N(CH2CH2CH2)CHCO-), 2.40 - 1.56 
(4H, m, (-N(CH2CH2CH2)CHCO-)}, 1.36 (3H, d, J = 6.4 Hz, -CHCH3),  1.21 (3H, t, J 
= 6.8 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 173.8 (C=O), 171.9 (C=O), 169.1 (C=O), 133.0 (Cq), 
131.2 (Cq), 128.9, 127.9, 90.7 (η
5
-C5H4-C≡C-), 84.4 (η
5
-C5H4-C≡C-), 72.0 (Cortho η
5
-
C5H4-C≡C-), 70.2 (η
5
-C5H5), 68.7 (Cmeta η
5
-C5H4-C≡C-), 67.3 (Cipso η
5
-C5H4-C≡C-), 
62.4 (OCH2CH3, -ve DEPT), 60.1 (-N(CH2CH2CH2)CHCO-), 50.6 (-
N(CH2CH2CH2)CHCO-, -ve DEPT), 48.4 (-CHCH3), 27.8 (-N(CH2CH2CH2)CHCO-, -
ve DEPT), 25.6 (-N(CH2CH2CH2)CHCO-, -ve DEPT), 18.9 (-CHCH3), 13.9 (-
OCH2CH3). 
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General procedure for the preparation of N-{6-(ferrocenyl) ethynyl-2-naphthoyl} 
amino acid and dipeptide ethyl esters 
  
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} glycine glycine ethyl ester (120) 
 
Glycine glycine ethyl ester hydrochloride (0.42 g, 2.63 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.38 g, 28%), m.p 128 - 130 
o
C; 
Mass spectrum: [M+Na]
+
  found:   545.1130 
C29H26N2O4FeNa requires:              545.1140 
I.R. υmax (KBr): 3261 (NH), 2204 (-C≡C-), 1736 (C=Oester), 1658 (C=Oamide), 1603 
(C=Oamide) cm
-1
; 
UV-Vis λmax EtOH: 400, 500 nm;
 
1
H NMR (400 MHz) δ (CDCl3): 8.13 (1H, s, ArH), 7.95 - 7.48 {7H, m, (ArH), (-
CONH-), (-CONH-)}, 4.61 (2H, t, J = 2.0 Hz,  ortho on η5-C5H4-C≡C-), 4.30 (2H, t, J 
= 2.0 Hz, meta on η5-C5H4-C≡C-), 4.19 - 4.15 {11H, m, (η
5
-C5H5), (-NHCH2CO-), (-
NHCH2CO-), (-OCH2CH3)}, 1.23 (3H, t, J = 7.2 Hz,  -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 172.7 (C=O), 170.9 (C=O), 169.6 (C=O), 133.9 (Cq), 
132.6 (Cq), 131.0 (Cq), 130.2 (Cq), 129.6, 129.3, 128.9, 128.1, 127.8, 125.8, 90.3 (η
5
-
C5H4-C≡C-), 84.7 (η
5
-C5H4-C≡C-), 72.1 (Cortho η
5
-C5H4-C≡C-), 70.0 (η
5
-C5H5), 69.7 
(Cmeta η
5
-C5H4-C≡C-), 67.8 (Cipso η
5
-C5H4-C≡C-), 61.6 (-OCH2CH3, -ve DEPT), 42.3 (-
NHCH2CO-, -ve DEPT), 40.1 (-NHCH2CO-, -ve DEPT), 14.8 (-OCH2CH3). 
  
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} glycine L-alanine ethyl ester (121) 
 
Glycine L-alanine ethyl ester hydrochloride (0.46 g, 2.63 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.23 g, 16%), m.p 58 - 60 
o
C;  
[α]D
20
 = -14 
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
 found:    559.1305 
C30H28N2O4FeNa requires:              559.1398 
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I.R. υmax (KBr): 3287 (NH), 2204 (-C≡C-), 1734 (C=Oester), 1658 (C=Oamide), 1625 
(C=Oamide) cm
-1
; 
UV-Vis λmax EtOH: 381, 512 nm;
 
1
H NMR (400 MHz) δ (CDCl3): 8.21 (1H, s, ArH), 7.87 - 7.51 {7H, m,  (ArH), (-
CONH-), (-CONH-)}, 4.48 - 4.47 {3H, m, (-CHCH3),  (ortho on η
5
-C5H4-C≡C-)}, 4.19 
- 4.07 {11H, m, (meta on η5-C5H4-C≡C-), (η
5
-C5H5), (-OCH2CH3), (-NHCH2CO-)}, 
1.36 (3H, d, J = 7.2 Hz, -CHCH3), 1.28 (3H, t, J = 6.8 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 171.8 (C=O), 169.1 (C=O), 167.9 (C=O), 134.5 (Cq), 
131.5 (Cq), 130.8 (Cq), 130.4 (Cq), 129.3, 128.9, 128.0, 127.7, 124.3, 123.4, 90.4 (η
5
-
C5H4-C≡C-), 84.9 (η
5
-C5H4-C≡C-), 71.3 (Cortho η
5
-C5H4-C≡C-), 70.1 (η
5
-C5H5), 69.5 
(Cmeta η
5
-C5H4-C≡C-), 65.9 (Cipso η
5
-C5H4-C≡C-), 60.3 (-OCH2CH3, -ve DEPT), 48.9 (-
CHCH3), 43.1 (-NHCH2CO-, -ve DEPT), 17.2 (-CHCH3), 13.7 (-OCH2CH3). 
   
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} sarcosine L-alanine ethyl ester (122) 
 
Sarcosine L-alanine ethyl ester hydrochloride (0.50 g, 2.63 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.19 g, 13%), m.p 59 - 61 
o
C;  
[α]D
20
 = -23 
o 
(c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   
 
573.1879 
C31H30N2O4FeNa requires:              573.1555 
I.R. υmax (KBr): 3308 (NH), 2206 (-C≡C-), 1732 (C=Oester), 1625 (C=Oamide), 1538 
(C=Oamide) cm
-1
; 
UV-Vis λmax EtOH: 405, 506 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.93 - 7.50 {7H, m, (-CONH-), (ArH)}, 4.53 - 4.40  
{3H, m, (ortho on η5-C5H4-C≡C-), (-CHCH3)}, 4.20 - 4.10 {11H, m, (meta on η
5
-C5H4-
C≡C-), (η5-C5H5), (-N(CH3)CH2CO-), (-OCH2CH3)}, 3.07 (3H, s, -N(CH3)CH2CO-), 
1.38 (2H, d, J = 7.2 Hz, -CHCH3), 1.21 (3H, t, J = 7.2 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 172.0 (C=O), 170.2 (C=O), 169.1 (C=O), 134.4 (Cq), 
132.7 (Cq), 131.6 (Cq), 130.6 (Cq), 129.4, 128.5, 128.0, 127.3, 125.0, 123.9, 91.3 (η
5
-
C5H4-C≡C-), 84.7 (η
5
-C5H4-C≡C-), 71.1 (Cortho η
5
-C5H4-C≡C-), 69.7 (η
5
-C5H5), 68.2 
(Cmeta η
5
-C5H4-C≡C-), 66.2 (Cipso η
5
-C5H4-C≡C-), 61.9 (-OCH2CH3, -ve DEPT), 49.7 (-
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CHCH3), 45.1 (-N(CH3)CH2CO-, -ve DEPT), 38.2 (-N(CH3)CH2CO-), 19.0 (-CHCH3), 
13.8. (-OCH2CH3). 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} L-proline glycine ethyl ester (123) 
 
L-Proline glycine ethyl ester hydrochloride (0.53 g, 2.63 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.22 g, 15%), m.p 53 - 55 
o
C;  
[α]D
20
 = 27 
o
 (c 0.1, EtOH); 
Mass spectrum: [M+Na]
+
  found:   
   
   585.1467 
C32H30N2O4FeNa requires:                   585.1555 
I.R. υmax (KBr): 3313 (NH), 2205 (-C≡C-), 1735 (C=Oester), 1652 (C=Oamide), 1604 
(C=Oamide) cm
-1
; 
UV-Vis λmax EtOH: 400, 513 nm;
 
1
H NMR (400 MHz) δ (CDCl3): 7.96 - 7.38 {7H, m, (ArH), (-CONH-)}, 4.82 (1H, t, J 
= 5.2 Hz, -N(CH2CH2CH2)CHCO-), 4.47 (2H, s, ortho on η
5
-C5H4-C≡C-), 4.21 - 4.18 { 
7H, m, (meta on η5-C5H4-C≡C-), (η
5
-C5H5)}, 4.16 (2H, q, J = 7.2 Hz, -OCH2CH3), 4.00 
(2H, d, J = 5.6 Hz, -NHCH2CO-), 3.61 - 3.50 ( 2H, m, -N(CH2CH2CH2)CHCO-), 2.40 - 
1.70 ( 4H, m, -N(CH2CH2CH2)CHCO-), 1.21 (3H, t, J = 7.2 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3):171.7 (C=O), 171.0 (C=O), 169.2 (C=O), 133.7 (Cq), 
131.5 (Cq), 130.6 (Cq), 129.4 (Cq), 128.1, 127.9, 127.0, 127.2, 124.9, 123.0, 90.1 (η
5
-
C5H4-C≡C-), 84.8 (η
5
-C5H4-C≡C-), 71.0 (Cortho η
5
-C5H4-C≡C-), 70.1 (η
5
-C5H5), 69.1 
(Cmeta  η
5
-C5H4-C≡C-), 64.9 (Cipso η
5
-C5H4-C≡C-), 61.4 (-OCH2CH3, -ve DEPT), 50.8  
(-N(CH2CH2CH2)CHCO-), 47.6 (-N(CH2CH2CH2)CHCO-, -ve DEPT), 42.5 (-
NHCH2CO-, -ve DEPT), 27.4 (-N(CH2CH2CH2)CHCO-, -ve DEPT), 25.0 (-
N(CH2CH2CH2)CHCO -, -ve DEPT), 13.2 (-OCH2CH3). 
 
 
 
 
 
 
 214 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} γ-aminobutyric acid ethyl ester (124) 
 
γ-Amino butyric acid ethyl ester hydrochloride (0.34 g, 2.63 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.42 g, 32%), m.p 71 - 73 
o
C; 
Mass spectrum: found: [M+Na]
+  
    516.1255 
C29H27NO3FeNa requires:                516.1340 
I.R. υmax  (KBr): 3283 (NH), 2205 (-C≡C-), 1726 (C=Oester), 1605 (C=Oamide) cm
-1
; 
UV-Vis λmax EtOH: 407, 504 nm; 
1
H NMR (400 MHz) δ (CDCl3): 8.18 (1H, s, ArH), 7.81{1H, s, ArH), 7.75 - 7.49 {5H, 
m, (-CONH-), (ArH)}, 4.47 (2H, t, J = 1.6 Hz,  ortho on η5-C5H4-C≡C-), 4.19 - 4.18 
{7H, m, (meta on η5-C5H4-C≡C-), (η
5
-C5H5)}, 4.04 (2H, q, J = 7.2 Hz,  -OCH2CH3), 
3.46 ( 2H, q, J = 5.6 Hz, -NHCH2CH2CH2-), 2.37 (2H, t, J = 6.8 Hz, -NHCH2CH2CH2-
), 1.87 (2H, quin, J = 6.4 Hz, -NHCH2CH2CH2-), 1.15 (3H, t, J = 7.2 Hz,  -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 171.5 (C=O), 167.4 (C=O), 131.5 (Cq), 130.1 (Cq), 
129.1 (Cq), 128.9 (Cq), 128.2, 127.6, 127.7, 126.0, 125.1, 123.0, 89.2 (η
5
-C5H4-C≡C-), 
85.0 (η5-C5H4-C≡C-), 71.9 (Cortho η
5
-C5H4-C≡C-), 69.2 (η
5
-C5H5), 68.4 (Cmeta η
5
-C5H4-
C≡C-), 63.8 (Cipso η
5
-C5H4-C≡C-), 60.0 (-OCH2CH3, -ve DEPT), 39.0 (-
NHCH2CH2CH2-, -ve DEPT), 31.2 (-NHCH2CH2CH2-, -ve DEPT), 23.3 (-
NHCH2CH2CH2-, -ve DEPT), 13.1 (-OCH2CH3). 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} L-proline L-alanine ethyl ester (125) 
 
L-Proline L-alanine ethyl ester hydrochloride (0.56 g, 2.63 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.17 g, 11%), m.p 56 - 58 
o
C;  
[α]D
20
 = -67 
o 
(c 0.1, EtOH); 
Mass spectrum: found: [M+Na]
+  
        599.1639 
C33H32N2O4FeNa requires:                   599.1711 
I.R. υmax (KBr): 3285 (NH), 2202 (-C≡C-), 1736 (C=Oester), 1672 (C=Oamide), 1608 
(C=Oamide) cm
-1
;   
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UV-Vis λmax EtOH: 409, 507 nm;
 
1
H NMR (400 MHz) δ (CDCl3): 8.12 (1H, s, ArH), 7.96 - 7.54 {6H, m, (ArH), (-
CONH-)}, 4.72 - 4.65 {3H, m, (-N(CH2CH2CH2)CHCO-), (ortho on η
5
-C5H4-C≡C-)}, 
4.55 - 4.45 (1H, m, -CHCH3), 4.33 (2H, s, meta on η
5
-C5H4-C≡C-), 4.33 - 4.12 {7H, m, 
(η5-C5H5), (-OCH2CH3)}, 3.61 - 3.49 (2H, m, -N(CH2CH2CH2)CHCO-),  
2.40 - 1.70 (4H, m, -N(CH2CH2CH2)CHCO-), 1.38 (3H, d, J = 4.4 Hz, -CHCH3), 1.17 
(3H, t, J = 7.2 Hz, -OCH2CH3);  
13
C NMR (100 MHz) δ (CDCl3): 172.1 (C=O), 169.7 (C=O), 168.2 (C=O), 134.5 (Cq), 
133.5 (Cq), 132.8 (Cq), 131.6 (Cq), 130.1, 128.4, 128.0, 127.1, 124.7, 121.0, 90.1 (η
5
-
C5H4-C≡C-), 85.8 (η
5
-C5H4-C≡C-), 71.9 (Cortho η
5
-C5H4-C≡C-), 70.2 (η
5
-C5H5), 69.4 
(Cmeta η
5
-C5H4-C≡C-), 67.6 (Cipso η
5
-C5H4-C≡C-), 61.9 (-OCH2CH3, -ve DEPT), 60.1 (-
N(CH2CH2CH2)CHCO-), 50.7 (-N(CH2CH2CH2)CHCO-, -ve DEPT), 48.5 (-CHCH3), 
27.2 (-N(CH2CH2CH2)CHCO-, -ve DEPT), 25.0 (-N(CH2CH2CH2)CHCO-, -ve DEPT), 
19.2 (-CHCH3), 14.0 (-OCH2CH3). 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} glycine L-leucine ethyl ester (126) 
 
Glycine L-leucine ethyl ester hydrochloride (0.57 g, 2.63 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.16 g, 11%), m.p 38 - 40 
o
C;  
[α]D
20
 = -10 
o 
(c 0.1, EtOH); 
Mass spectrum: found: [M+Na]
+              
601.1871 
C33H34N2O4FeNa requires:                   601.1868 
I.R. υmax (KBr): 3275 (NH), 2206 (-C≡C-), 1727 (C=Oester), 1640 (C=Oamide), 1605 
(C=Oamide) cm
-1
; 
UV-Vis λmax EtOH: 408, 503 nm;
 
1
H NMR (400 MHz) δ ( CDCl3): 8.22 (1H, s, ArH), 8.08 (1H, s, ArH), 7.78 - 7.74 {6H, 
m, (ArH), (-CONH-),(-CONH-)}, 4.65 - 4.50 (3H, m, -CHCH2CH(CH3)2), (ortho on 
η5-C5H4-C≡C-)}, 4.30 - 4.00 {11H, m, (meta on η
5
-C5H4-C≡C-), (η
5
-C5H5), (-
NHCH2CO-), (-OCH2CH3)}, 1.67 - 1.55 {3H, m, -CHCH2CH(CH3)2}, 1.17 (3H, t, J = 
7.2 Hz - OCH2CH3), 0.86 - 0.84 ( 6H, m, -CHCH2CH(CH3)2);  
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13
C NMR (100 MHz) δ (CDCl3): 172.9 (C=O), 169.4 (C=O), 167.8 (C=O), 135.0 (Cq), 
133.1 (Cq), 130.7 (Cq), 130.2 (Cq), 128.8, 128.0, 127.8, 127.4, 124.0 120.8, 90.7 (η
5
-
C5H4-C≡C-), 85.6 (η
5
-C5H4-C≡C-), 71.0 (Cortho η
5
-C5H4-C≡C-), 69.7 (η
5
-C5H5), 68.4 
(Cmeta η
5
-C5H4-C≡C-), 67.3 (Cipso η
5
-C5H4-C≡C-), 61.4 (-OCH2CH3, -ve DEPT), 51.2 (-
CHCH2CH(CH3)2), 43.8 (-NHCH2CO-, -ve DEPT), 41.2 (-CHCH2CH(CH3)2, -ve 
DEPT), 24.9  (-CHCH2CH(CH3)2), 22.8 (-CHCH2CH(CH3)2), 21.9 (-
CHCH2CH(CH3)2), 14.2. (-OCH2CH3). 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} sarcosine glycine ethyl ester (127) 
 
Sarcosine glycine ethyl ester hydrochloride (0.46 g, 2.63 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.19 g, 13%), m.p 32 - 34 
o
C; 
Mass spectrum: found: [M+Na]
+ 
      559.1307 
C30H28N2O4FeNa requires:                 559.1398 
I.R. υmax (KBr): 3284 (NH), 2205 (-C≡C-), 1744 (C=Oester), 1676 (C=Oamide), 1605 
(C=Oamide) cm
-1
; 
UV-Vis λmax EtOH: 391, 509 nm;
 
1
H NMR (400 MHz) δ (CDCl3): 7.92 - 7.49 {7H, m, (-CONH-), (ArH)}, 4.48 (2H, s, 
ortho on η5-C5H4-C≡C-), 4.30 - 3.90 {13H, m, (meta on η
5
-C5H4-C≡C-), (η
5
-C5H5), (-
N(CH3)CH2CO-), (-NHCH2CO-) (-OCH2CH3)}, 3.10 (3H, s, -N(CH3)CH2CO-), 1.19 
(3H, t, J = 7.2 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 172.7 (C=O), 170.4 (C=O), 167.2 (C=O), 133.6 (Cq), 
132.7 (Cq), 131.9 (Cq), 130.8 (Cq), 129.5, 128.5, 128.1, 127.3, 125.0, 122.9, 90.1 (η
5
-
C5H4-C≡C-), 85.9 (η
5
-C5H4-C≡C-), 71.8 (Cortho η
5
-C5H4-C≡C-), 70.5 (η
5
-C5H5), 69.5 
(Cmeta η
5
-C5H4-C≡C-), 65.4 (Cipso η
5
-C5H4-C≡C-), 61.7 (-OCH2CH3, -ve DEPT), 48.2 (-
N(CH3)CH2CO-, -ve DEPT), 41.2 (-NHCH2CO-, -ve DEPT), 38.4 (-N(CH3)CH2CO-), 
14.2 (-OCH2CH3). 
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N-{6-(ferrocenyl) ethynyl-2-naphthoyl} glycine-L-phenylalanine ethyl ester (128)  
 
Glycine L-phenylalanine ethyl ester hydrochloride (0.66 g, 2.63 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.14 g, 9%), m.p 48 - 50 
o
C;  
[α]D
25
 = -15 
o 
(c 0.1, EtOH); 
Mass spectrum: found: [M+Na]
+ 
     635.1639 
C36H32N2O4FeNa requires:                635.1711 
I.R. υmax (KBr): 3359 (NH), 2205 (-C≡C-), 1743 (C=Oester), 1631 (C=Oamide), 1605 
(C=Oamide) cm
-1
; 
UV-Vis λmax EtOH: 408, 505 nm;
 
1
H NMR (400 MHz) δ (CDCl3): 8.15 (1H, s, ArH), 8.00 (1H, s, ArH), 7.80 - 7.70 {6H, 
m, (ArH), (-CONH-),(-CONH-) },7.16 - 7.00 (5H, m,  -CHCH2Ph), 4.87 - 4.85 (1H, m, 
-CH(CH2Ph)),  4.58 (2H, s, ortho on η
5
-C5H4-C≡C-), 4.26 (2H, s, meta on η
5
-C5H4-
C≡C-), 4.20 - 3.95 {9H, m, (η5-C5H5), (-OCH2CH3), (-NHCH2CO-)}, 3.15 - 2.95 (2H, 
m, -CHCH2Ph), 1.15 (3H, t, J = 7.2 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 171.4 (C=O), 168.0 (C=O), 167.6 (C=O), 135.8 (Cq), 
134.5 (Cq), 130.9 (Cq), 130.6 (Cq), 130.2, 129.3, 128.6, 128.0, 127.8, 127.1, 126.7, 
124.2, 123.4, 122.1, 91.7 (η5-C5H4-C≡C-), 85.0 (η
5
-C5H4-C≡C-), 71.6 (Cortho η
5
-C5H4-
C≡C-), 70.1 (η5-C5H5), 69.5 (Cmeta η
5
-C5H4-C≡C-), 65.8 (Cipso η
5
-C5H4-C≡C-), 61.3 (-
OCH2CH3, -ve DEPT), 53.6 (-CHCH2Ph), 43.0 (-NHCH2CO-, -ve DEPT), 38.5 (-
CHCH2Ph, -ve DEPT), 14.9 (-OCH2CH3). 
  
General procedure for the preparation of N-{5-(ferrocenyl) ethynyl-2-furanoyl} 
amino acid and dipeptide ethyl esters 
 
N-{5-(ferrocenyl) ethynyl-2-furanoyl} glycine glycine ethyl ester (129) 
 
Glycine glycine ethyl ester hydrochloride (0.50 g, 3.12 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.55 g, 38%), m.p 94 - 96 
o
C; 
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Mass spectrum: found: [M+Na]
+                      
485.0752
  
C23H22N2O5FeNa requires:                        485.0776                
I.R. υmax (KBr): 3276 (NH), 2206 (-C≡C-), 1739 (C=Oester), 1631 (C=Oamide), 1610 
(C=Oamide) cm-
1
; 
UV-Vis λmax EtOH: 370, 476 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.28 (1H, t, J = 4.8 Hz, -CONH-), 7.08 - 7.07 {2H, m, 
(-CONH-), (ArH)}, 6.53 (1H, d, J = 3.6 Hz, ArH), 4.47 (2H, s, ortho on η5-C5H4-C≡C-
), 4.23 - 4.12 {11H, m, (meta on η5-C5H4-C≡C-), (η
5
-C5H5), (-NHCH2CO-), (-
OCH2CH3)}, 4.00 (2H, d, J = 5.2 Hz, -NHCH2CO-), 1.20 (3H, t, J = 7.2 Hz, - 
OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3):168.7 (C=O), 167.9 (C=O), 157.1 (C=O), 145.4 (Cq), 
138.2 (Cq), 115.1, 115.0, 93.9 (η
5
-C5H4-C≡C-), 74.0 (η
5
-C5H4-C≡C-), 70.6 (Cortho η
5
-
C5H4-C≡C-), 69.2 (η
5
-C5H5), 68.5 (Cmeta η
5
-C5H4-C≡C-), 62.7 (Cipso η
5
-C5H4-C≡C-), 
60.6 (-OCH2CH3, -ve DEPT), 41.7 (-NHCH2CO-, -ve DEPT), 40.4 (-NHCH2CO-, -ve 
DEPT), 13.1 (-OCH2CH3). 
 
N-{5-(ferrocenyl) ethynyl-2-furanoyl} glycine L-alanine ethyl ester (130) 
 
Glycine L-alanine ethyl ester hydrochloride (0.54 g, 3.12 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red oil (0.28 g, 19%),  
[α]D
20
 = -20 
o 
( c 0.1, EtOH ); 
Mass spectrum: found: [M+Na]
+ 
                  499.0919 
C24H24N2O5FeNa requires:                             499.0932             
I.R. υmax (KBr): 3287 (NH), 2206 (-C≡C-), 1734 (C=Oester), 1646 (C=Oamide), 1612 
(C=Oamide) cm
-1
 
UV-Vis λmax EtOH: 374, 475 nm; 
1
H NMR (400 MHz) δ (CDCl3 ): 7.06 (1H, d, J = 3.6 Hz, ArH), 7.02 (1H, t, J = 5.6 Hz, 
-CONH-), 6.59 - 6.54 {2H, m, (ArH), (-CONH-)}, 4.56 - 4.47 {3H, m, (-CHCH3), 
(ortho on η5-C5H4-C≡C-) }, 4.24 - 4.21 {7H, m, (meta on η
5
-C5H4-C≡C-), (η
5
-C5H5)}, 
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4.17 - 4.07 (4H, m, (-NHCH2CO-), (-OCH2CH3)}, 1.38 (3H, d, J = 7.2 Hz, -CHCH3), 
1.21 (3H, t, J = 7.2 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 172.7 (C=O), 167.2 (C=O), 158.0 (C=O), 146.5 (Cq), 
139.3 (Cq), 116.1, 116.0, 94.5 (η
5
-C5H4-C≡C-), 75.0 (η
5
-C5H4-C≡C-), 71.7 (Cortho η
5
-
C5H4-C≡C-), 70.2 (η
5
-C5H5), 69.5 (Cmeta η
5
-C5H4-C≡C-), 62.8 (Cipso η
5
-C5H4-C≡C-), 
61.7 (-OCH2CH3, -ve DEPT), 48.4 (-CHCH3), 42.8 (-NHCH2CO-, -ve DEPT), 18.3 (-
CHCH3), 14.1 (-OCH2CH3). 
 
N-{5-(ferrocenyl) ethynyl-2-furanoyl} glycine D-alanine ethyl ester (131) 
 
Glycine D-alanine ethyl ester hydrochloride (0.54 g, 3.12 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.23 g, 16%), m.p 132 - 134 
o
C;  
[α]D
20
 = +20 
o 
(c 0.1, EtOH); 
Mass spectrum: found: [M+Na]
+ 
                  499.0917 
C24H24N2O5FeNa requires:                            499.0932             
I.R. υmax (KBr): 3287 (NH), 2208 (-C≡C-), 1739 (C=Oester), 1642 (C=Oamide), 1617 
(C=Oamide) cm
-1 
; 
UV-Vis λmax EtOH:  373, 471 nm; 
1
H NMR (400 MHz) δ (CDCl3 ): 7.08 (1H, d, J = 3.6 Hz, ArH), 7.00 (1H, t, J = 5.6 Hz, 
-CONH-), 6.61 - 6.58 {2H, m, (ArH), (-CONH-)}, 4.54 - 4.45 {3H, m, (-CHCH3), 
(ortho on η5-C5H4-C≡C-)}, 4.27 - 4.25 {7H, m, (meta on η
5
-C5H4-C≡C-), (η
5
-C5H5)}, 
4.10 -4.04 (4H, m, (-NHCH2CO-), (-OCH2CH3)} 1.40 (3H, d, J = 7.2 Hz, -CHCH3), 
1.25 (3H, t, J = 7.2 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 173.7 (C=O), 163.9 (C=O), 158.6 (C=O), 140.5 (Cq), 
137.3 (Cq), 117.1, 116.9, 94.0 (η
5
-C5H4-C≡C-), 74.0 (η
5
-C5H4-C≡C-), 71.2 (Cortho η
5
-
C5H4-C≡C-), 70.5 (η
5
-C5H5), 65.5 (Cmeta η
5
-C5H4-C≡C-), 64.0 (Cipso η
5
-C5H4-C≡C-), 
61.1 (-OCH2CH3, -ve DEPT), 49.4 (-CHCH3), 42.8 (-NHCH2CO-, -ve DEPT), 19.3 (-
CHCH3), 15.0 (-OCH2CH3). 
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N-{5-(ferrocenyl) ethynyl-2-furanoyl} glycine L-phenylalanine ethyl ester (132)  
 
Glycine L-phenylalanine ethyl ester hydrochloride (0.78 g, 3.12 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.18 g, 10%), m.p 85 - 86 
o
C;  
[α]D
20
 = +16 
o 
(c 0.1, EtOH); 
Mass spectrum: found: [M+Na]
+   
                  575.1365
                     
C30H28N2O5FeNa requires:                             575.1348                    
I.R. υmax (KBr): 3278 (NH), 2207 (-C≡C-), 1739 (C=Oester), 1642 (C=Oamide), 1620 
(C=Oamide) cm
-1
 
UV-Vis λmax EtOH: 375, 478 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.35 - 7.12 {8H, m, (ArH), (-CONH-), (-CONH-), (-
CHCH2Ph)}, 6.87 (1H, d, J = 3.6 Hz, ArH),  4.91 - 4.86 (1H, m, -CHCH2Ph),  4.58 
(2H, s, ortho on η5-C5H4-C≡C-), 4.30 - 4.29 {7H, m, (meta on η
5
-C5H4-C≡C-), (η
5
-
C5H5)}, 4.12 (2H, q, J = 7.0 Hz -OCH2CH3), 4.11 (2H, d, J = 6.8 Hz, -NHCH2CO-), 
3.17 - 3.10 (2H, m, -CHCH2Ph), 1.31 (3H, t, J = 7.0 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3):171.2 (C=O), 168.0 (C=O), 157.9 (C=O), 146.5 (Cq), 
139.3 (Cq), 135.6, 129.3, 128.6, 127.2, 116.1, 116.0, 94.9 (η
5
-C5H4-C≡C-), 75.0 (η
5
-
C5H4-C≡C-), 71.7 (Cortho η
5
-C5H4-C≡C-), 70.2 (η
5
-C5H5), 69.5 (Cmeta η
5
-C5H4-C≡C-), 
62.9 (Cipso η
5
-C5H4-C≡C-), 61.7 (-OCH2CH3, -ve DEPT), 53.3 (-CHCH2Ph),  42.8 (-
NHCH2CO-, -ve DEPT), 37.9 (-CHCH2Ph, -ve DEPT), 14.2 (-OCH2CH3). 
 
N-{5-(ferrocenyl) ethynyl-2-furanoyl} glycine L-leucine ethyl ester (133) 
 
Glycine L-leucine ethyl ester hydrochloride (0.68 g, 3.12 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red oil (0.20 g, 12%); 
 [α]D
20
 = -14 
o 
(c 0.1, EtOH); 
Mass spectrum: found: [M+Na]
+   
                  541.1385
                     
C27H30N2O5FeNa requires:                              541.1402                    
 221 
I.R. υmax (KBr): 3285 (NH), 2205 (-C≡C-), 1735 (C=Oester), 1674 (C=Oamide), 1612 
(C=Oamide) cm
-1
 
UV-Vis λmax EtOH: 373, 474 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.11 - 7.05 {2H, m, (ArH), (-CONH-)}, 6.65 - 6.60 
{2H, m, (ArH), (-CONH-)}, 4.60 - 4.54 {1H, m, -CHCH2CH(CH3)2}, 4.48 (2H, t, J = 
2.0 Hz, ortho on η5-C5H4-C≡C-), 4.25 - 4.05 {11H, m, (meta on η
5
-C5H4-C≡C-), (-
NHCH2CO-), (η
5
-C5H5), (-OCH2CH3)}, 1.66 - 1.47 {3H, m, -CHCH2CH(CH3)2},  1.21 
(3H, t, J = 7.0 Hz - OCH2CH3), 0.88 - 0.86 { 6H, m, -CHCH2CH(CH3)2};  
13
C NMR (100 MHz) δ (CDCl3): 172.7 (C=O), 168.2 (C=O), 158.0 (C=O), 147.0 (Cq), 
139.3 (Cq), 116.0, 115.9, 94.9 (η
5
-C5H4-C≡C-), 75.0 (η
5
-C5H4-C≡C-), 71.7 (Cortho η
5
-
C5H4-C≡C-), 70.3 (η
5
-C5H5), 69.5 (Cmeta η
5
-C5H4-C≡C-), 63.1 (Cipso η
5
-C5H4-C≡C-), 
61.9 (-OCH2CH3, -ve DEPT), 51.3 (-CHCH2CH(CH3)2), 42.8 (-NHCH2CO-, -ve 
DEPT), 41.4 (-CHCH2CH(CH3)2, -ve DEPT), 25.0 (-CHCH2CH(CH3)2), 22.4 (-
CHCH2CH(CH3)2), 21.9 (-CHCH2CH(CH3)2), 14.7 (-OCH2CH3). 
 
N-{5-(ferrocenyl) ethynyl-2-furanoyl} sarcosine glycine ethyl ester (134) 
 
Sarcosine glycine ethyl ester hydrochloride (0.54 g, 3.12 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.13 g, 9%), m.p 136 - 138 
o
C;  
Mass spectrum: found: [M+Na]
+   
                  499.0918 
C24H24N2O5FeNa requires:                              499.0932                          
I.R. υmax (KBr): 3311 (NH), 2208 (-C≡C-), 1742 (C=Oester), 1681 (C=Oamide), 1620 
(C=Oamide) cm
-1
; 
UV-Vis λmax EtOH:  374, 478 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.05 {(1H, d, J = 3.2 Hz, ArH), 6.85 (1H, bs, -CONH-
), 6.55 (1H, d, J = 3.2 Hz, ArH), 4.46 (2H, s, ortho on η5-C5H4-C≡C-), 4.23 - 3.99 
{13H, m, (meta on η5-C5H4-C≡C-), (η
5
-C5H5), (-N(CH3)CH2CO-), (-NHCH2CO-), (-
OCH2CH3)}, 3.20 (3H, s, -N(CH3)CH2CO-), 1.28 (3H, t, J = 6.8 Hz, -OCH2CH3); 
 
13
C NMR (100 MHz) δ (CDCl3): 171.9 (C=O), 169.1 (C=O), 158.0 (C=O), 147.0 (Cq), 
139.6 (Cq), 118.0, 117.5, 94.2 (η
5
-C5H4-C≡C-), 75.0 (η
5
-C5H4-C≡C-), 71.0 (Cortho η
5
-
C5H4-C≡C-), 70.4 (η
5
-C5H5), 69.7 (Cmeta η
5
-C5H4-C≡C-), 63.8 (Cipso η
5
-C5H4-C≡C-), 
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61.0 (-OCH2CH3, -ve DEPT), 51.7 (-N(CH3)CH2CO-, -ve DEPT), 41.0 (-NHCH2CO-, -
ve DEPT), 38.7 (-N(CH3)CH2CO-), 13.5 (-OCH2CH3). 
 
N-{5-(ferrocenyl) ethynyl-2-furanoyl} L-proline glycine ethyl ester (135) 
 
L-Proline glycine ethyl ester hydrochloride (0.67 g, 3.12 mmol) was used as a starting 
material. The crude product was purified by column chromatography (eluent 1:1 
hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.16 g, 10%), m.p 128 - 130 
o
C; 
 [α]D
20
 = 13 
o 
(c 0.1, EtOH); 
Mass spectrum: found: [M+Na]
+   
             525.1078 
C26H26N2O5FeNa requires:                        525.1089                           
I.R. υmax (KBr): 3284 (NH), 2210 (-C≡C-), 1742 (C=Oester), 1641 (C=Oamide), 1610 
(C=Oamide) cm
-1
; 
UV-Vis λmax EtOH:  379, 477 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.34 (1H, t, J = 5.2 Hz, -CONH-), 7.10 (1H, d, J = 3.6 
Hz, ArH), 6.56 (1H, d, J = 3.6 Hz, ArH), 4.80 - 4.78 (1H, bs, -N(CH2CH2CH2)CHCO-), 
4.47 (2H, s, ortho on η5-C5H4-C≡C-), 4.14 - 3.95 {13H, m, (meta on η
5
-C5H4-C≡C-), 
(η5-C5H5), (-OCH2CH3), (-N(CH2CH2CH2)CHCO-), (-NHCH2CO-)}, 2.36 - 1.88 (4H, 
m, -N(CH2CH2CH2)CHCO-), 1.23 (3H, t, J = 6.8 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 168.7 (C=O), 167.9 (C=O), 157.1 (C=O), 145.4 (Cq), 
138.2 (Cq), 117.6, 115.7, 94.1 (η
5
-C5H4-C≡C-), 75.7 (η
5
-C5H4-C≡C-), 71.6 (Cortho η
5
-
C5H4-C≡C-), 69.9 (η
5
-C5H5), 68.5 (Cmeta η
5
-C5H4-C≡C-), 64.8 (Cipso η
5
-C5H4-C≡C-), 
61.0 (-OCH2CH3, -ve DEPT), 52.8 (-N(CH2CH2CH2)CHCO-),  
48.4 (-N(CH2CH2CH2)CHCO-, -ve DEPT), 41.4 (-NHCH2CO-, -ve DEPT), 27.5 (-
N(CH2CH2CH2)CHCO-, -ve DEPT), 24.9 (-N(CH2CH2CH2)CHCO-, -ve DEPT), 13.0 
(-OCH2CH3). 
 
N-{5-(ferrocenyl) ethynyl-2-furanoyl} L-proline L-alanine ethyl ester (136) 
 
L-Proline L-alanine ethyl ester hydrochloride (0.71 g, 3.12 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
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1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red solid (0.14 g, 9%), m.p 34 - 36 
o
C;  
[α]D
20
 = -45 
o 
(c 0.1, EtOH); 
Mass spectrum: found: [M+Na]
+          
  539.1249 
C27H28N2O5FeNa requires:                  539.1245                      
I.R. υmax (KBr): 3289 (NH), 2206 (-C≡C-), 1736 (C=Oester), 1674 (C=Oamide), 1630 
(C=Oamide) cm
-1
; 
UV-Vis λmax EtOH:  376, 479 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.30 (1H, t, J = 5.2 Hz, -CONH-), 7.09 (1H, d, J = 3.6 
Hz, ArH), 6.56 (1H, d, J = 3.6 Hz, ArH), 4.47 (1H, t, J = 7.0 Hz,  -
N(CH2CH2CH2)CHCO-), 4.46 - 4.43 {3H, m, (ortho on η
5
-C5H4-C≡C-), (-CHCH3)}, 
4.23 - 4.19 {7H, m, (meta on η5-C5H4-C≡C-), (η
5
-C5H5)}, 4.12 (2H, q, J = 7.2 Hz, -
OCH2CH3), 3.73 - 3.56 (2H, m, -N(CH2CH2CH2)CHCO-), 2.50 - 1.80 (4H, m, -
N(CH2CH2CH2)CHCO-), 1.34 (3H, d, J = 7.2 Hz, -CHCH3) 1.20 (3H, t, J = 7.2 Hz, -
OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 173.4 (C=O), 170.9 (C=O), 158.5 (C=O), 147.4 (Cq), 
140.7 (Cq), 118.5, 115.7, 94.7 (η
5
-C5H4-C≡C-), 75.1 (η
5
-C5H4-C≡C-), 71.7 (Cortho η
5
-
C5H4-C≡C-), 70.2 (η
5
-C5H5), 69.5 (Cmeta η
5
-C5H4-C≡C-), 63.0 (Cipso η
5
-C5H4-C≡C-), 
61.4 (-OCH2CH3, -ve DEPT), 49.3 (-N(CH2CH2CH2)CHCO-),  
48.1 (-N(CH2CH2CH2)CHCO-, -ve DEPT ), 46.8 (-CHCH3),  
27.0 (-N(CH2CH2CH2)CHCO-, -ve DEPT), 25.6 (-N(CH2CH2CH2)CHCO-, -ve DEPT), 
18.2 (-CHCH3), 14.2 (-OCH2CH3). 
 
N-{5-(ferrocenyl) ethynyl-2-furanoyl} sarcosine L-alanine ethyl ester (137) 
 
Sarcosine L-alanine ethyl ester hydrochloride (0.59 g, 3.12 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red oil (0.12 g, 8%);  
[α]D
20
 = -19 
o 
(c 0.1, EtOH); 
Mass spectrum: found: [M+Na]
+   
           513.1080 
C25H26N2O5FeNa requires:                       513.1089      
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 I.R. υmax (KBr):
 
3317 (NH), 2206 (-C≡C-), 1745 (C=Oester), 1671 (C=Oamide), 1640 
(C=Oamide) cm
-1
; 
UV-Vis λmax EtOH:  375, 474 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.05 (1H, d, J = 3.2 Hz, ArH), 6.85 - 6.86 (1H, bs, -
CONH-), 6.55 (1H, d, J = 3.2 Hz, ArH), 4.48 - 4.45 {3H, m, (ortho on η5-C5H4-C≡C-), 
(-CHCH3)}, 4.19 - 3.90 {11H, m, (meta on η
5
-C5H4-C≡C-), (η
5
-C5H5), (-
N(CH3)CH2CO-), (-OCH2CH3)}, 3.00 (3H, s, -N(CH3)CH2CO-), 1.35 (2H, d, J = 7.2 
Hz, -CHCH3), 1.23 (3H, t, J = 6.8 Hz, -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 173.7 (C=O), 168.6 (C=O), 159.0 (C=O), 145.0 (Cq), 
138.6 (Cq), 118.0, 116.5, 93.9 (η
5
-C5H4-C≡C-), 76.0 (η
5
-C5H4-C≡C-), 71.9 (Cortho η
5
-
C5H4-C≡C-), 70.8 (η
5
-C5H5), 67.7 (Cmeta η
5
-C5H4-C≡C-), 63.9 (Cipso η
5
-C5H4-C≡C-), 
61.3 (-OCH2CH3, -ve DEPT), 47.2 (-CHCH3), 40.1 (-N(CH3)CH2CO-, -ve DEPT), 38.5 
(-N(CH3)CH2CO-), 18.5 (-CHCH3), 14.2 (-OCH2CH3). 
 
N-{5-(ferrocenyl) ethynyl-2-furanoyl} γ-aminobutyric acid ethyl ester (138)  
 
γ-Amino butyric acid ethyl ester hydrochloride (0.41 g, 3.12 mmol) was used as a 
starting material. The crude product was purified by column chromatography (eluent 
1:1 hexane: ethyl acetate) and recrystallisation from hexane: ethyl acetate yielded the 
desired product as a red oil (0.34 g, 25%);  
Mass spectrum: found: [M+Na]
+             
456.0854 
                  
C23H23NO4FeNa requires:                    456.0874                       
I.R. υmax  (KBr): 
 
3287 (NH), 2206 (-C≡C-), 1735 (C=Oester), 1640 (C=Oamide) cm
-1
  
UV-Vis λmax EtOH: 372, 484 nm; 
1
H NMR (400 MHz) δ (CDCl3): 7.06 (1H, d, J = 3.5 Hz, ArH), 7.02 (1H, t, J = 5.6 Hz, 
-CONH-), 6.65 {1H, d, J = 3.5 Hz, ArH), 4.56 (2H, t, J = 2.0 Hz,  ortho on η5-C5H4-
C≡C-), 4.27 (2H, t, J = 2.0 Hz, meta on η5-C5H4-C≡C-), 4.16 (5H, s, η
5
-C5H5), 4.04 
(2H, q, J = 7.2 Hz, -OCH2CH3), 3.43 {2H, q, J = 6.4 Hz, (-NHCH2CH2CH2-)}, 2.38 
(2H, t, J = 6.8 Hz, -NHCH2CH2CH2-), 1.90 {2H, quin, J = 6.4 Hz, -NHCH2CH2CH2-), 
1.17 ( 3H, t, J= 7.2 Hz,  -OCH2CH3); 
13
C NMR (100 MHz) δ (CDCl3): 173.4 (C=O), 170.9 (C=O), 147.0 (Cq), 141.0 (Cq), 
117.3, 115.7, 94.2 (η5-C5H4-C≡C-), 75.7 (η
5
-C5H4-C≡C-), 71.2 (Cortho η
5
-C5H4-C≡C-), 
70.9 (η5-C5H5), 69.0 (Cmeta η
5
-C5H4-C≡C-), 63.7 (Cipso η
5
-C5H4-C≡C-), 60.4 (-
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OCH2CH3, -ve DEPT), 39.8 (-NHCH2CH2CH2-,   -ve DEPT), 34.0 (-NHCH2CH2CH2-, 
-ve DEPT), 25.3 (-NHCH2CH2CH2-, -ve DEPT), 13.5 (-OCH2CH3). 
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Appendix 1: Abbreviations and Units 
 
A 
A  absorbance 
ATR  attenuated total reflection 
AR  androgen receptor 
 
B 
BF4
-  
tetrafluoroborate ion 
Br  bromine 
bs                     broad singlet (spectroscopy) 
 
BuLi                Butyllithium 
 
C 
 
C  carbon; concentration 
Calc.  calculated 
Cq                    quaternary carbon 
CDCl3                   deuterated chloroform 
Cl  chlorine 
Co  cobalt 
Cu(1)  copper (1) 
CO2  carbon dioxide 
Cp  cyclopentadienyl ring 
COSY  correlated spectroscopy 
C=O   carbonyl 
CBr4 
 
D 
d  doublet (spectroscopy) 
DCC  1,3-dicyclohexylcarbdiimide 
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DCM  dichloromethane 
DCU  Dublin City University 
dd  doublet of doubles 
DEPT-135 distortionless enhancement by polarisation transfer 
DMSO-d6 deuterated dimethylsulfoxide 
 
 
E 
e
-
  electron 
EDC  N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
ESR  electron spin resonance 
ER  estrogen receptor 
ER(+)  estrogen receptor positive cells 
ER(-)  estrogen receptor negative cells 
EtOH                ethanol 
 
F 
Fc/Fc
+
  ferrocene/ferrocenium ion 
Fe  iron 
Fe(II)  ferrous ion 
Fe(III)  ferric ion 
FT  Fourier transform 
 
G 
Ga  gallium 
Gly  glycine 
Gaba               gamma-amino butyric acid         
 
H 
H  hydrogen 
H2O  water 
HCl  hydrochloric acid 
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HQMC Heteronuclear multiple quantum coherence 
HOBt  1-hydroxybenzotriazole 
H3PO4             phosphoric acid 
I 
IC50  half maximal inhibitory concentration 
IR  infra red spectroscopy 
 
 
J 
 
J  coupling constant 
 
K 
KBr  potassium bromide 
 
L 
l  path length (cm) 
L-Ala  L-alanine 
L-Phe              L-phenyalanine 
L-Leu              L-leucine 
L-pro               L-proline 
Lit                    literature 
 
M 
m  meta; mass 
m  multiplet (spectral) 
M  metal; mitosis phase 
MeOH  methanol 
MgSO4 magnesium sulphate 
MLCT  metal-ligand charge transfer 
mp  melting point 
MS  mass spectrometry 
 230 
N 
NICB  National Institute for Cellular Biotechnology 
NMR  nuclear magnetic resonance 
NaOH  sodium hydroxide 
NHS  N-hydroxysuccinimide 
NSCLC non-small cell lung carcinoma 
 
O 
o  ortho 
O  oxygen 
OH  hydroxy 
 
P 
p  para 
P  phosphorous 
Pt  platnium 
ppm  parts per million 
POCI3                     phosphorus oxychloride  
PPh3                         triphenylphosphine 
Pd                     palladim 
 
 
Q 
q  quartet 
 
R 
Rh  rhodium 
Ru  ruthenium 
RNA  ribonucleic acid 
RSD  relative standard deviation 
ROS  reactive oxygenated species 
 
 231 
S 
s  singlet 
SARS  structure activity relationship 
SERM  selective estrogen receptor modulator 
SCLC  small cell lung carcinoma 
Sar                   sarcosine 
T 
TEA  triethylamine 
TMS  tetramethylsilane 
TFA  trifluoroacetic acid 
Ti  titanium 
THF               tetrahydrofuran 
 t-BuOK         potassium tert-butoxide 
 
U 
 
UV  ultraviolet 
 
V 
V  vanadium 
Vis  visible 
 
W 
 
WHO  World Health Organisation 
 
Units 
 
cm  centimetre 
cm
-1  
wavenumber / per centimetre 
g  gram 
hr  hour 
 232 
Hz  hertz 
M  molar 
MHz  megahertz 
ml  millilitre 
mm  millimetre 
mM  millimolar 
mmol  millimolar 
µl  microlitre 
µM  micromolar 
o
C  degree celcius 
ppm  parts per million 
s  second 
δ  chemical shift 
%  percentage 
 
 
 
 
 
 
 
 
 
.  
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Appendix 11: Publication 
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